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ABSTRACT 
 
Heterogeneity of Hepatocellular Malignant Phenotype 
 
Nuri Öztürk 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Öztürk 
August, 2006, 155 Pages 
 
 
Hepatocellular carcinoma (HCC) is one of the most wide-spread carcinomas 
throughout the world - responsible for more than 600,000 deaths annually - and is 
strongly associated with several etiological factors; including aflatoxin B1, alcohol, and 
Hepatitis virus B and C.  In HCC, many genes undergo somatic aberrations with a 
tendency to cluster at genes involved in cell cycle regulation, in the p53 and canonical 
Wnt signaling pathways, and in the TGF-β/IGF axis. Almost a third of HCCs display 
mutations affecting canonical Wnt signalling. However, the role of canonical Wnt 
signaling aberrations in HCC is not known in detail, since transgenic mice which express 
mutant β-catenin (an integral component of canonical Wnt signaling) do not develop liver 
tumours. 
To study the heterogeneity of hepatocellular malignancies, we have concentrated 
on canonical Wnt signaling in HCC cell lines. We have found that canonical Wnt 
signaling was active in 80% of well-differentiated, and 14% of poorly-differentiated cell 
lines respectively. Furthermore, ectopic expression of a mutant β-catenin resulted in 
strong canonical Wnt activity in well-differentiated, but not in poorly-differentiated HCC 
cells. Our findings suggested that heterogeneity in HCC exists even in the same pathway 
as exemplified by differential canonical Wnt signaling activity in well- and poorly-
differentiated HCC cell lines. During this study, we produced monoclonal antibodies 
against β-catenin to distinguish between the pools of nuclear/cytoplasmic and membrane-
associated β-catenin in cells, since it is believed that the nuclear β-catenin pool is more 
potent in tumorigenesis. Monoclonal antibody (MAb), 4C9 recognised β-catenin out of 
adherens junctions, while another MAb, 9E10 recognised all β-catenin forms even 
though their epitopes were adjacent.  
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Differential Wnt signaling activity in HCC cell lines prompted us to investigate 
the interactions between β-catenin and other molecules, which have important functions 
in hepatocytes and may affect β-catenin/TCF transcriptional activity. C/EBPα is a potent 
inhibitor of cell proliferation in HCC cell lines and is involved in liver-specific gene 
expression, and some somatic alterations of it have been observed in AML and HCC. We 
investigated the effect of C/EBPα on β-catenin signalling. We have found that C/EBPα 
inhibits mutant β-catenin-TCF transcriptional activity, and physically interacts with β-
catenin in HCC cells. 
While we were analyzing some stably mock-transfected Huh7 clones to use as 
controls, we observed heterogeneity in their proliferation rates. Further analysis of these 
clones revealed that some clones ceased to proliferate when passaged extensively. One of 
these clones (C3) was not tumorigenic in immunodeficient mice. Based on these 
observations, we hypothesized that some cancer cells could produce senescencent 
progeny in cell culture. Indeed, we showed that breast- and liver-cancer-derived cells 
display senescencent phenotypes at variable ratios. By using our experimental system, we 
also showed that replicative senescence program may work independently of functional 
p53 and p16 pathways, and the SIP1 gene is partially responsible for replicative senescent 
phenotypes in our Huh7-derived senescent clone C3. Overexpression of mouse SIP1 in 
p53- and Rb-deficient Hep3B cells induced partial senescent phenotypes at early 
passages. However, stable Hep3B cells repressed mouse SIP1 expression by an unknown 
mechanism and escaped senescent arrest in late passages. 
Our results suggest that Wnt pathway may have a dual role in hepatocellular 
malignancy, as it is active/easily inducible in well-differentiated HCC cells and 
inactive/repressed in poorly-differentiated ones. The further study of β-catenin in tumor 
samples by using our monoclonal antibodies may reveal new aspects in β-catenin 
signaling. However, the mechanism of these phenomena and the inhibition of β-catenin-
TCF signaling by C/EBPα require more study to reach a more comprehensive 
conclusion. The study of reprogramming of replicative senescence in HCC-derived cells 
indicated that senescence program may work independent of p53 and p16 pathways and 
heterogeneity of hepatocellular malignancy exists even within the established HCC 
derived cell lines. 
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                                                     ÖZET 
Hepatoselüler Malignansi Fenotipinin Heterojenliği 
Nuri Öztürk 
Moleküler Biyoloji ve Genetik Doktorası 
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk 
Ağustos, 2006, 155 sayfa 
 
Hepatoselüler karsinoma (HCC), en yaygın karsinomlardan olup dünya genelinde 
her yıl 600.000’den fazla ölüme sebep olmaktadır ve aflatoksin B1, alkol ve Hepatit B ve 
C gibi etiyolojik faktörlerle ilişkilendirilmektedir. HCC’de bir çok gen somatik değişime 
uğramakla birlikte hücre döngüsünde, p53 ve kanonik Wnt yolaklarında ve TGFβ/IGF 
ekseninde bulunan genler daha çok etkilenmektedir. HCC’lerin yaklaşık üçte birinde 
kanonik Wnt yolağını etkileyen mutasyonlara rastlanmaktadır. Bununla birlikte, mutant 
β-katenin (kanonik Wnt sinyalinin temel öğelerinden biri) anlatımı yapan transgenik 
fareler karaciğer tümörü geliştirmediği için, bu yolak değişimlerinin karaciğer  
tümörlerindeki etkileri ayrıntılı bilinmemektedir. 
Karaciğer tümörlerindeki heterojenliği çalışmak amacıyla, HCC hücre hatlarında 
kanonik Wnt yolağı üzerine yoğunlaştık. Kanonik Wnt yolağının %80 oranında iyi 
farklılaşmış  ve %14 oranında az farklılaşmış  HCC hücre hatlarında etkin olduğunu 
tespit ettik. Bu bulguya ek olarak, mutant β-katenininin ektopik anlatımı iyi farklılaşmış 
HCC hücre hatlarında az farklılaşmış olanların aksine kuvvetli kanonik Wnt aktivitesine 
sebep oldu. Elde ettiğimiz sonuçlar HCC’deki heterojenliğin aynı sinyal yolağı içinde 
bile olabileceğine işaret etmektedir ve bu olgu, kanonik Wnt yolağının iyi ve az derecede 
farklılaşmış HCC hücrelerinde farklı olmasıyla örneklendirilmiştir. Bu çalışma sırasında, 
nükleer/sitoplazmik β-katenin havuzunun tümör gelişiminde daha önemli olduğu 
varsayıldığından, bu havuzu zardaki β-kateninden ayırt edebilmek amacıyla monoklonal 
β-katenin antikorları ürettik. 4C9 ve 9E10 epitopları birbirine yakın olmakla birlikte, 4C9 
monoklonal antikoru (MAb) sadece yapışma kavşakları dışındaki β-katenini 
tanımaktayken diğer MAb, 9E10, tüm β-katenin formlarını tanımıştır. 
Kanonik Wnt yolağının HCC hücrelerinde farklı aktivite göstermesi, bizi HCC’de 
önemli fonksiyonları olan ve β-katenin ile etkileşerek β-katenin/TCF yazılım aktivesini 
değiştirebilecek molekül adaylarını araştırmaya yöneltti. C/EBPα karaciğer hücrelerinde 
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hücre büyümesini durdurmakta ve karaciğere özgü genlerin anlatımını düzenlemektedir. 
Bu genin somatik değişimleri AML ve hepatoselüler karsinomada gözlenmiştir. Bu 
sebeple, C/EBPα’nın β-katenin sinyali üzerine etkisini araştırdık. Hepatoselüler 
karsinoma hücre hatlarında, C/EBPα’nın mutant β-katenin-TCF yazılım aktivitesini 
inhibe ettiğini ve β-katenin proteini ile fiziksel olarak etkileştiğini bulduk. 
Kontrol olarak kullanmak amacıyla elde edilen kararlı eşdeğer Huh7 hücre hattı 
klonlarında büyüme hızlarının farklı olduğunu gözlemledik. Bu hücrelerin ayrıntılı 
analizlerinde, kültürde uzun dönem üretildiklerinde büyümeyi kestikleri gösterilmiştir. 
Bu klonlardan birisi (C3)  yabancı dokuya cevap veremeyen farelerde tümör 
oluşturamamıştır. Bu gözlemlere dayanarak bazı kanser hücrelerinin kültür ortamında 
kendiliğinden yaşlanmış yavru hücreler verebilecekleri tezini oluşturduk. Gerçekten de, 
meme ve hepatoselüler kanser hücrelerinin değişen oranlarda yaşlanmış hücreler 
ürettiğini tespit ettik.  Buna ek olarak, elimizdeki modeli kullarak replikatif yaşlanmanın 
fonksiyonel p53 ve p16 yolakları olmadan da gerçekleşebildiğini ve SIP1 geninin 
Huh7’den türetilmiş bir klonda (C3) gözlemlenen replikatif yaşlanmada kısmen sorumlu 
olduğunu gösterdik. Bunlara ek olarak,  p53 ve Rb bakımından eksik Hep3B hücre 
hattında fare SIP1 geninin anlatımı kısmi yaşlanmaya yol açmıştır. Fakat, bu hücreler 
uzun süre kültürde tutulduğunda bilinmeyen bir mekanizma ile fare SIP1 geninin 
anlatımını baskıladılar ve yaşlanma bariyerinden kaçtılar.  
Kanonik Wnt sinyalinin iyi derecede farklılaşmış hücrelerde aktif/kolayca 
indüklenebilir olması ve az derecede farklılaşmış hücrelerde inaktif/baskılanmış olması 
sebebiyle bu yolak karaciğer hücrelerinde çift yönlü rol oynamaktadır. Tümör 
örneklerinde β-kateninin bizim antikorlarımızla incelenmesi β-katenin sinyalinin yeni 
yönlerini açığa çıkarabilir.  Bu bulguların mekanizmasının açıklanması ve β-katenin-TCF 
sinyalinin C/EBPα tarafından baskılanmasının net olarak yorumlanması için daha fazla 
çalışma yapılmalıdır. Hepatoselüler karsinomadan türetilmiş hücrelerde yaşlanmanın 
yeniden programlanabilmesi çalışması, replikatif yaşlanmanın p53 ve p16 yolaklarından 
bağımsız gerçekleşebileceğini ve hepatoselüler karsinomada heterejonliğin yıllardır 
kültürde tutulmuş HCC hücre hatlarının kendi içinde bile olduğuna işaret etmektedir.  
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CHAPTER 1. INTRODUCTION 
 
1.1 Hepatocellular malignancy 
The liver is the largest internal organ in the body, filling the upper right side of the 
abdomen and protected by the rib cage. The physiological functions of the liver can be 
summarized as follows: 1) Bile production and excretion. 2) Excretion of bilirubin, 
cholesterol, hormones, and drugs. 3) Metabolism of fats, proteins, and carbohydrates. 4) 
Enzyme activation. 5) Storage of glycogen, vitamins, and minerals. 6) Synthesis of 
plasma proteins, such as albumin and globulin, and clotting factors 7) Blood 
detoxification and purification.   
A malignancy is cancerous growth, in which a mass of cells grows in an 
uncontrolled fashion, with a tendency to create daughter cells that break away and grow 
elsewhere, invading and damaging surrounding tissue. Primary liver cancer is different 
from cancers that have spread from other places in the body to the liver (liver 
metastases). There are two main kinds of primary liver cancer, hepatoma and 
cholangiocarcinoma. Hepatoma originates from the hepatocytes, the main functioning 
liver cells, while cholangiocarcinoma originates in the bile ducts.  
Hepatoblastoma (HB) is the most common pediatric liver malignancy, comprising 
approximately 1% of all pediatric cancers (Schnater JM. et al., 2003). Liver 
angiosarcoma is a very rare type of primary liver cancer developing from the cells of 
blood vessels within the liver. 
Hepatocellular carcinoma (HCC), the most frequent primary liver cancer, is the 
fifth most common cancer world-wide and one of the most deadly cancers with 
approximately 600,000 yearly deaths (Llovet JM., 2003). Hepatocarcinogenesis nearly 
always develops in the setting of chronic hepatitis or cirrhosis; conditions in which many 
hepatocytes are killed, inflammatory cells invade the liver and connective tissue 
(Thorgeirsson SS. and Grisham GW., 2002). Infection with hepatitis B virus (HBV), 
hepatitis C virus (HCV) and chronic exposure to aflatoxin B1 (AFB1) are responsible for 
about 80% of all HCCs in humans (Bosch FX. et al., 1999).  Development of HCC is 
slow process requiring 10-30 years from the initiation of to the fully malignant 
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phenotype. The preneoplastic liver is often the site of chronic hepatitis, cirrhosis, or both.  
Hepatocyte cycling leads to the production of monoclonal populations of aberrant and 
dysplastic hepatocytes that have telomere erosion and telomerase re-expression, 
sometimes microsatellite instability, and occasionally structural aberrations in genes and 
chromosomes. Development of dysplastic hepatocytes in foci and nodules and emergence 
of hepatocellular carcinoma are associated with the accumulation of irreversible 
structural alterations in genes and chromosomes, however the genomic basis of the 
malignant phenotype is heterogeneous (Thorgeirsson SS. and Grisham GW., 2002). The 
sequential events leading to HCC may be summarized in five steps: chronic liver injury 
that produces inflammation, cell death, cirrhosis and regeneration, DNA damage, 
dysplasia, and finally HCC (Figure 1.1) (Tannapfel A. and Wittekind C., 2002). More 
than 60–80% of HCC cases arise in cirrhotic liver.  
 
 
Figure 1.1: Multistage process of hepatocarcinogenesis (Tannapfel A. and Wittekind C., 2002) (See text 
for details). 
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1.2 Pathogenesis of hepatocellular carcinoma 
1.2.1 Significance of viral hepatitis in hepatocellular carcinoma  
 The epidemiologic association of chronic HBV or HCV infection with HCC has 
been well established. The availability of cloned HBV and HCV genomes made it 
possible to detect hepatitis viruses in hepatocellular carcinomas, and their involvement in 
hepatocarcinogenesis. Oncogenic mechanism of HBV and HCV infection may be simply 
defined as releasing the growth control of hepatocytes by coding for a factor like the X 
protein of HBV (HbX) that activates otherwise dormant genes or activates proto-
oncogenes or silences anti-oncogenes; by inserting its DNA sequences that can activate 
and influence the transcription of cellular genes; by causing chronic inflammation with 
cell death and hepatocyte regeneration and with fibrosis; and by activation of the immune 
system liberating cytokines at the wrong time at the wrong place. Following liver cell 
necrosis, inflammation, regeneration, and fibrosis, quiescent hepatocytes start to 
proliferate. During this physiological process, irregular regeneration of hepatocytes 
through clonal expansion may lead to loss of control over growth and development of 
HCC (Ueno Y. et al., 2001). 
 Regarding the contribution of HBV to hepatocarcinogenesis, the role of 
integration of HBV DNA into host chromosomes and the subsequent chromosomal 
instabilities is an interesting issue. Integration of HBV DNA into HepG2 cells or into 
transgenic mouse chromosomes has resulted in chromosomal instability that may lead to 
loss of heterozygosity (LOH) in many loci during chronic infection (Hino O. et al., 1991; 
Livezey KW. and Simon D., 1997). It has also been shown that HBV chronic carriers 
display a higher incidence of chromosomal instabilities than the corresponding the 
uninfected population (Simon D. et al., 1991; Laurent-Puig P. et al., 2001).    
Transcriptional activation of a wide range of viral, as well as cellular genes such 
as c-fos , c-myc, insulin-like growth factor 2 (IGF2), insulin-like growth factor I receptor 
(IGFR1)  and β-interferon , were shown to be induced by HBV encoded X  antigen 
(HBxAg) (Twu JS. and Schloemer RH., 1987; Colgrove R. et al., 1989; d'Arville CN. et 
al., 1991; Caselmann WH., 1996; Kim SO. et al., 1996). In chronic HBV infection, it has 
been shown that HBxAg binds and functionally inactivates the tumor suppressor p53 
(Ueda H. et al., 1995; Huo TI. et al., 2001) and the negative growth regulator p55sen 
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(Feitelson MA., 1999), both of which are involved in senescence related pathways. 
Inactivation of the retinoblastoma (Rb) tumor suppressor by hyperphosphorylation 
resulting in the activation of E2F1 and the trigger of the cell cycle has been reported in 
HbxAg-positive HCC cells (Sirma H. et al., 1999). It has also been shown that HBxAg 
can down regulate the expression of translational factor sui1, and cyclin-dependent kinase 
inhibitor p21WAF1/CIP1/SDI1 (Sirma H. et al., 1999).  As with HbxAg, carboxyterminal 
truncated middle hepatitis B surface protein (MHBSt) can activate various viral and 
cellular gene promoters (Caselmann WH. et al., 1990; Kekule AS. et al., 1990). Recent 
data suggests that HbxAg contributes to HCC development also by mechanisms other 
than transactivation. HBxAg binds to the X-associated protein 1 and possibly disturbs its 
function in nucleotide excision repair mechanism (Becker SA. et al., 1998). It has also 
been shown that HBxAg-stimulated cell growth is associated with constitutive activation 
of the ras/raf/MAPK and NFκ-B signal transduction pathways (Lucito R. and Schneider 
RJ., 1992; Benn J. and Schneider RJ., 1994; Shirota Y. et al., 2001).  
Studies have recently begun to clarify the molecular mechanisms of HCV-induced 
carcinogenesis. Studies with HCV proteins showed that viral proteins interact with 
various cellular proteins, including 14-3-3 protein, apolipoprotein AII, tumor necrosis 
factor (TNF) receptor, lymphotoxin-ß receptor, DEAD domain of RNA helicase, nuclear 
ribonucleoprotein, double-stranded RNA protein kinase (PKR), p53 and SNARE-like 
protein (Ghosh AK. et al., 1999; Shimotohno K., 2000; Ray RB. and Ray R., 2001). 
In chronic HCV infection, inactivation of p53 can be achieved either by HVC core 
protein which transcriptionally represses the p53 promoter (Ray RB. et al., 1997; 
Pontisso P. et al., 1998), or by nonstructural protein 3 (NS3) and NS5A which bind and 
most likely inactivates p53 (Ishido S. and Hotta H., 1998; Majumder M. et al., 2001). 
Recently, stable expression of  HCV core protein in HepG2 cells was shown to result in 
constitutive activation of the mitogen activated protein kinase/extracellular signal-
regulated kinase (MAPK/ERK) pathway (Hayashi J. et al., 2000). 
Chronic infection by HBV, HCV and chronic hepatitis lead to the activation of 
cytokines and growth factors such as transforming growth factor-α (TGF-α) and insulin-
like growth factor-2 (IGF2), and the simultaneous decrease in IGF-binding proteins 
(IGFBPs), which increases the bioavailability of the insulin-like growth factors (IGFs). 
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IGF2 and TGFα in preneoplastic hepatocytes conbribute to the increase in the rate of 
proliferation (Grisham JW., 2001). Structural genomic alterations accumulate slowly 
during the preneoplastic phase (Thorgeirsson SS. and Grisham JW., 2002; Suriawinata A. 
and Xu R., 2004). However, once the hepatocytes acquire a dysplastic phenotype, 
characterized by small cell size, increased nuclear to cytoplasmic ratio, basophilia and 
abnormal nuclear morphology the rate at which these cells acquire additional disruptions 
to the genome increases dramatically (Hytiroglou P.,  2004) (Figure 1.2). 
 
 
Figure 1.2: Simplified model of molecular changes during hepatocellular carcinogenesis. Normal 
hepatocytes proliferate at a very slow rate. Chronic infection by HBV, HCV and chronic hepatitis lead to 
the activation of cytokines and growth factors such as TGFα and IGF2, and the simultaneous decrease in 
IGFBPs, which increases the bioavailability of the IGFs. These changes lead to an increased rate of 
proliferation, which for many years is balanced by loss of hepatocytes through apoptosis. During the 
preneoplastic period, additional changes are acquired, including multiple chromosomal abnormalities, loss 
of tumor suppressors, decreased expression of EGR1 and C/EBPα, and increased expression of FOXM1b. 
At later stages, increased expression of TGF-β is thought to promote angiogenesis and metastasis 
(Greenbaum LE, 2004). 
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1.2.2 Alcohol and cirrhosis 
Beside for the HBV and mostly HCV-associated cirrhosis, non-viral induced 
cirrhosis is also coupled with elevated risk of HCC (Furuya K. et al., 1988; Floreani A. et 
al., 1999).  
It has been shown that alcoholic cirrhosis is associated with both HCC and 
cholangiocarcinoma. In the absence of cirrhosis, however, alcohol has not been shown to 
be carcinogenic in animal studies. It appears that, in large part, the relationship of 
alcoholic cirrhosis to liver cancer may be due to concomitant infection with HCV (Farber 
E., 1996).  The effects of ethanol metabolism on DNA integrity and repair mechanisms 
are likely to play a significant role in the process of transformation. However, it is 
becoming increasingly apparent that ethanol, the metabolism of ethanol, or both also 
affect cell signaling pathways that regulate normal and abnormal hepatocyte function, 
proliferation, and apoptosis (McKillop IH. and Schrum LW., 2005). 
 
1.2.3 Hepatotoxic chemicals 
 Aflatoxin B1 (AFB1), benzo(a)pyrene and vinly chloride were shown to have a 
well-defined genotoxic effect in hepatocarcinogenesis. Consumption of food 
contaminated with aflatoxins, toxic metabolites of some species of Aspergillus fungi, has 
been allied with both human and animal HCCs. Aflatoxin metabolism produces aflatoxin 
B1-8,9-epoxide, a toxic product that induces a G to T mutation of the p53 gene at codon 
249 up-regulating insulin-like growth factor II , which leads to a reduction of apoptosis 
(Bressac B. et al., 1991; Hsu IC. et al., 1991; Lee YI. et al., 2000).The  genotoxic effects 
of benzo(a)pyrene and vinly chloride on p53 gene has been supported by human and 
animal data (Puisieux A. et al., 1991; Barbin A. et al., 1997). 
 
1.2.4 Hemochromatosis and iron  
 Alteration in iron absorption and deposition in the liver and other organs occurs in 
hereditary hemochromatosis (HH), which is an autosomic recessive disease (Bailey MA. 
et al., 2002). Iron overload has been associated with a high risk of HCC in patients with 
untreated hemochromatosis and dietary iron intake in patients without hereditary iron 
overload (Hann HW. et al., 1989; Fargion S. et al., 1992). Iron overload as a cofactor for 
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hepatocarcinogenesis is the iron deposition which occurs in hepatocytes, Kupffer cells 
and bile ducts. It results in increased production of oxygen free radicals, peroxidation of 
membrane lipids, and other reactive oxygen species (ROS)-mediated damages (Kicic A. 
et al., 2001). 
 
1.2.5  Obesity and HCC 
 Recently, several epidimological observations have implicate obesity as a risk 
factor for certain malignancies such as endometrium cancer, breast cancer etc. Obesity 
and diabetes mellitus were suggested as important risk factors for cryptogenic chronic 
liver disease in patients with HCC is supported by the analysis of surgically treated 
patients (Regimbeau JM. et al., 2004). 
 
1.3  Liver cirrhosis and senescence 
Liver cirrhosis, the irreversible terminal stage of chronic liver disease, 
characterized by widespread fibrous scarring, is a major cause of morbidity and mortality 
worldwide, with no effective therapy. Independent of its cause, cirrhosis is considered a 
major clinical and histopathological risk factor for HCC development. A variety of 
factors induce liver cirrhosis, including viral hepatitis, alcohol abuse, prolonged biliary 
obstruction, genetically transmitted metabolic disorders, and others. Serious 
complications of liver cirrhosis includes those: accumulation of fluid in the abdomen 
(ascites), bleeding disorders (coagulopathy), increased pressure in the blood vessels 
(portal hypertension), and confusion or a change in the level of consciousness (hepatic 
encephalopathy). Regenerative nodules are characteristic lesions of the cirrhotic liver. 
They exhibit a lack of bile ducts and poorly organized hepatocytes surrounded by fibrosis 
and proliferating cholangiocytes. Dysplastic foci, which are smaller than 1 mm, can be 
found in regenerative nodules. There are two types of dysplastic foci in cirrhotic livers, 
small cell-dysplasia (SCD) and the large cell-dysplasia (LCD), according to the 
nuclear/cytoplasmic ratio. SCD are thought to be HCC precursor lesions that result from 
the proliferation of hepatocytes and oval cells. On the other hand, LCD apparently arise 
from persistent necroinflammation-induced senescent hepatocytes and are therefore not 
considered to be HCC precursor lesions (Libbrecht L. et al., 2005). 
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Hepatocyte telomere shortening and senescence are general markers of human 
liver cirrhosis, and correlates with progression of fibrosis in cirrhosis samples (Wiemann SU. 
et al., 2002). Additionally, Paradis V. et al. observed an increasing percentage of 
replicative senescent liver cells from normal liver to chronic hepatitis and HCC (Paradis 
V. et al., 2002). 
 
1.3.1 Cellular senescence 
In 1961, Leonard Hayflick and Paul Moorhead discovered that human cells 
derived from embryonic tissues can only divide a finite number of times when cultured 
(Hayflick and Moorhead, 1961). This phenomenon is now known as replicative 
senescence. Hayflick and Moorhead worked with fibroblasts, a cell type found in 
connective tissue, but replicative senescence has been found in other cell types: 
keratinocytes, endothelial cells, lymphocytes, adrenocortical cells, vascular smooth 
muscle cells, chondrocytes, etc.  
Senescence is now understood to be the final phenotypic state adopted by a cell in 
response to several distinct cell physiological processes. A variety of cell physiological 
stimuli can provoke a cell to enter senescence, telomere uncapping, DNA damage, 
oxidative stress, oncogenic activation, improper cell contacts, and lack of growth 
stimulating factors (Figure 1.3). 
Senescent cells have a large, flat morphology, senescence associated β-
galactosidase (SABG) activity, cease to proliferate. Even though, different stimuli result 
similar phenotype in senescent cells, they use distinct but not mutually exclusive 
effectors of senescence. For example, the replicative senescence is accompanied by 
telomere shortening, but stress-induced senescence caused by ectopic expression of the 
Ras oncoprotein is not accompanied by telomere shortening. 
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Figure 1.3: Cell physiological stimuli provoking a cell to enter senescence. (Ben-Porath I. and Weinberg 
RA., 2005) 
 
1.3.2 Replicative senescence and telomere shortening 
Telomeres are specialized nucleoprotein structures at the end of eukaryotic 
chromosomes (Blackburn EH., 1991). They serve as protective caps to distinguish the 
natural ends from random breaks, preventing the activation of DNA repair mechanisms 
and the resultant chromosome fusions (de Lange T., 2004). Expression of telomerase 
reverse transcriptase (TERT) is not detected in most human cell types (Ducrest AL. et al., 
2002). This ensures that tumor suppression, by the telomere counting mechanism, is 
adequately enforced in the soma. However telomere erosion is counter-balanced by the 
de novo synthesis of telomeric repeats in germline cells, some stem cells, and most tumor 
cells. In other words, chromosome ends are stabilized by telomerase, a specialized 
reverse transcriptase that adds telomeric repeats (TTAGGG) to these ends in these cells. 
The main components of this telomerase complex are a reverse transcriptase (hTERT, 
human telomerase) and an integral RNA component (hTR). On the other had, 
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noncanonical functions of hTERT have also been described. To name a few, Sharma GG. 
et al. suggested that hTERT associates with human telomeres and enhances genomic 
stability and DNA repair (Sharma GG. et al., 2003). It has been recently shown that 
hTERT has a novel role in the modulation of cyclin D1 expression (Jagadeesh S. and 
Banerjee PP., 2006). Telomerase activity is not the sole means by which telomere 
maintenance may be achieved in human cells. An alternative to the telomerase-dependent 
lengthening of telomeres was discovered when it was observed that telomeres elongated 
in the absence of detectable telomerase (Bryan TM. et al., 1995). The mechanism of 
alternative lengthening of telomeres (ALT) resembles homologous recombination and 
requires many protein factors, such as Rad50, MRE11 and NBS1 (Bechter OE. et al., 
2003; Jiang WQ. et al., 2005). 
With each round of cell division and DNA replication, loss of telomeric DNA via 
the end replication problem limits the proliferative capacity of primary cells in vitro at the 
stage of cellular senescence (Harley CB. et al., 1990; Yu GL. et al., 1990; Wright WE. 
and Shay JW., 1992).  Cells in culture display progressively shorter telomeres as the cells 
approach replicative senescence (Harley CB. et al., 1990), and cells collected from older 
organisms, which have presumably undergone more cell divisions in vivo, display both 
shorter replicative lifespans in culture and shorter telomeric DNA (Hastie ND. et al. 
1990). Ectopic expression of hTERT, the catalytic subunit of telomerase, restores 
telomere length in fibroblasts and results in immortalization of primary human fibroblasts 
(Bodnar AG. et al., 1998).  However, the ectopic expression of hTERT in keratinocytes, 
mammary epithelial cells, and other cell types restores telomerase enzymatic function and 
telomere lengths but still does not allow these cells to bypass senescence (Kiyono T. et 
al., 1998; Dickson MA. et al. 2000). These data suggest that in certain cell types, even 
when shortened telomeres are restored by the ectopic expression of hTERT, additional 
signals activate or enforce the senescence program (Lundberg AS. et al., 2000).  
 
1.3.3  The p53 and p16 pathways in replicative senescence 
Replicative senescence (permanent growth arrest also called M1 stage) is believed 
to be initiated by a DNA damage-type signal generated by critically shortened telomeres, 
or by the loss of telomere integrity, leading to the activation of cell cycle checkpoint 
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pathways involving p53, p16INK4a and/or retinoblastoma (pRb) proteins (Campisi J., 
2005; Dimri GP., 2005). In the absence of functional p53 and/or p16INK4a /pRb pathway 
responses telomeres continue to shorten resulting in crisis (also called M2 stage). Cells 
that bypass the M2 stage by reactivating hTERT expression gain the ability for indefinite 
cell proliferation, also called immortality. (Ben-Porath, I. and Weinberg, RA., 2004; 
Campisi J., 2005; Shay JW. and Wright WE., 2005). There is accumulating evidence that 
cancer cells undergo a similar process during carcinogenesis to acquire immortality.  
Telomerase activity associated with hTERT re-expression is observed in ~80% of human 
tumors (Shay JW. and Bacchetti S., 1997), and senescence controlling p53 and p16INK4a 
genes are commonly inactivated in the majority of human cancers (Sherr CJ. and 
McCormick F., 2002). Moreover, experimental transformation of normal human cells to 
tumor cells requires hTERT-mediated immortalization, as well as inactivation of p53 and 
pRb genes (Boehm JS. and Hahn WC., 2005).  Another signal implicated in replicative 
senescence is p21cip1 (Noda A. et al., 1994). p21cip1 has since been well characterized as a 
downstream effector of p53-mediated growth arrest following DNA damage. Although 
p53 mediates growth arrest in senescence, the involvement of its p21cip1 effector remains 
unclear (Bond JA. et al., 1995; Pantoja C. and Serrano M., 1999). 
The aberrant expression of hTERT, together with the loss of p53 and p16INK4a/pRB 
control mechanisms suggests that the replicative immortality is a permanent and 
irreversible characteristics of cancer cells. Although some cancer cells may react to some 
extrinsic factors by a senescence-like stress response, this response is immediate, 
telomere-independent and can not be qualified as replicative senescence (Roninson IB. 
2003). Experimental inactivation of telomerase activity in cancer cells mostly results in 
cell death (Shay JW. and Roninson IB., 2004), whereas ectopic expression of p53, 
p16INK4a, or pRb provocate an immediate senescence-like growth arrest, rather than 
replicative senescence programming (Roninson IB., 2003). Thus, do date there is no 
experimental evidence for spontaneous reprogramming of replicative senescence in 
immortalized cancer cells.  
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1.3.4  SIP1 and telomerase 
The SIP1 gene (Zinc finger homeobox 1B; ZFHX1B) encodes a transcriptional 
repressor protein that interacts with SMAD proteins of the TGF-β signalling pathway and 
CtBP co-repressor (Verschueren K. et al., 1999; Postigo AA. et al., 2003). The SIP1 gene 
is expressed at high levels in almost all human somatic tissues tested, including liver 
(Cacheux V. et al., 2001). Although the SIP1, as a repressor of E-cadherin promoter, has 
been suggested to be a promoter of invasion in malignant epithelial tumors (Comijn J. et 
al., 2001), this gene has recently been implicated in TGF-β-dependent regulation of 
hTERT expression in breast cancer cells (Lin SY. and Elledge SJ., 2003).  
 
1.4 Genetics of HCC 
 Cancer proceeds through the accumulation of mutations in genes that govern cell 
proliferation and death. The long latency period of tumor development indicates at least 
five different genetic events may be required to reach the fully malignant phenotype 
(Fearon, ER. and Vogelstein B., 1990). It is believed that hepatocarcinogenesis also 
shares this common molecular pathogenesis as well as common biological features. The 
genetic (Table 1.1) and epigenetic alterations generally result in disruption of p53, Wnt or 
Rb-p16 pathways in HCC.  
 
gene mutation % references 
p53 28-50% 
Oda T..et al., 1992; 
Puisieux A. and Ozturk M., 
1997 
M6P/IGF2R 25-55% De Souza AT. et al., 1995; Yamada T. et al., 1997 
β-catenin 18-41% Nhieu JT. et al., 1999 ; Terris B. et al., 1999 
p16 10% Liew  CT. et al., 1999 
Axin1&Axin2 5-10% Taniguchi  K. et al., 2002 
Smad2&Smad4 3-6% Yakicier MC. et al., 1999 
BRCA2 5% Katagiri T. et al., 1996 
Rb rare Zhang X. et al., 1994 
Ras rare Shen HM. and Ong CN., 1996 
Table 1.1: Mutations in tumor suppressor genes and oncogenes in HCC. 
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1.4.1  Allelic imbalance and microsatellite instability 
Conventional cytogenetic methods were first used for genetic analysis of 
hepatoma cell lines and primary liver tumors, and they revealed that most HCCs are 
aneuploid and harbor multiple different chromosomal abnormalities, with recurrent 
deletions of the short arm of chromosome 1 (Simon D. et al., 1991). By comparative 
genomic hybridization, chromosomes 1q, 8q, and 17q show gene dose increase while 
chromosomes 1p, 4q, 8p, 9p, 13q, 16p, 16q, and 17p show gene dose loss. Frequent LOH, 
or more comprehensive, allelic imbalance (AI), is consistently observed on chromosomes 
1p, 4q, 6p, 8p, 13q, 16q, and 17p by whole-genome allelotyping (Tannapfel A. and 
Wittekind C., 2002). The chromosome regions with gene dose increase may contain 
critical oncogenes while those with gene dose loss may contain tumor-suppressor genes. 
For chromosomes 17p, 13q, 9p, 6q, and 16p, LOH could be related to p53, 
Retinoblastoma 1(RB1), p16, Insulin-like Growth Factor2 Receptor (IGF2R) inactivation 
(Feitelson MA. et al., 2002). In dysplastic nodules LOH has been observed with a 
prevalence of about 50% and 80%, respectively (Thorgeirsson SS. and Grisham JW., 
2002). Microsatellite instability is associated with a mutator phenotype at the nucleotide 
level; it is caused by defects in the DNA mismatch repair genes MSH2 and MLH1 located 
on chromosomes 2 and 3 (Lengauer C. et al., 1998). In HCC, however, these 
chromosomal regions are not frequently affected by allelic losses, and microsatellite 
instability has not been detected by microsatellite marker analysis. But mutations in a 
mismatch repair gene know as Human Mut S homolog-2 (hMSH2) has been reported at 
about 30% of HCCs examined (Yano M. et al., 1999). Furthermore, very few mutations 
have been detected in the mononucleotide repeats in Bax, IGF-IIR, or MLH genes in 
HCC (Kondo Y. et al., 1999; Salvucci M. et al., 1999). 
 
1.4.2 Cell cycle regulation 
Cells respond to proliferative or anti-proliferative signals through the cyclinD1-
Rb-Cdk 4/6 pathway or the p53-p14ARF pathway. As cells enter the cycle from 
quiescence (G0), one or more D-type induced in response to mitogenic signals. These 
cyclins associate with either Cdk 4 or Cdk 6 subunits and the complex becomes activated 
by phosphorylation. Active cyclin/CDK complexes drive the cell cycle forward via 
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phosphorylation of substrates such as Rb in late G1 phase (Weinberg RA., 1995). Rb is 
thereby inactivated, and its growth repressive functions abolished, resulting in release of 
a class of associated transcription factors known as E2Fs. Then “free” E2F transactivates 
cyclin E gene and promote DNA synthesis necessary cell cycle progression. According to 
this, loss of Rb or its aberrant phosphorylation leads to a loss of growth control at the G1 
phase. To maintain Rb protein in its active, anti-proliferative state, p16INK4a inhibit the 
activity of Cdk 4 by specifically binding thus preventing its association with cyclin D 
and/or blocking the catalytic activity of kinase (Hirai H. et al., 1995). The p14ARF tumor 
suppressor, encoded by an alternative reading frame of the INK4a-ARF locus (9q21), 
senses "mitogenic current" flowing through the Rb pathway and is induced by abnormal 
growth promoting signals. By antagonizing Mdm2, a negative regulator of the p53 tumor 
suppressor, ARF triggers a p53-dependent transcriptional response that diverts incipient 
cancer cells to undergo growth arrest or apoptosis. Although ARF is not directly activated 
by signals that damage DNA, its loss not only dampens the p53 response to abnormal 
mitogenic signals but also renders tumor cells resistant to treatment by cytotoxic drugs 
and irradiation.  
Taken together, disturbances in the p16-cyclin D-Cdk 4-Rb and p14-Mdm2-p53 
pathways could be a main axis of genetic events in HCC because all "players" in these 
pathways seem to be altered in HCC. The Rb gene, one of the main players, is localized 
to chromosome 13q, which is a common deletion site for HCC and Rb mutations are 
also observed at 15% of HCCs (Ozturk M., 1999). Moreover, Rb protein is a target 
for ubiquitin dependent degradation and the degradation mechanism was shown to be 
dysregulated in HCCs by overexpression of a pRb specific ubiquitin ligase, gankyrin 
(Higashitsuji H. et al., 2000). Additionally, overexpression of cyclin D has been 
observed in about 10-13% of HCC cases (Ozturk M., 1999). It has recently been shown 
in a transgene mouse model that overexpression of cyclin D1 is sufficient to initiate 
hepatocellular carcinogenesis (Deane NG. et al., 2001). The transduction of antisense 
cyclin D1 inhibits tumor growth in a xenograft hepatoma model. Correcting alterations 
that have occurred in the G1 phase regulatory machinery may therefore provide a novel 
weapon to treat and prevent HCC (Deane NG. et al., 2001). Also, it was reported that 
about 50% of HCC display de novo methylation of INK4a-ARF locus that encodes 
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p16INK4 and p14ARF and LOH at the same locus with 20 % (Ozturk M. 1999; Liew CT. et 
al., 1999). 
 
1.4.3 Alterations of the TGF-β /IGF-axis 
Transforming growth factor-β (TGF-β) is a cytokine with pleiotropic activity, and 
is released in an inactive form. To exhibit its biological activity, it requires binding to 
extracellular matrix proteins and, after that, proteolytic elimination of latent associated 
protein (LAP) and latent TGF- β Binding Protein (LTBP). Active TGF-β is a 
homodimeric 25kDa protein. TGF-β initiates signaling through heteromeric complexes of 
transmembrane type I and type II serine/threonine kinase receptors. Activated TGF-β 
receptors phosphorylate receptor-regulated Smads which induces both inhibition and 
apoptosis in hepatocytes. Genetic alterations of the TGF-β pathway are mediated by 
mutations of the Smad2 and Smad4 gene, which occur in about 10% of HCC cases 
(Yakicier CM. et al., 1999). Mutations of the TGF-β receptor (TGF-β1RII) gene itself are 
detected in patients with HCC and may also abrogate TGF-β signaling (Enomoto A. et 
al., 2001). It has been suggested that Smad7, expressed in tumor cells, is considered to be 
one of resistance mechanisms to increased TGF-β1 in late stage hepatocarcinogenesis, 
especially in advanced HCCs without reduced TGF-beta receptor II. Smad4, in stellate 
cells of HCCs, might be involved in the host resistance to hepatocarcinogenesis (Park 
YN. et al., 2004). 
A potent activator of TGF-β is the mannose-6-phosphate/insulin-like growth 
factor 2 receptor (M6P/IGF2R) which suppresses cell growth through binding to the 
insulin-like growth factor (IGF) 2 and latent complex of TGF-β. The deregulation of the 
IGF axis, including the autocrine production of IGFs, IGF binding proteins (IGFBPs), 
IGFBP proteases, and the expression of the IGF receptors, has also been identified in the 
development of HCC. Also, both LOH and mutations of the M6P/IGF2R have been 
reported in about 30% HCC patients (Oka Y. et al., 2002; Piao Z. et al., 1997, De Souza 
AT. et al., 1995).          
PTEN/MMAC1/TEP1 (PTEN) tumor suppressor gene was shown to block growth-
stimulatory and survival signals mediated by PI-3 kinase and converging on the 
activation of protein kinase B/Akt. Alterations, mainly mutations but also LOH, of PTEN 
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have been reported in about 27% of HCC cases (Kawamura N. et al., 1999). Recently it 
has been shown that PTEN expression is down-regulated in HCC cell lines probably due 
to loss of activity of PTEN promoter (Ma DZ. et al., 2005). 
 
1.4.4  Wnt signaling 
Aberrant Wnt/β-catenin (canonical Wnt) signaling has been found in 30%–40% 
of human hepatocellular carcinomas (de La Coste A. et al., 1998; Giles RH. et al., 2003).  
Axin, an important regulator of β-catenin, is mutated in about 10% of HCC cases, 
leading to an activation of the Wnt pathway. However, mutations in the axin gene have 
until now been identified only in HCC that lack mutations in the β-catenin gene  It was 
shown that transduction of the wild-type axin gene (AXIN1) induces apoptosis in HCC 
cells, indicating that axin 1 may be an effective growth suppressor of hepatocytes (Satoh 
S. et al., 2000). 
Somatic APC mutations are rare events in HCC, but it was reported that biallelic 
inactivation of the APC gene contributed to the development of HCC in a patient with 
familial adenomatous polyposis (FAP) and a known germline mutation of the APC gene 
at codon 208 (Su LK. et al., 2001).  E-cadherin, a compenet of adherens junctions, which 
is essential both for maintenance of tissue structure and regulation of free cytoplasmic β-
catenin level, is rarely mutated in HCC. However, loss of function of E-cadherin due to 
LOH or de novo methylation occurs in about 30% of HCC cases (Slagle BL. et al., 1993). 
 
1.4.4.1 Wnt signaling pathways 
          Wnt proteins constitute a large family of cysteine rich secreted ligands that regulate 
cell growth, motility, and differentiation during embryonic development. Wnts act in a 
paracrine fashion by activating at least three diverse signaling cascades inside the target 
cells (Figure 1.4). 
1)  The canonical Wnt pathway (Wnt/β-catenin signaling): The ‘‘classical’’, also called 
canonical, Wnt pathway activates target genes through stabilization of β-catenin and 
relocalization in the nucleus. The function of this pathway during embryonic 
development has been originally elucidated by experimental analysis of axis development 
in the frog Xenopus laevis and of segment polarity and wing development in the fly 
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Drosophila melanogaster. The abnormalities of this pathway lead to several human 
diseases, including tumor formation and bone abnormalities. 
2) The planar cell polarity pathway: This pathway involves RhoA and Jun Kinase (JNK) 
and controls cytoskeletal rearrangements. Its main role is the temporal and spatial control 
of embryonic development, as exemplified in the polar arrangement of cuticular hairs in 
Drosophila or the convergent-extension movements in Xenopus embryos. On a cellular 
level, this pathway regulates the polarity of cells through effects on their cytoskeletal 
organization. To date, there is no evidence for the involvement of the planar cell polarity 
pathway in tumor development (Veeman MT. et al., 2003; Nelson WJ. and Nusse R., 
2004; Bejsovec A., 2005). 
 
 
Figure 1.4: Wnt signaling pathways (Kikuchi A. et al., 2006). Wnts act in a paracrine fashion by 
activating at least the diverse signaling cascades inside the target cells. The Canonical Wnt signaling 
regulates gene expression through the stabilization and translocation of β-catenin into nucleus. The Planar 
cell polarity pathway activates Dvl, small G proteins (Rho or Rac), and Rho kinase or JNK, resulting in 
regulation of the cytoskeleton, cell migration, and cell polarity. Wnt/Ca2+ pathway activates CaMK, PKC, 
TAK, and NLK, resulting in the inhibition of the β-catenin pathway and regulates gastrulation. Dvl, 
Dishevelled;  JNK, Jun N-terminal kinase; CaMK, calmodulin-dependent protein kinase. 
 
 
3) Wnt/Ca2+ pathway: This pathway is stimulated by Wnt 5a and Wnt 11 and involves an 
increase in intracellular Ca2+ and activation of Ca2+-sensitive signaling components, such 
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as calmodulin-dependent kinase, the phosphatase calcineurin, and the transcription factor 
NF-AT (Veeman MT. et al., 2003; Nelson WJ. and Nusse R., 2004; Bejsovec A., 2005). 
The Wnt/Ca2+ pathway can counteract the canonical Wnt pathway (Weidinger G. and 
Moon RT., 2003). It is not clear whether this pathway is conserved in mammals and 
whether it is implicated in tumorigenesis. 
 
1.4.4.2 Canonical Wnt signaling pathway 
 
Wnt/β-catenin signaling pathway, named also canonical Wnt pathway, refers to 
the molecular cascade initiated by a Wnt ligand and culminating in the stabilization and 
translocation of the β-catenin protein into nucleus. Wnt-1 (originally named int-1, in 
Drosophila the homologous gene is called wingless, and the combination of both names 
led to the term) was the first identified as a gene activated by integration of the LTR of 
the mouse mammary tumor virus resulting in the development of mammary tumors in 
mice (Nusse R. and Varmus HE., 1982). β-catenin is the main executer of canonical Wnt 
signaling. In the absence of Wnts, β-catenin is phosphorylated by casein kinases 1α at 
serine residue 45; this in turn enables glycogen synthase kinase 3β to phosphorylate 
serine/threonine residues 41, 37, and 33. Phosphorylation of these amino acids triggers 
ubiquitination of β-catenin by β-transduction repeat containing protein (β-TrCP) and 
degradation in proteasomes. Phosphorylation of β-catenin occurs in a multiprotein 
complex containing the scaffold protein axin and/or its homologue axin2/conductin, the 
tumor suppressor gene product APC and GSK3β. In the presence of Wnts, β-catenin can 
be stabilized by two mechanisms. According to first model, Wnt signaling triggers CKIε-
dependent phosphorylation of Dvl (Dsh in Drosophila) and enhances the binding of Dvl 
(Dsh) to Frat-1. Frat-1 binds to GSK-3β in the Axin complex, resulting in a reduction of 
the phosphorylation of β-catenin by GSK-3β. According to second model, Wnt triggers 
the phosphorylation of LRP6 by CK1γ and GSK-3β, which provides a docking site for 
Axin and recruits it to the plasma membrane. Wnt also enhances the binding of Dvl (Dsh) 
to Frizzled, and Dvl (Dsh) bound to Frizzled is necessary for the formation of a complex 
between Axin and LRP6, resulting in reduced phosphorylation of β-catenin and Axin by 
GSK-3β (Figure 1.5).  
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Figure 1.5: Wnt-dependent stabilization of β-catenin . A) Through the Dvl/Frat complex. Wnt signaling 
inhibits β-catenin phosphorylation by GKS3β through Dvl and Frat1.B) Through the Axin and LRP6 
complex. Wnt triggers the phosphorylation of LRP6 by CKγ1 and GSK3β. Axin is recruited to the plasma 
membrane, which is a component of destruction complex, leading to the inhibition of β-catenin 
phosphorylation.  
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Stabilized β-catenin translocates into the nucleus and makes complexes with TCF 
transcription factors, leading to the transcription of Wnt target genes.  
 
 
Figure 1.6: Overview of the canonical Wnt signaling pathway (Lee HC. et al, 2006). A) In the absence 
of Wnt, the cytoplasmic β-catenin is degraded in the destruction complex, consisting of APC, 
axin/conductin, and GSK-3β. First, β-catenin is phosphorylated on Ser 45 residue by CKIα (priming), 
primed β-catenin is further phosphorylated at Thr 41, Ser 37, and Ser 33 residues by GSK-3β. 
Phosphorylation of these amino acids triggers ubiquitination of β-catenin by β-TrCP and degradation in 
proteasomes. Therefore, the cytoplasmic level of β-catenin is kept low in the absence of Wnt. The 
LEF/TCFs cannot activate the target genes without β-catenin. The WIF-1, sFRP, and/or Dkk can inhibit the 
Wnt signaling by binding to Wnt ligands or LRP5/6. B) In the presence of Wnt, a) Wnt signaling triggers 
CKIε-dependent phosphorylation of Dvl (Dsh) and enhances the binding of Dvl (Dsh) to Frat-1. Frat-1 
binds to GSK-3β in the Axin complex, resulting in a reduction of the phosphorylation of β-catenin by 
GSK-3β; or b) Wnt triggers the phosphorylation of LRP6 by CK1γ and GSK3β, which provides a docking 
site for Axin and recruits it to the plasma membrane. Wnt also enhances the binding of Dvl (Dsh) to 
Frizzled, and Dvl (Dsh) bound to Frizzled is necessary for the formation of a complex between Axin and 
LRP6, resulting in reduced phosphorylation of β-catenin and Axin by GSK3β. Therefore, β-catenin escapes 
from phosphorylation and subsequent ubiquitylation, and accumulates in the cytoplasm. The accumulated 
cytoplasmic β-catenin goes into the nucleus, where it binds to LEF/TCFs and activates the transcription of 
target genes. 
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Transcriptional activation is mediated by the interaction of TCF and β-catenin 
complexes with various activators, such as the histone acetyl transferase CBP and the 
chromatin remodeling SWI/SNF complex. Additionally, legless/bcl-9 recruits the nuclear 
protein pygopus to β-catenin thereby activating the TCF and β-catenin complex. A 
variety of Wnt/β-catenin target genes have been identified which include regulators of 
cell proliferation, developmental control genes, and genes implicated in tumor 
progression (Figure 1.6). 
The canonical Wnt signaling is involved in a number of developmental processes, 
including establishment of the dorsoventral body axis (Parr BA. and McMahon AP., 
1994). β-catenin accumulates in dorsal nuclei as one of the earliest indicators of dorsal 
development in Spemann organizer of Xenopus embryo (Schneider, S. et al. 1996). Wnt 
knock-out mice revealed different phenotypes. To name few, the expansion of the CNS 
fails in Wnt1 mutants (Megason SG. and McMahon AP., 2002). Wnt3−/− mice develop a 
normal egg cylinder but do not form a primitive streak, mesoderm or node (Liu P. et al., 
1999). In adult organism it regulates tissue homeostasis, stem cells maintenance and if 
perturbed leads to several diseases including cancer. The best-known example of a 
disease involving a Wnt pathway mutation that produces tumors is familial adenomatous 
polyposis (FAP), an autosomal, dominantly inherited disease in which patients display 
hundreds or thousands of polyps in the colon and rectum. This disease is caused most 
frequently by truncations in APC (Kinzler KW. et al., 1991). To name a few more, Tetra-
amelia, a rare human genetic disorder characterized by absence of limbs, has been 
proposed to result from WNT3 loss-of-function mutations (Niemann S. et al., 2004). An 
LRP mutation has been identified that causes increased bone density at defined locations 
such as the jaw and palate (Boyden LM. et al., 2002; Little RD. et al., 2002). Mutations in 
LRP5 were correlated with decreased bone mass (Gong Y. et al., 2001). A nonsense 
mutation in Axin2 has been shown to produce severe tooth agenesis, or oligodontia, a 
condition in which multiple permanent teeth are missing (Lammi L. et al., 2004). 
Recently, mutations of Wnt10B have been linked to human obesity (Christodoulides C. et 
al., 2006). Canonical Wnt signaling has been linked to tumor development since the 
discovery of Int-1 integration site in viral carcinogenesis experiments in mice. To date, 
besides colorectal cancer and hepatocellular carcinoma which harbor the highest rate of 
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Wnt pathway gene mutations, canonical Wnt pathway abnormal reactivation has been 
linked to many other cancer types including those which do not harbor any activating 
mutation such as breast cancer.   
 
1.4.4.3 Major components of the canonical Wnt signaling pathway 
1.4.4.3.1   Wnts 
19 Wnt genes were identified in human and mouse, seven in Drosophila and five 
in C. elegans (Nusse R., 2005).Wnt molecules are palmitoylated on a conserved cysteine 
and therefore much more hydrophobic than predicted from the primary amino acid 
sequence (Willert K. et al., 2003). Wnt proteins are secreted from cells and act on target 
cells through a complex pathway, and subject to extensive feed-back control. They are 
defined by characteristic primary amino acid sequences rather then functional properties. 
They contain a signal sequence followed by a highly conserved cysteine distribution. 
Although, heparan sulfate proteoglycans have been shown to have a role in stabilizing 
Wnt protein or aiding them to move between cells, the transport mechanism of Wnt 
proteins remains to be fully characterized molecularly. It is widely accepted that the 
Frizzled (Fz) molecules are primary receptors for Wnts (Bhanot P. et al., 1996). Wnt 
signaling requires not only a functional Fz, but also the presence of a long single pass 
transmembrane molecule of the LRP (LDL receptor related protein) class, identified as 
the gene arrow in Drosophila (Wehrli M. et al.,2000) and as LRP5 or 6 in vertebrates. 
Wnt molecules can also bind to LRP and form a trimeric complex with a Frizzled. The 
cytoplasmic tail of LRP may interact directly with Axin, one of the downstream 
components in Wnt signaling (Tolwinski NS. et al., 2003). 
 
 1.4.4.3.2   Frizzleds 
Frizzleds, the primary receptors of the Wnt proteins, are seven-transmembrane 
receptors with a long N-terminal extension called a cysteine-rich domain (CRD). The 
human genome has ten different frizzleds genes: Frizzled-1 to -10. All frizzled proteins 
contain a conserved extracellular CRD followed by seven transmembrane segments. 
Contrarily, their C-terminal cytoplasmic regions differ significantly in length and in 
sequence. As transmembrane receptor, frizzled proteins engage in multiple interactions 
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with different partners in the extracellular and intracellular milieu. Similarly to Wnt 
ligands, frizzled receptors have been shown to activate distinct Wnt signaling pathways 
and can be loosely classified accordingly. In Xenopus, Frizzled-3, -4, and –7, have been 
shown to activate Wnt/β-catenin pathway  while  human Frizzled-6 and rat Frizzled-2 
have been shown to inhibit it (Umbhauer M. et al., 2000). The mechanism of action of 
frizzled signaling is not fully elucidated. However, heptahelical structure of frizzled 
molecules suggests that they are able to signal through heterotrimeric G proteins. 
Disheveled (Dsh, Dvl) is a candidate molecule that may directly interact with Frizzleds 
and, known to be required for Wnt signaling (Chen W.  et al., 2003; Wong HC. et al., 
2003). Wnt signaling leads to differential phosphorylation of Dsh. A conserved motif 
(Lys-Thr-X-X-X-Trp) located two amino acids after the seventh transmembrane domain 
of frizzleds was shown to be engaged in the frizzled/dishevelled interaction and required 
for Wnt/β-catenin activation via mediating Disheveled relocalization and phosphorylation 
(Umbhauer M. et al., 2000). The co-receptor, LRP, may also contact a cytoplasmic 
component of the pathway, as it has been reported that Axin can interact with the 
cytoplasmic tail of LRP (Tolwinski NS. et al., 2003). It has been suggested that Wnt 
signaling can lead to the formation of a complex including the two receptors, plus Axin 
and Dsh. Direct interactions between Axin and Dsh can be the first step in reconfiguring 
the destruction complex containing (Nusse R., 2005). 
  
1.4.4.3.3 LRP/Arrow co-receptors 
In addition to frizzleds, the canonical Wnt signaling pathway also requires single-
span transmembrane proteins that belong to a subfamily of low-density-lipoprotein 
(LDL) receptor related proteins (LRPs): vertebrate Lrp5 and Lrp6, and their Drosophila 
ortholog Arrow. Human LRP5 was isolated through its homology to LDLR (Hey P. et al., 
1998). Human LRP6 was identified by its homology to LRP5 (Brown SD. et al., 1998). 
LRP5 and LRP6 share 73% and 64% identity in extracellular and intracellular domains, 
respectively. The concrete evidence of LRP role for canonical Wnt signaling comes from 
several experiments. A mutant Lrp6 protein lacking the intracellular domain is 
completely inactive, and in fact blocks Wnt and Fz signaling in a dominant-negative 
fashion (Tamai K. et al., 2000). Additionally, mutant Lrp6 protein that lacks the 
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extracellular domain but is anchored on the membrane activates the canonical Wnt 
signaling constitutively in mammalian cells (Liu G. et al., 2003) and in Xenopus embryos 
(Tamai K. et al., 2004). 
1.4.4.3.4 Extracellular inhibitors 
In the extracellular milieu, Wnt signaling can be inhibited by two groups of 
inhibitory factors. The first group composed of secreted frizzled-related proteins (sFRPs), 
Wnt-inhibitory factor-1 (WIF-1), Cerberus and Coco can sequester Wnt ligand and 
prevent its interaction with the receptors.  In human, sFRP family consists of five 
members. They contain a cysteine-rich domain (CRD), which shares 30-50 % sequence 
homology with the CRD of Frizzled receptors (Melkonyan HS. et al., 1997). WIF-1 
contains a unique conserved WIF domain and five EGF–like repeats. Cerberus and Coco 
are related proteins interacting with a variety of growth factors including Wnt ligands and 
bone morphogenetic protein (BMP) to inhibit the signaling of the respective pathways in 
Xenopus.   The inhibitory effect of Cerberus and Coco mammalian orthologs on Wnt 
signaling has not yet been proved. The second group inhibits Wnt signaling by binding to 
LRP5 and LRP6. In human three members of the Dickkopf (Dkk) family (Dkk-1, -2 and 
–4) were found. The inhibitory effect of Dkk-2 and Dkk-4 proteins requires the 
participation of Kremen2 to form a tertiary complex with LRP co-receptor that will lead 
to the internalization of LRP and make it unavailable for Wnt reception (Mao BY. et al., 
2003). 
1.4.4.3.5 Dishevelled  
Dishevelled is an essential component for the canonical Wnt signaling as well as 
for the Drosophila PCP pathways. In mammals, there are three homologs of the 
Drosophila Dishevelled, named Dishevelled-1, -2 and –3. Dishevelled protein is 
composed of three conserved domains, an N-terminal DIX domain, a central PDZ domain 
and a C-terminal DEP domain. Mutations in the DEP domain affect the PCP pathway, 
whereas mutations in the DIX domain affect cell-fate signaling (Penton A. et al., 2002). 
Although the mechanism by which Dishevelled transduces the Wnt signal remains 
debatable, some mechanisms have been suggested.  1) Upon Wnt signaling, Dishevelled 
can interact with the C-terminal cytoplasmic tail of Frizzled and gets phosphorylated 
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most likely by the Wnt –regulated protein kinase Par-1 (Sun TQ. et. al., 2001).  2) Wnt 
stimulation of mammalian cells induces the Lrp5-Axin association within minutes (Mao 
J. et al., 2001), Importantly, Axin preferentially binds to the phosphorylated PPPSP motif 
of Lrp6, whose phosphorylation is rapidly induced by Wnt (Tamai K. et al., 2004). 
Therefore, it was  proposed that Wnt activates Lrp6 signaling by inducing Lrp6 
phosphorylation at the PPP(S/T)P motifs, which serve as inducible docking sites for 
Axin, thereby recruiting Axin to the plasma membrane (He X. et al, 2004). 3) It was 
proposed that Wnt binding to frizzled and LRP could promote a direct interaction 
between Axin and Dishevelled through their DIX domains to dissociate the protein 
complex that regulate β-catenin degradation (Logan CY. and Nusse R., 2004). 
1.4.4.3.6 Axin 
Axin-1 is an inhibitor of the canonical Wnt signaling pathway acting as a 
scaffolding protein. Axin has specific binding sites for β-catenin, GSK3β, CKIα, APC, 
Dvl, LRP, and protein phosphatase 2A (PP2A). Its main function is to bring together β-
catenin and the protein kinases CKIα and GSK3β, thus promoting the phosphorylation 
and consequent destruction of β-catenin. Upon Wnt signaling, this function is overcome, 
allowing β-catenin to accumulate and enter the nucleus. The major product of the Axin 
gene is a protein of 832 or 868 amino acids (depending on alternative splicing) containing 
two highly conserved domains: 1) RGS domain, encompasses the binding site for APC. 
2) DIX domain, a region of homology with Dvl proteins that is implicated in the binding 
of Axin to Dvl as well as in homodimerization. 
Axin-2 (also known as Conductin) is 44% identical to Axin and shares the RGS 
and DIX domains as well as the binding sites for β-catenin, GSK3β, Diversin, and 
Smad3. While Axin2 has been studied less extensively than Axin, most data suggest that 
they are similar in function. 
The function of Axin as an inhibitor of canonical Wnt signaling has been 
confirmed through different approaches. Axin mRNA injection into frog embryos 
inhibited dorsal axis formation (Zeng L. et al., 1997). Furthermore, truncating mutations 
of Axin-1 leads to the nuclear accumulation of β-catenin in hepatocellular carcinomas 
and the adenoviral transfer of wild-type Axin-1 into these cell or HepG2 cells decreased 
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the nuclear accumulation of β-catenin and lowered TCF/LEF mediated transcriptional 
activity (Satoh S. et al., 2000). Additionally, Axin-1 loss of function has been found in 8-
10% of HCCs (Satoh S. et al., 2000; Taniguchi K. et al., 2002), in 7% of 
hepatoblastomas. Axin-2 mutations are rare in human cancer and have been found only in 
3% of HCC (Taniguchi K. et al., 2002).  
 
1.4.4.3.7 APC  
Activating mutations of the Wnt pathway are the only known genetic alterations 
present in early pre-malignant lesions in the intestine (Powell SM. et al., 1992). APC is a 
negative regulator of the canonical Wnt signaling and mutated up to 85% of all sporadic 
CRCs. The vast majority of these mutations, which are insertions, deletions or non-sense 
mutations, lead to frame-shifts or premature stop codons in the APC transcript and non-
functional APC protein (Giles RH. et al., 2003). APC bind to β-catenin and promotes its 
degradation. Three different structural motifs in APC are responsible for its β-catenin-
regulating function: three 15-amino acid repeats binding β-catenin and plakoglobin, 
seven 20-amino acid repeats involved with both binding and down-regulating these 
proteins, and three so-called SAMP repeats facilitating axin and conductin binding. 
Additionally, APC can capture and escort nuclear β-catenin to the cytoplasmic 
destruction machinery (Neufeld KL. et al., 2000). A paralogue of APC termed APC2 or 
APCL was identified in humans and mouse. APC2 can bind h-catenin and regulate its 
concentrations as efficiently as APC (van Es JH. et al., 1999; Nakagawa H. et al., 1998). 
 
1.4.4.3.8 GSK3β 
The serine/threonine kinase GSK3β is an integral component and negative 
regulator of Wnt signaling. An alternative spliced form has been described (Mukai F. et 
al., 2002). GSK3β activity is significantly reduced by phosphorylation of Ser9, and 
facilitated by phosphorylation of Tyr216. In the absence of Wnt signaling, the GSK3β 
phosphorylates primed β-catenin (phosphorylated β-catenin at Ser45 by Casein Kinase I) 
at Thr41 and, subsequently, at Ser37 and Ser33, which triggers the degradation of β-
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catenin). The down-regulatory nature of GSK-3β  is qualified as putative tumor 
suppressor. However, GSK-3β mutations were not found in cancers. 
 
1.4.4.3.9 Protein phosphatase 2A 
Protein phosphatase 2A (PP2A) is a serine-threonine phosphatase. Its catalytic 
subunit binds to the C terminal domain of axin which suggested that PP2A interacts with 
the APC-β-catenin-axin-GSK3β complex. PP2A antagonize the phosphorylation of β-
catenin from GSK3β by dephosphorylation of β-catenin (Hsu W. et al., 1999). However, 
overexpressing a regulatory subunit of PP2A (B56), which binds to the amino-terminal 
third of APC, reduces the amount and signaling of β-catenin. This suggests that PP2A 
may dephosphorylate GSK3β thereby increasing its activity, which in turn increases the 
phosphorylation of β- catenin and its subsequent degradation (Seeling JM. et al., 1999).  
 
1.4.4.3.10 β−catenin 
The β-catenin is 92 kDa multifunctional protein, and initially identified as a 
component of adherens junctions (AJs) (Ozawa M. et al., 1989; McCrea PD. et al., 1991). 
There, β-catenin links cadherin adhesion receptors to α-catenin, which in turn links to the 
cytoskeleton. This adhesion function is based on a membrane associated and stable form 
of β-catenin (Figure 1.7).  
 
Figure 1.7: β-catenin in adherens junctions. E-cadherin dimers interact in a zipper-like fashion in 
adherens junctions. E-cadherin cytoplasmic tail interacts with β-catenin armadillo repeats, α-catenin 
interacts with the amino-terminal domain of β-catenin and with actin cytoskeleton. Phosphorylation of 
tyrosine-654, for instance by c-src, leads to loss of E-cadherin-binding. The tyrosine kinases Fer, Fyn or 
Met can induce phosphorylation of tyrosine-142 of  β-catenin. This induces loss of binding to α-catenin 
and promotes the interaction with the nuclear co-factor BCL9-2 
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Variable level of free β-catenin is found in the cytoplasm and occasionally in the 
nuclei depending on the cell type indicating the presence of a second function of β-
catenin related with gene transcriptional regulation. Contrarily to the stable membrane 
bound form, the cytoplasmic β-catenin is unstable and continuously degraded by the 
proteasomal machinery in most of the normal cells of an adult organism. Free β-catenin 
functions as an essential component of the canonical Wnt signaling pathway. The 
primary structure of the β-catenin protein reveals that it contains a 130 amino acid amino-
terminal domain, an armadillo domain composed of 12 imperfect repeats of 42 amino 
acids (arm repeats), and a carboxy-terminal domain of 100 amino acids.  Several proteins 
bind to β-catenin through the central region (arm repeats) and this positively-charged 
groove may serve as a binding motif including TCF/LEF, APC and adherent junction 
protein E-cadherin. 
Even though, β-catenin has no DNA−binding domain or activity was identified, 
the carboxyl terminal domain functions as a transcriptional activator when fused to the 
GAL4 DNA-binding domain (van de Wetering M. et al., 1997). It uses the DNA binding 
propriety of the LEF/TCF family of transcription factors to transactivate its target genes 
expression. The amino terminus of β-catenin is known to be important for regulating the 
stability of β-catenin. This region of β-catenin, also called destruction box, contains a 
series of serine and threonine residues, which may be phosphorylated. Phosphorylation of 
serine/threonine residues at positions 29, 33, 37, 41 and 45 by CKIα and GSK-3β in 
complex with Axin and APC appears to be a prerequisite for ubiquitination. 
Phosphorylated β-catenin is then recognized by the β-transduction repeat containing 
protein (β-TrCP) of the E3 ubiquitin ligase complex and led to the proteasomal 
degradation system (Ilyas, M. 2005). Although, GSK-3β-mediated degradation of β-
catenin is the main mechanism that controls its cytoplasmic low level, another GSK-3β-
independent mechanism has been shown to promote β-catenin degradation. In the Siah-1-
dependent pathway, Siah-1 interacts with the carboxyl terminus of APC, recruits the 
ubiquitination complex, and promotes the degradation of β-catenin through a pathway 
independent of both GSK-3β and β-TrCP, an F-box protein in the E3 ubiquitin ligase 
complex (Liu J. et al., 2001) (Figure 1.8). 
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The β-catenin is frequently mutated in many types of cancer. Most of these mutations 
affects in the destruction box, encoded by the exon3 of the CTNNB1 gene, on the GSK-
3β phosphorylation target residues. In frame-deletions covering this region are seen as 
well in hepatoblastomas. These mutations renders β-catenin resistant to proteasomal 
degradation. Stabilized β-catenin translocates to the nucleus, cooperate with the 
LEF/TCF family of transcription factors to exercise transcriptional activation of target 
genes depending on the cell type and context.  
 
 
 
Figure 1.8: Primary β-catenin structure and protein interactions. CBP (P300), Histone acetylase.  Brg-
1, a component of mammalian SWI/SNF and Rsc chromatin-remodelling complexes. E-cad, E-cadherin. 
ICAT,  inhibitor of b-catenin and T cell factor. Tsh, Teashirt. Chi, Chibby. Arm, armadillo repeat. 
 
 
1.4.4.3.11 T-Cell Factor/Lymphocyte enhancer binding factor (TCF/LEF) family of 
transcriptional factors and other components in nucleus 
Although LEF/TCFs bind directly to DNA through their HMG-domains, they are 
incapable of activating gene transcription (Roose J. and Clevers H. 1999). HMG-domain 
proteins appear to have intrinsic ability to either activate or repress transcription of target 
gene, a decision that may be regulated by interaction with β-catenin (Brannon M. et al., 
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1997). So far, TCF-1, LEF-1, TCF3 and TCF4 were identified as family members 
involved in Wnt signaling. All members of the TCF family can bind β-catenin through a 
conserved N-terminal stretch of 55 amino acids. β-catenin thus functions as a classical 
co-activator of transcription (Molenaar M. et al., 1996; Korinek V. et al., 1998; Duval A.  
et al., 2000).  TCF/LEF mRNAs undergo extensive alternative splicing. Alternative 
promoter usage in the TCF-and LEF-1 gene generates protein isoforms that either carry 
or lack the N-terminal β-catenin interaction domain. The TCFs mutations do not directly 
contribute to cancer progression but can act in additive manner. Regarding this 
suggestion, it has been shown that TCF-4 was mutated in a subset of colorectal tumors 
(Brannon M. et al., 1997), and also transgenic mice homozygous for mutations in TCF-1 
developed adenomatous intestinal polyps (Roose J. et al., 1999). 
In the absence of the Wnt signal, TCF acts as a repressor of the canonical Wnt signaling 
target genes (Brannon M.  et al., 1997) by forming a complex with Groucho (Cavallo R. 
et al., 1998). The repressing effect of Groucho is mediated by interactions with histone 
deacetylases (HDAC), which are thought to make DNA refractive to transcriptional 
activation (Chen G. et al., 1999). In the nucleus, β-catenin converts the TCF repressor 
complex into a transcriptional activator complex by displacing Groucho from TCF/LEF 
and recruiting the histone acetylase CBP/p300 (cyclic AMP response element-binding 
protein). CBP may bind to the β-catenin/TCF complex as a coactivator (Hecht A. et al., 
2000; Takemaru KI. and Moon RT., 2000). Another activator, Brg-1, is a component of 
the SWI/SNF (switching-defective and sucrose nonfermenting) chromatin remodeling 
complex which, with CBP, may induce chromatin remodeling that favors target gene 
transcription (Barker N. et al., 2001). Further interactions between the TCF-β-catenin 
complex and chromatin could be mediated by Legless (Bcl9) and Pygopos (Kramps T. et 
al., 2002; Parker DS. et al., 2002, Thompson B. et al., 2002). Mutations in either of these 
genes result in wingless-like phenotypes in Drosophila, and both genes promote Wnt 
signaling in mammalian cell culture experiments (Thompson B. et al., 2002). Wnt 
signaling in the nucleus are controlled by a number of protein partners. For example, the 
protein Chibby is a nuclear antagonist that binds to the C terminus of β-catenin 
(Takemaru K. et al., 2003). Another β-catenin-binding protein, ICAT (Tago K. et al., 
2000), not only blocks the binding of β-catenin to TCF (Tago K. et al., 2000) but also 
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leads to dissociation of complexes between β-catenin, LEF, and CBP/p300 (Daniels DL. 
and Weis WI., 2002; Graham TA. et al., 2002). Additionally, it was shown that β-catenin 
can interact with other binding partners in the nucleus, such as Pitx2. β-catenin can 
convert Pitx2 from a transcriptional repressor into an activator (Kioussi C. et al., 2002), 
similar to its interaction with LEF1/TCF.  
 
1.4.4.4 On/Off states of the canonical Wnt signaling pathway 
1.4.4.4.1 Off state 
 
When there is no canonical Wnt signaling, the inhibitory mechanisms act to 
ensure that β-catenin protein membrane unbound β-catenin levels stay below the 
threshold. β-catenin is constitutively produced and degraded to keep low level 
monomeric protein pool in the cytoplasm.  The main mechanism for controlling 
cytoplasmic β-catenin level is through ubiqitin dependent proteolysis in a large multi-
protein complex. Axin1, the central scaffold of this complex, provides binding sites for β-
catenin, APC, GSK3β, CKIα, and PP2A. The complex is stabilized by GSK3β-mediated 
phosphorylation of Axin and APC (Seeling JM. et al., 1999). β-catenin is phosphorylated 
at serine 45 by CKIα (primed). Thereafter, GSK3β phosphorylates primed β-catenin at 
threonine-41, serine-37, and serine-33 sequentially. Phosphorylated, β-catenin is 
recognized by β-transducin repeat containing protein (β-TrCP) as a protein which is to be 
ubiquitinated (Latres E. et al., 1999; Hart M. et al., 1999). β-TrCP is an F-box containing 
protein which, together with Skp1, Cullen, and Rbx-1, constitutes the enzyme ubiquitin 
ligase (E3). Ubiquitin activation enzyme (E1), ubiquitin conjugating enzyme (E2) and E3 
cause ubiquitination of β-catenin, which is then destroyed by the proteasome system 
(Ciechanover A., 1998). 
In off state, β-catenin cannot accumulate since it is kept below the threshold. . In 
the absence of nuclear β-catenin, the LEF/TCF proteins are found in complex with the 
transcriptional repressor Groucho (Roose J. et al., 1998). Other transcriptional repressors, 
suchas histone deacetylases, are also recruited to the complex, thereby ensuring that the 
target genes are not activated. If β-catenin inappropriately enters the nucleus, Chibby can 
compete with β-catenin for the LEF/TCF proteins (Takemaru KI. et al., 2003). 
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1.4.4.4.2 On state 
Canonical Wnt signaling is initiated when Wnt ligands interact with frizzled 
receptors in the presence of LRP-5 or -6 (Mao JH. et al., 2001; Pinson KI. et al., 2000). 
The formation of the trimolecular complex (Wnt–Frizzled–LRP5/6) has two 
consequences. Firstly, Dishevelled is recruited to the cell surface and phosphorylated by 
casein kinase Iε (CK Iε) (Kishida M. et al., 2001). The phosphorylated Dishevelled 
protein can form a complex with Frat1 and GSK3β which serves to inhibit the activity of 
GSK3β (Lee E. et al., 2001). Secondly, LRP can interact with Axin. This will result in 
the accumulation of β-catenin. Additionally, all four serine/ threonine residues in the 
GSK3β recognition motif of β-catenin must be phosphorylated in order to be recognized 
by β-TrCP. Any mutations causing the failure to phosphorylate even one of the residues 
will result in failure to ubiquitinate and degrade β-catenin. The net effect is stabilization 
of β-catenin and accumulated β-catenin translocates into the nucleus. The mechanism by 
which β-catenin translocates into the nucleus is not completely clear, as it does not 
contain a nuclear localization signal and thus may be transported by other proteins. APC 
protein has been shown to shuttle in and out of the nucleus and it has been suggested that 
this may be another method of transporting β- catenin to the nucleus (Rosin-Arbesfeld R. 
et al., 2000; Neufeld KL. et al., 2000). More recently, it has been shown that the proteins 
pygopus and Bcl9/legless can form a complex with β-catenin in the cytoplasm and, due to 
the inherent nuclear localization activity of pygopus, the complex can translocate into the 
nucleus (Townsley FM. et al., 2004). Once within the nucleus, β-catenin can compete 
with Groucho for binding with the LEF/TCF proteins. The LEF/TCF family consists of 
four proteins (LEF1, TCF1, TCF3, and TCF4) which complex with DNA at the 
heptameric consensus motif (A/T)(A/T)CAA(A/T)G (Brantjes H. et. al., 2002). These 
proteins serve to provide a DNA binding domain for β-catenin. The complex includes the 
essential co-factors pygopus and Bcl9/legless (Kramps T. et. al., 2002). Together with a 
large array of other proteins [such as p300/Creb binding protein (CBP)], which allow 
specific target genes to be transcribed (Brantjes H. et. al., 2002; Roose J. and Clevers H., 
1999).  The amount of available β-catenin for target gene activation can also be increased 
by shifting protein from E-cadherin-bound pool to the cytoplasmic pool. A number of 
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receptor tyrosine kinases (RTK), on binding of their cognate ligand, are able to 
phosphorylate β-catenin at tyrosine residues, which causes dissociation of β-catenin from 
E-cadherin–catenin complex. The β-catenin protein thus liberated can be recycled to the 
cytoplasmic pool, which is then followed by increased expression of β-catenin target 
genes. Thus, surface receptors, such as c-RON, epidermal growth factor receptor (EGFR) 
and c-ErbB2, can stimulate canonical Wnt signaling (Graham NA. and Asthagiri AR., 
2004; Bonvini P. et al., 2001) as well as activating the signaling pathways with which 
they are more usually associated. 
Just as other signaling pathways can inhibit Wnt signaling, they are also able to 
activate Wnt signaling or facilitate the effects of Wnt signaling (Eger A. et. al., 2004). 
Integrin signaling, through integrin-linked kinase, can cause nuclear localization of β-
catenin. The mechanisms by which the other signaling pathways achieve their effects are 
uncertain, although it will most likely be through the manipulation of the various ‘On’ 
and ‘Off’ switches. For example, GSK3β is integral to the insulin-like growth factor 
(IGF) signaling pathway, and IGF-1 and -2 can activate Wnt signaling through inhibition 
of GSK3β (Morali OG. et. al., 2001; Desbois-Mouthon C. et. al., 2001; Playford MP. et. 
al., 2000; D’Amico M. et. al., 2000; Novak A. et al., 1998). 
Finally, certain oncogenic viruses are associated with the development of 
malignancy. The Epstein–Barr virus (EBV) is associated with both epithelial and 
lymphoid malignancies. It has been shown that EBV can activate canonical Wnt 
signaling through GSK3β inhibition (Morrison JA. et. al., 2003), HBV-X protein (HBX) 
upregulates β-catenin (Ding Q. et. al., 2005). HCV core protein stimulates HCC cell 
proliferation at least partly through up-regulation of Wnt-1 at the transcriptional level 
(Fukutomi T. et. al., 2005). 
 
1.4.4.5 Canonical Wnt signaling in HCC 
Studies in recent years clearly established that the deregulation of Wnt signaling 
pathway via oncogenic activation of β-catenin plays a key role in hepatocellular 
carcinomas. Activating mutations in β-catenin are quite prevalent in human 
hepatocellular cancers (de La Coste A. et al., 1998; Miyoshi Y. et al., 1998). Succeeding 
studies have demonstrated that prevalence of aberrant accumulation of β-catenin is 
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between 33-69%, while only 8-13% of studied HCCs display β-catenin mutations (Hsu 
HC. et al., 2000; Wong CM. et al., 2001). The second most likely component of Wnt 
pathway for oncogenic β-catenin activation is Axin 1, a putative tumor suppressor gene. 
The overall mutational and/or LOH screening studies in HCC samples have shown that 
only a small fraction of screened samples (7-9%) were subject to Axin 1 mutations (Satoh 
S. et al., 2000; Laurent-Puig P. et al., 2001; Taniguchi K. et al., 2002).The molecular 
etiology for accumulation of β-catenin in HCC is not completely understood. Studies in 
transgenic mice and chemical carcinogenesis have shown that both the pattern and 
frequency of β-catenin mutations are heterogeneous (Tsujiuchi T. et al., 1999; Calvisi 
DF. et al., 2001; Devereux TR. et al., 2001). Almost half of the β-catenin aberrations in 
human hepatoblastoma are interstitial deletions covering the third exon of the gene (Koch 
A. et al., 1999; Wei Y. et al., 2000). However, the role of β-catenin in cancer formation 
and/or progression in cholangiocarcinoma has not been well-studied. There are only two 
reports which showed that β-catenin mutations were present in 8 of 107 (7.5%) studied 
biliary tract cancer form China, and only 15% of cholangiocarcinoma displayed aberrant 
nuclear accumulation of β-catenin without genetic mutation (Sugimachi K. et al., 2001). 
The finding of mutated β-catenin in early stages of human HCC (de La Coste A. et al., 
1998; Miyoshi Y. et al., 1998; Hsu HC. et al., 2000), in adenomas in c-myc transgenic 
mice, and rapid development of hepatomegaly in mutated β-catenin expressing transgenic 
mice suggest (Cadoret A. et al., 2001; Calvisi DF. et al., 2001) that aberrations in Wnt 
pathway can be considered as an early event in hepatocarcinogenesis. An unexpected 
feature of HCC is the high frequency of β-catenin accumulation despite the presence of 
rather low levels of β–catenin and Axin1 mutations. This suggests that β-catenin 
accumulation can be caused by additional mechanisms. 
 
1.4.4.6 β-catenin mutations in well-differentiated and poorly-differentiated HCC 
Several years ago, two independent studies showed that β-catenin mutations are 
associated with distinct subsets of HCCs (Hsu HC. et al., 2000; Laurent-Puig P. et al., 
2001). According to Hsu et al., β-catenin mutations are associated with a subset of well 
differentiated and low-stage HCCs with a favorable prognosis (Hsu HC. et al., 2000). On 
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the other hand, Laurent-Puig P. et al. determined that HCCs form two distinct groups 
according to the chromosome stability status. One group demonstrates chromosome 
stability, β-catenin mutation and chromosome 8p losses. The other group demonstrates 
chromosome instability and frequent Axin1 and p53 mutations (Laurent-Puig P. et al., 
2001). These observations have now been confirmed and extended by many other studies 
based on mutation analysis or nuclear β-catenin staining. High frequencies of β-catenin 
mutation and nuclear β-catenin staining were detected in early stage well differentiated 
HCCs, but both aberrations were declining in late stage less differentiated HCCs (Wong 
CM. et al., 2001; Mao TL. et al., 2001; Inagawa S. et al., 2002; Fujito T. et al., 2004). 
Although a few studies did not agree with some of the findings (Suzuki T. et al., 2002; 
Tien LT. et al., 2005), these observations are consistent with the hypothesis that β-catenin 
aberrations in HCC occur during the initial step of neoplastic transformation at the time 
when the well-differentiated HCC lesions emerge from dysplastic nodules. Indeed, 
dysplastic nodules display no β-catenin mutation (Prange W. et al., 2003; Park JL. et al., 
2005). As APC mutations (leading to aberrant activation of β-catenin) are the earliest 
changes detected in colorectal cancers (Gregorieff A. and Clevers H., 2005), a similar 
finding in HCC does not come as a surprise. However, the progressive decline of β-
catenin aberrations in less differentiated and more aggressive HCCs is unexpected. As 
stated earlier, constitutive activation of the canonical Wnt signaling as a result of aberrant 
β-catenin accumulation is considered to play a key role in colorectal cancers. 
 
1.5  C/EBPα  
 CAAT/enhancer binding proteins (C/EBPs) are members of basic region leucine 
zipper (bZIP) protein family. First members of C/EBPs was discovered as  a heat-stable 
DNA-binding protein found in rat liver nuclei and was shown to be capable to bind 
selectively to the CCAAT motif of several viral promoters, as well as to the “core 
homology” sequence of several viral enhancers (Landschulz WH. et al., 1988). Several 
C/EBPs (C/EBPα, C/EBPβ, C/EBPγ, C/EBPδ, C/EBPε, and C/EBPζ) were discovered 
and characterized and designated according the proposal by Cao et al, who suggested a 
systematic nomenclature in which C/EBP name is  followed by a Greek letter, indicating 
the chronological order of their discovery (Cao Z. et al., 1991). C/EBP subfamily 
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members consist of three structural components in a modular fashion that include a C-
terminal leucine-zipper, a basic DNA-binding region, and an N-terminal transactivating 
region (Ramji DP. and Foka P., 2002) (Figure 1.9). 
 
 
Figure 1.9: Schematic representation of the C/EBP family members (Ramji DP. and Foka P., 
2002).The leucine zipper is shown in yellow, with black vertical lines indicating the leucine residues, and 
the basic region is coloured red. The position of the activation domains (AD) and negative regulatory 
domains (RD) are shown in green and blue respectively. ? indicates that the N-terminus of C/EBPζ contains 
an activation domain, although its exact position remains to be determined. C/EBPβ mRNA can produce at 
least three isoforms, 38 kDa (LAP*), 35 kDa (LAP) and 20 kDa (LIP), with the LAP and the LIP forms 
being the major polypeptides produced in cells. Although C/EBPε and C/EBPζ are members of the C/EBP 
subfamily, both do not belong to the exclusive group of liver-enriched transcription factors. 
 
C/EBPα gene has one exon that encodes a 2.7kb mRNA translated into two 
isoforms; 42kDa and 30kDa due to leaky ribosome scanning. The human C/EBPα is 
expressed in a tissue restricted manner with high expression in placenta, liver, lung, 
skeletal muscle, pancreas, small intestine, colon and peripheral blood leukocytes but no or 
low expression is detected in brain, kidney, thymus, testis and ovary (Antonson P. and 
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Xanthopoulos KG., 1995). C/EBPs bind to CCAAT box motif found in the promoter 
regions of several genes through DNA binding domain and leucine zipper domains at the 
C terminus. The consensus binding site, RTTGCGYAAY (R = A or G, and Y = C or T), 
are similar with small variations within the C/EBP family members (Osada S. et al., 
1999). C/EBPα activates the transcription of several genes in hepatocytes, adipocytes and 
hematopoietic cells. The C/EBPα gene is conserved among species, especially in its DNA 
binding region. It has 90% homology to the rat C/EBPα, 100% identity in DNA binding 
region (Hendricks-Taylor LR. and Darlington GJ., 1995). The gene C/EBPα gene is 
autoregulated by C/EBPα, but other C/EBP-related proteins may also be involved in its 
regulation (Legraverend C. et al., 1993). Activation of the murine C/EBPα promoter by 
direct binding of C/EBPα to a site within 200 bp of the transcriptional start was shown to 
elevate activity by approximately 3-fold (Legraverend C. et al., 1993; Timchenko N. et al., 
1995). However, the human C/EBPα gene promoter does not contain a cis element where 
C/EBPα protein. However, cotransfection studies in human hepatoma derived Hep3B2 
cells show that C/EBPα stimulates transcription of a reporter gene driven by 437 bp of the 
C/EBPα promoter. The human C/EBPα protein stimulates upstream stimulating factor 
(USF) to bind to a USF consensus element within the C/EBPα promoter and activates it 
by 2- to 3-fold (Timchenko N. et al., 1995).  
 
1.5.1  C/EBPα isoforms 
C/EBPα mRNA is translated into two major isoforms (42 kDa and 30 kDa) differing in 
their content of N-terminus by differential use of translation initiation codons (Lin FT. et 
al., 1993) The C/EBPα mRNA has four AUG start codons. When the conditions are 
favorable, the activity of the translation initiation factors, elF2α and elF4E, increases and 
translation start from first AUG (suboptimal initiation site). Translation from this site 
generates small upstream open reading frame and translation is reinitiated from fourth 
AUG that generates p30 isoform. When the activity of these translation initiation factors 
are low, translation is initiated from second AUG (optimal initiation site) which generates 
p42 isoform (Calkhoven CF. et al., 2000). The full-length p42 form acts as a 
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transactivator in the liver, whereas the N-terminally truncated p30 form lacks 
transcription activation potential (Ossipow V. et al., 1993; Calkhoven CF. et al., 1994).  
p42 isoform has three activation domains. Activation domains, TEI and TEII 
interact with components of the basal transcription machinery TBP/TFIIB and histone 
acetyltransferases CBP/p300, respectively (Nerlov C. et al., 1995; Kovacs KA. et al., 
2003). TEI and TEII are not present in p30 form, which lacks the N terminal 117 amino 
acids. The third activation domain (TEIII) which recruits chromatin remodeling complex 
SWI/SNF (Pedersen TA. et al., 2001) and DNA binding domain are present in both 
isoforms (Figure 1.10).  
Figure 1.10: Functional domains of C/EBPα isoforms (Johnson PF., 2005). p42 isoform has the all three 
transactivation elements, TE-I, TE-II, TE-III while the p30 isoform lacks the TE-I and TE-II. Basic region 
and leucine zipper domain are present in both isoforms. The interacting protein domains are indicated. 
 
Generation of C/EBPα isoforms is tightly regulated by PKR and mTOR 
signaling pathways and the ratio of these isoforms determine the cell fate (Calkhoven CF. 
et al., 2000). p42 to p30 ratio regulates the proliferation and differentiation control (Figure 
1.11). p42 isoform has the ability to block proliferation and induces adipogenic and 
granulocytic differentiation unlike p30 isoform, which is not antimitotic and although it 
induces early adipocyte differentiation, it inhibits terminal differentiation (Lin FT. et al., 
1993). p30 isoform binds DNA less efficiently comparing to p42 and acts as dominant 
negative mutant (Figure 1.10). 
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Figure 1.11: Translation initiation factor activity determines cell fate through modulation of the 
C/EBP isoform ratio. (Calkhoven CF. et al., 2000). Two C/EBP isoforms are formed by alternative use of 
translation initiation codons, which is regulated by mTOR and PKR pathways. p42 to p30 ratio regulates the 
proliferation and differentiation control. 
 
The nuclear matrix protein CAAT displacement protein (CDP) is a competitive repressor 
for CCAAT binding factors in experiments on gene regulation of the sperm histone H2B-
1 of the sea urchin Psammechinus miliaris (Barberis A. et al., 1987). The repression of 
the human cholesterol 7α-hydroxylase CYP7A1 gene is mediated by the matrix 
attachment site-bound repressor CDP, involves displacement of two hepatic 
transcriptional activators, HNF-1α and C/EBPα, from their binding sites within intron 1 
of the CYP7A1 gene, and thus represses transactivation mediated by these two activators 
(Antes TJ. et al., 2000). CDP is abundant in undifferentiated cells and is down-regulated 
in differentiated epithelial cells (Ai W. et al., 1999). This might indicate that the 
availability of CDP for its sites within intron 1 of the CYP7A1 gene is high early in liver 
development and thus binding of the liver-specific transcription factors may be blocked 
(Antes TJ. et al., 2000) Calreticulin interacts with the GC-rich regions of the C/EBPα and 
C/EBPβ mRNAs and inhibits translation of full-length C/EBP proteins (Timchenko LT. 
et al., 2002). 
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1.5.2  Physiological roles of C/EBPα 
C/EBPα plays a central regulatory role in energy metabolism in the liver (Crosson 
SM. et al., 1997). High levels of C/EBPα mRNA were observed in tissues known to 
metabolize lipid and cholesterol related compounds at uncommonly high rates and 
included liver, fat, intestine, lung, adrenal gland, and placenta. C/EBPα is essential for 
adipogenesis and neonatal gluconeogenesis (Arizmendi C. et al., 1999).The involvement 
of C/EBPα in diverse physiological contexts highlights the important roles of these 
transcription factors in liver biology (Figure 1.12). 
 
Figure 1.12: The involvement of C/EBPα in diverse physiological contexts. (Schrem H. et al.,  2004) 
 
 
1.5.3 C/EBPα knock-out and knock-in mice  
C/EBPα knockout mice die soon after birth due to hypoglycemia and impaired 
energy homeostasis in liver and adipose tissue (Wang ND. et al., 1995). C/EBPα -/- mice 
have reduced expression of genes involved in glycogenesis such as glycogen synthase, 
phosphoenolpyruvate carboxykinase and glucose-6-phosphatase (Wang ND et al., 1995; 
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Lee YH. et al., 1997). C/EBPα -/- mice also have abnormality in control of hepatic growth 
and lung development. The liver architecture of the mice lacking C/EBPα is impaired, 
resembling regenerating liver after partial hepatoectomy or pseudoglandular 
hepatocellular carcinoma. C/EBPα -/- mice show induced hepatic proliferation and 
expression of c-myc, c-jun, β-actin and α-fetoprotein are increased several folds. In 
addition, induced levels of PCNA/cyclin is observed showing that the hepatocytes are in 
the G1/S phase of the cell cycle (Flodby P. et al., 1996). Blood ammonia concentrations in 
mutant mice are several-fold higher than wild-type mice, thus C/EBPα is crucial for 
ammonia detoxification by ornithine cycle enzymes (Kimura T. et al., 1998). 
Targeted disruption of C/EBPα prevents neutrophil differentiation. C/EBPα -/- 
mice do not have mature neutrophils and eosinophils in the blood or fetal liver; however, 
the other blood cells are not affected. The defect in the differentiation of neutrophils is 
due to reduced expression of granulocyte colony-stimulating factor receptor (Zhang DE. 
et al., 1997).  Tan EH. et al. investigated the potential of reactivating C/EBPα expression 
during hepatic carcinogenesis to prevent tumor cell growth by investigated the potential 
of reactivating C/EBPα expression during hepatic carcinogenesis to prevent tumor cell 
growth. Diethylnitrosamine produced half the number of hepatocellular nodules in 
knock-in mice as in WT mice. Nuclear p21 was absent in WT nodules whereas 
cytoplasmic p21 was abundant; knock-in nodules were positive for nuclear p21. Results 
suggested that controlled C/EBP production can inhibit liver tumor growth in vivo (Tan 
EH. et al., 2005). 
 
1.5.4 The role of C/EBPα in adipocyte differentiation  
C/EBPα is expressed at high levels in terminally differentiated adipocytes and it 
has role in the differentiation of adipocytes together with peroxisome proliferators- 
activated receptor γ (PPARγ) (Rosen ED. et al., 2002).When the expression of C/EBPα is 
inhibited by antisense RNA in 3T3-L1 preadipocyte cell line, adipocyte specific genes 
are not expressed and differentiation is blocked (Lin FT. and Lane MD., 1994). 
Adipocyte differentiation is induced by the rapid and transient increase in the expression 
of C/EBPβ and C/EBPδ upon treatment with the differentiation inducers. C/EBPβ and 
C/EBPδ induce the expression of C/EBPα, which leads to cell cycle arrest and 
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transcriptional activation of many genes involved in adipocyte differentiation such as 
GLUT4, SCD1, leptin and 422/aP2. PPARγ and C/EBPα induce each other’s expression 
and promotes and maintains differentiated state (Rosen ED. et al., 2002). 
 
1.5.5 The role of C/EBPα in lung development and lung cancer 
C/EBPα is expressed in bronchial cells and type II pneumocytes in the lung and 
regulates expression of several genes involved in lung differentiation. C/EBPα knockout 
mouse shows abnormal proliferation of type II pneumocytes (Flodby P. et al., 1996). 
C/EBPα is proposed to be a candidate tumor suppressor gene in lung cancer since its 
expression is downregulated in large proportion of lung cancers (Halmos B. et al., 2002). 
Berg T. et al. generated transgenic mice ectopically expressing C/EBPα in the lung 
epithelium using the human surfactant protein-C promoter. Lungs from these mice were 
of normal size but exhibited a phenotype characterized by fewer and larger developing 
epithelial tubules, indicating that the branching process was affected. The results 
suggested a role for C/EBPα in lung development and suggest a function in the later 
stages of lung branching morphogenesis (Berg T. et al., 2006). 
 
1.5.6 The role of C/EBPα in granulopoiesis and in acute myeloid leukemia     
Granulopoiesis is the formation of mature neutrophil granulocytes from immature 
myeloblasts. C/EBPα expressed in the stem and myeloid progenitor cells but not in other 
cells in the hematopoietic system. C/EBPα expression is initiated during the commitment 
of multipotential precursors to the myeloid lineage and its expression is up regulated 
during granulocytic differentiation, and is rapidly downregulated during the monocytic 
pathway (Scott LM. et al., 1992; Radomska HS. et al., 1998). C/EBPα activates the 
transcription of granulocyte specific genes; receptors for the growth factors, macrophage 
colony-stimulating factor, granulocyte colony stimulating factor (G-CSF) (Smith LT. et 
al., 1996; Zhang DE. et al., 1996). 
The importance of C/EBPα in granulocytic differentiation comes from the 
evidences from knockout mice studies and mutations of C/EBPα in acute myeloid 
leukemia (AML). C/EBPα knockout mice have disruption in granulopoiesis and do not 
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have any mature neutrophils while the other blood cells are not affected (Zhang DE. et 
al., 1997).  
C/EBPα is mutated approximately 9% of the AML patients, especially M2 
subtype where the C/EBPα mutation is 20%. Mutations in C/EBPα have not been found 
in patients with the t(8;21), inv 16 (Timchenko NA. et al., 1998) and t(15;17) 
translocations in which the function or expression of C/EBPα is repressed by other 
mechanisms (Nerlov C., 2004). AML1-ETO, the fusion product of t(8;21) translocation, 
repress the C/EBPα expression by inhibiting positive autoregulation of the C/EBPα 
promoter (Pabst T. et al., 2001). PML-RARα fusion protein of acute promyelocytic 
leukemia is reported to repress C/EBPα activity by trapping it in the cytoplasm (Truong 
BT. et al., 2003). Therefore, inactivation of C/EBPα by either mutation or other 
mechanisms is common in AML and thought to be important in malignant 
transformation. 
 
1.5.7 The role of C/EBPα in hepatocyte proliferation and differentiation 
The liver enriched transcription factors (C/EBP, HNF1, HNF3, HNF4 and HNF6) 
accomplish the transcription of hepatocyte specific genes through interacting 
promoter/enhancer sites. Distinct classes of transcription factors regulate the liver 
development, differentiation and regeneration. C/EBPα has role in liver differentiation 
regulating transcription of genes involved in hepatic glycogen synthesis, gluconeogenesis 
and lipid homeostasis and it negatively regulates hepatocyte proliferation (Costa RH. et 
al, 2003). 
C/EBPα plays a role in maintaining the quiescent state of hepatocytes and other 
cells. Furthermore, it appears that the effects of C/EBP are not mediated through p53 or 
Rb and are not altered by T-antigen (Hendricks-Taylor LR. and Darlington G.J., 1995). 
C/EBPα functions as a growth arrest gene in hepatocytes (Diehl AM. et al., 1996). The 
expression of C/EBPα is reduced during hepatocyte proliferation in regenerating liver and 
in hepatocellular carcinoma (Mischoulon D. et al., 1992). It was proposed that the growth 
inhibition function of C/EBPα in liver is not to be due to reduced transcriptional activity 
but due to protein-protein interactions (Wang H. et al., 2001). 
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C/EBPα inhibits cell proliferation by increasing p21 gene expression and by post-
translational stabilization of p21 protein. Since transcription of antisense p21 mRNA 
eliminates growth inhibition by C/EBPα, induction of p21 is responsible for the C/EBPα- 
dependent inhibition of cell proliferation Additionally, C/EBPα mediated growth 
inhibition can be through the stabilization of p21 protein by C/EBPα (Timchenko NA. et 
al., 1996). C/EBPα directly interacts with p21 and protects it from proteolytic degradation 
(Timchenko NA. et al., 1997), and cooperates with p21 to inhibit cyclin-dependent 
kinase-2 activity and induces growth arrest independent of DNA binding (Harris TE. et 
al., 2001). However, other studies suggest that the p21 is not important for C/EBPα 
mediated growth inhibition since p21 knockout mice do not show any alteration in 
hepatocyte proliferation (Deng C. et al., 1995), and p21 is not the critical target of C/EBP-
mediated growth inhibition in murine fibroblasts (Muller C. et al., 1999). 
In addition to p21, C/EBPα interacts with several other proteins, which have role 
in the cell cycle progression and transcription. One of these proteins is cyclin-dependent 
kinases, which regulate the cell cycle progression through association with cyclins. Cdk2-
cyclin E, A and cdk4-cyclinD mediate the S phase transition of cell cycle through Rb-
dependent repression of E2F. C/EBPα directly interacts with cdk2 and cdk4 and arrests 
cell proliferation by inhibiting these kinases. A short-growth inhibitory region of C/EBPα 
has been mapped between amino acids 175 and 187. This portion of C/EBPα is 
responsible for direct inhibition of cyclin-dependent kinases and causes growth arrest in 
cultured cells. C/EBPα inhibits cdk2 activity by blocking the association of cdk2 with 
cyclins. C/EBPα knockout liver has the increased activities of the cdk2 and cdk4 
consistent with increased rate of proliferation. These data demonstrate that C/EBPα 
brings about growth arrest through direct inhibition of cdk2 and cdk4 (Wang H. et al., 
2001). C/EBPα also reduces the protein level of cdk4 by mediating proteasome-
dependent degradation of cdk4 (Wang H. et al., 2002). C/EBPα also interacts with the 
SWI/SNF chromatin-remodeling complex during the regulation of genes involved in 
differentiation. C/EBPα cannot inhibit the proliferation in cells, which are defective in 
SWI/SNF (Muller C. et al., 2004). 
C/EBPα- mediated repression of E2F is believed to be important for proliferation 
arrest. E2F regulates the transcription of genes, which are involved in DNA synthesis and 
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mitosis and E2F-dependent transcription is regulated by Rb-mediated phosphorylation. A 
region of C/EBPα that has sequence similarity to E2F is sufficient for the disruption of 
the E2F/p107 complexes. Despite its role as a DNA binding protein, C/EBPα brings 
about a change in E2F complex composition through a protein/protein interaction. The 
disruption of E2F-p107 complexes correlates with C/EBPα-mediated growth arrest of 
hepatocytes in newborn mice. E2F interacts with Rb and Rb-like proteins, p107 and 
p130, at different stages of cell cycle. In quiescent cells, p130-E2F complex is seen and 
p107-E2F complex is seen in dividing cells. C/EBPα disrupts the p107-E2F complex 
through interacting with p107 (Timchenko NA. et al., 1999). 
 In liver extracts of the young mice, C/EBPα interacts with cdk2, and this 
interaction represses the E2F and c-myc expression. Ageing leads to increase in the 
Brahma protein (Brm), which replaces the cdk2 and binds to C/EBPα, leading to 
formation of C/EBPα-Rb-E2F complex. This complex represses the E2F dependent 
expression of c-myc and it is not disrupted after partial hepatoectomy. This explains the 
reduced proliferative capacity of liver by aging (Iakova P. et al., 2003). However, this 
complex involves the Rb and it has been previously shown that the growth-inhibitory 
function of the C/EBPα is independent of Rb (Hendricks-Taylor LR. and Darlington GJ., 
1995). 
The CDK2/CDK4 inhibitory domain of C/EBPα was pinpointed to a 15-amino-
acid sequence (QPPPPPPPPHPHASP; 180 to 194 of the rat C/EBPα protein) containing 
S193 (Wang HP. et al., 2001). This serine was later shown to be dephosphorylated in 
liver tumors as well as in hepatoma cell lines through a PI3K/Akt-mediated 
dephosphorylation, and mutation of S193A disabled the growth-inhibitory effect of 
C/EBP (Wang GL. et al., 2004). However, homozygous C/EBPα PHR/PHR mice, 
carrying a modified cebpa allele lacking amino acids 180 to 194, were born at the 
Mendelian ratio, reached adulthood, and displayed no apparent adverse phenotypes. 
Additionally, Porse BT. et al. failed to detect any CDK2 in the precipitates when nuclear 
extracts from cells transfected with FLAG-tagged wild-type C/EBP Additionally, 
C/EBP  knockout fetal livers did not express increased levels of either PCNA or of cyclin 
A, and did not displayed any overall increase of BrdU incorporation. As a result, Porse 
BT. et al. concluded that The Proline-Histidine-Rich (PHR) CDK2/CDK4 Interaction 
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Region of C/EBPα is dispensable for C/EBPα-mediated growth regulation in vivo (Porse 
BT. et al., 2006).  
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CHAPTER 2. OBJECTIVES AND RATIONALE 
 
Hepatocellular carcinoma (HCC) is a heterogeneous disease, and originates from 
hepatocytes as a well differentiated tumor and progresses with a stepwise process of 
dedifferentiation (Kojiro M. et al., 2005). HCC derived from different stages of cellular 
differentiation may have different clinical and pathobiological behavior. Early well-
differentiated tumors are highly proliferative and become less differentiated when they 
reach 1-1.5 cm. At this stage, HCC cells start to acquire the abilities of angiogenesis, 
tissue invasion and metastasis. Later on, they become undifferentiated and are able to 
invade vessels and form extra-hepatic metastases (Bruix J. et al., 2004). This 
dedifferentiation process is associated with a progressive accumulation of genomic 
changes including chromosomal gains and losses, as well as p53 mutations 
(Thorgeirsson, SS. and J. W. Grisham., 2002). Laurent-Puig P. et al. suggested that HCCs 
could be classified into two distinct groups according to the chromosome stability status. 
One group demonstrates chromosome stability, β- catenin mutation and chromosome 8p 
losses. The other group demonstrates chromosome instability and frequent Axin1 and p53 
mutations (Laurent-Puig P. et al., 2001). Almost a third of HCCs displays constitutive 
activity of canonical Wnt signaling caused by mutations in CTNNB1 or Axin1 genes 
(Reya T. and Clevers H., 2005). Indeed, in HCC, β-catenin mutations have been found in 
22% of cases in average, and an additional 7% display Axin1 mutations (Buendia MA., 
2002). Interestingly, the status of the CTNNB1 gene makes the exception for the general 
picture. Unlike the other genomic changes accumulating during HCC evolution such as 
chromosomal instability, p53 and Axin1 mutations; high frequencies of CTNNB1 
mutation and nuclear β-catenin protein staining were detected in early-stage well 
differentiated HCCs, but both aberrations were declining in late-stage less differentiated 
HCCs (Wong CM. et al., 2001; Mao J. et al., 2001; Inagawa S. et al., 2002; Fujito T. et 
al., 2004). This data prompted us to analyze canonical Wnt signaling in HCC cell lines, 
and classify them according to differentiation status and TCF/LEF activity.  
β-catenin is tightly regulated at protein and localization levels, and the β-catenin 
pool out of adherens junctions is likely to be more important for tumor development. 
Therefore, it is important to have molecular tools distinguishing the pools of β-catenin. 
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For this aim, we decided to produce our own monoclonal antibodies against a 
recombinant human β-catenin protein in order to distinguish between different cellular β-
catenin pools.  
C/EBPα is a potent inhibitor of cell cycle in hepatocytes, and its mutations are 
observed also in AML patients. Additionally, genetic alterations of C/EBPα in HCC cell 
lines and samples were found (Yuva Y. et al., unpublished data). Moreover, it has been 
shown that overexpressed β-catenin and C/EBPα co-immunoprecipitated from Hek293 
cells (Kennell JA. et al., 2003). Therefore, we hypothesized that C/EBPα and β-catenin 
may interact in HCC cell lines. For this aim, we focused on the effect of C/EBPα on 
mutant β-catenin/TCF dependent transcriptional activity and β-catenin protein level. 
While we were analyzing stably transfected Huh7 clones related our Wnt 
signaling study, we noticed that some mock-transfected clones ceased proliferation when 
cultured extensively. Additionally, we knew that differentiated cells had stem-like 
properties based on their heterogeneous staining for AFP, CK19 (Erdal E. et al., 
unpublished data), Therefore, we hypothesized that some HCC cell lines could produce 
progeny programmed to terminal differentiation, as manifested by replicative senescent 
phenotype. We decided to investigate the mechanism of spontaneous senescence in HCC-
derived cells. We also hypothesized that the replicative senescent phenotype is a 
reflection of cirrhosis in liver, and senescent cells should exist in cirrhotic tissues and 
primary tumors. Therefore, we decided to screen cirrhotic liver samples, non-tumor, and 
tumor samples from different tissues for senescent phenotype. 
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CHAPTER 3. MATERIALS AND METHODS 
 
3.1 MATERIALS 
 
3.1.1 Reagents 
 All laboratory chemicals were analytical grade from Sigma (St. Louis, MO, 
U.S.A), Farmitalia Carlo Erba (Milano, Italy) and Merck (Schucdarf, Germany) with the 
following exceptions: Ethanol was from Delta Kim Sanayi ve Ticaret A.S (Turkey). 
Midi-prep kit and Qiaex kit kit (for recovery and extraction of DNA from agarose gel) 
were from Qiagen (Chatsworth, CA, U.S.A). Agar, tryptone and yeast extract were 
obtained from Gibco, BRL Life Technology Inc. (Gaithersburgs, MD, U.S.A). 
Tetralcycline was purchased from Appligene (France). 
 
3.1.2 Bacterial Strains 
 The bacterial strains used in this work were DH5α and M15 (E. coli strains). 
 
3.1.3 Enzymes 
 Restriction endonucleases used for gene cloning were purchased from MBI 
Fermentas GmbH (Germany). Shrimp Alkaline Phosphatase was purchased from 
Invtrogen (Carlsbad, CA, USA). T4 DNA ligase was purchased from Promega (Madison, 
WI, USA). 
 
3.1.4 Nucleic Acids 
 DNA molecular weight standard and ultrapure deoxyribonucleotides were 
purchased from MBI Fermentas GmbH (Germany). pEGFP-N2 (Clontech, Palo Alto, 
CA), pcDNA3 (Invitrogen), pCI-Neo (Promega), pSuper, pSuperior.puro, 
pSuper.retro.gfp.neo (Oligoengine), and pGEX-4T1 (Amersham/Pharmacia, NJ, USA) 
were commercially obtained.  pCI-Neo-S33Y,  pGL3-OT and pGL3-OF constructs were 
a gift from Bert Vogelstein (John Hopkins Oncology Center, Baltimore, MD, USA). 
pCDNA3-S33Y were prepared by inserting of  S33Y cDNA from pCI-Neo-S33Y into 
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pcDNA3. pAUCT-∆N-β-catenin were prepared by inserting  Xho I/Not I fragment of 
pCI-Neo-S33Y into pAUCT/CCW vector.  pcDNA3.C/EBPα was kindly provided by 
Gokhan S.  Hotamisligil, (Harvard University). pAUCT-C/EBPα was prepared by 
inserting BamHI-XhoI from pCDNA3.C/EBPα into pAUCT/CCW. pSuper.puro was 
prepared by EcoRI/Hind III fragment from pSuper into EcoRI/Hind III into 
pSuperior.puro.  
 
3.1.5 Oligonucleotides 
 The sequencing-primer used for cycle sequencing reactions  oligonucleotides used 
in polymerase chain reactions (PCR), and 60 bp. HPLC grade oligos used for gene 
knock-down experiments were synthesized by İONTEK (Istanbul, Turkey).  
 
3.1.6 Electrophoresis and photography, luciferase assay, ELISA readings and 
spectrophotometry 
Electrophoresis grade agarose was obtained from Sigma Biosciences Chemical 
Company Ltd. (St. Louis, MO, USA). Horizontal electrophoresis apparatuses were from 
Stratagene (Heidelberg, Germany) and E-C Apparatus Corporation (Florida, USA). The 
power supply Power-PAC300 and Power-PAC200 was from Bio Rad Laboratories (CA, 
USA). The Molecular Analyst software used in agarose gel profile visualizing was from 
BioRad Laboratories (CA, USA). The Reporter Microplate Luminometer Reader was 
from Turner BioSystems Inc (Sunnyvale, CA, USA). ELISA reader and 
Spectrophotometer were from Backman. 
 
3.1.7 Tissue culture reagents and cell lines 
 Dulbecco’s modified Eagle’s medium (DMEM), fetal calf serum was obtained 
from BIOCHROM AG (Berlin, Germany).  L-glutamine, calcium and magnesium-free 
phosphate buffered saline (PBS), Penicillin/Streptomycin mixture was from Biological 
Industries (Haemel, Israel). Tissue culture flasks, petri dishes, 15 ml polycarbonate 
centrifuge tubes with lids and cryotubes were purchased from Costar Corp. (Cambridge, 
England). Geneticin-G418 sulfate was purchased from GibcoBRL, Life tech. (USA), 
Puromycin was purchased from Sigma (St. Louis, MO, USA) 
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3.1.8 Antibodies and chemiluminescence  
 The antibodies used in immunoblotting (western blotting) were obtained from 
different sources, and their working dilutions are given in Table 3.1. 
ECL Western Blotting detection kit was purchased from Amersham Pharmacia 
Biotech Ltd. (Buckinghamshire, UK). 
 
3.1.9 TRAP and Telomere Length Assays Kits  
TeloTAGGG Telomerase PCR ELISAPLUS and TeloTAGGG Telomere Length 
Assay were purchased from Roche Diagnostics (Mannheim, Germany). 
 
3.2 SOLUTIONS AND MEDIA 
 
3.2.1 General Solutions 
50X Tris-acetic acid-EDTA (TAE):  2 M Tris-acetate, 50 mM EDTA pH 8.5 
 Diluted to 1X for working solution.  
 
Ethidium bromide:    10 mg/ml in water (stock solution), 
       30 ng/ml (working solution) 
 
1X Gel loading buffer:   0.25% bromophenol blue, 0.25% xylene  
      cyanol, 50% glycerol, 1mM EDTA 
 
 
3.2.2 Solutions for plasmid DNA isolation  
Solution I 50 mM Glucose, 25 mM Tris.Cl, pH 8.0, 10 
M EDTA. Sterilized in autoclave. 
 
Solution II               0.2 N NaOH, 1% (wt/vol) SDS 
 
Solution III               3 M Potassium acetate, pH 4.8 
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Bradford Stock Solution  4.75 ml of 95 % ethanol, 10 ml of 85% 
phosphoric acid , 17.5 mg Coomassie 
Brilliant Blue. Stored in dark at 4°C. 
 
Bradford Working Solution  21.25 ml double distilled water, 0.75 ml of 
95% ethanol, 1.5 ml of 85% phosphoric acid, 
1.5 ml of Bradford stock solution. Filtered 
through Whatman No.1 paper and prepared 
freshly. 
 
3.2.3 Microbiological media, reagents and antibiotics 
Luria-Bertani medium (LB) Per liter: 10 g bacto-tryptone, 5 g bacto-
yeast extract, 10 g NaCl. For LB agar plates, 
add 15 g/L bacto agar. 
 
Glycerol stock solution 65% glycerol, 0.1 M MgSO4, 0.025 M 
Tris.Cl, pH 8.0 
 
Ampicillin 100 mg/ml solution in double-distilled water, 
sterilized by filtration and stored at -20°C 
(stock solution).100 µg/ml (working 
solution) 
 
Kanamycin 300 mg/ml solution in double-distilled water 
sterilized by filtration and stored at -20°C 
(stock solution). Working solution was 30 
µg/ml. 
0.1 M IPTG                                 1.41 g IPTG in 50 ml double-distilled water,            
sterilized by filtration and stored at -20oC. 
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Luria-Bertani medium (LB) Per liter: 10 g bacto-tryptone, 5 g bacto-
yeast extract, 10 g NaCl. For LB agar plates, 
15 g/L bacto agar was added. 
SOB medium:   Per liter: 20 g tryptone (2%), 5 g yeast 
extract (0.5%), 0.584 gr NaCl (10 mM), 
0.1864 g KCl (2.5 mM) autotclaved to 
sterilize. Then, 2.46 g MgSO4 and 2.03 g 
MgCl2 (10 mM) are added. 
 
SOC medium:  SOB + 20 mM glucose from filter sterilized 1 
M glucose stock solution in ddH2 O. 
 
Transformation Buffer (TB):    10 mM K.PIPES, 55 mM MnCl2, 15 mM 
CaCl2, 250 mM KCl. Filter sterilized and 
stored at 4 oC. 
 
Glycerol stock solution 65% glycerol, 0.1 M MgSO4, 0.025 M 
Tris.Cl, pH 8.0. were mixed with 50% 
bacteria culture. Alternatively, 25% glycerol 
were added into bacteria culture.  
 
 
3.2.4 Tissue culture solutions 
DMEM/RPMI working medium 10% FBS, 1% penicillin/streptomycin, 1% 
Non-Essential Amino Acid were added and 
stored at 4oC.  
 
 
10X Phosphate-buffered saline (PBS) Per liter: 80 g NaCl, 2 g KCl, 14.4 g 
Na2HPO4, 2.4 g KH2PO4, pH 7.4 
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BES Transfection solutions 
2.5 M CaCl2 3.675 g CaCl2 in 10 ml double-distilled 
water. Sterilized by filtration through 0,2µm 
filter. Stored at -20°C 
 
100 mM BES, pH 6.95 0.2132 g BES (N,N-bis(2-hydroxyethly) in 
double-distilled water. pH was adjusted to 
6.95 with NaOH at room temperature. Stored 
at -20°C 
 
2X BBS (BES buffer saline) 50 mM BES, pH 6.95, 280 mM NaCl, 1.5 
mM Na2HPO4 in double-distilled water. 
Sterilized by filtration through 0,2µm filter. 
Stored at -20°C. 
Antibiotics 
Geneticin-G418 Sulfate) 500 mg/ml solution in double-distilled water. 
Sterilized by filtration and stored at -20°C 
(stock solution). 500 µg/ml (working solution 
for stable cell line selection), and 250 µg/ml 
(working solution for maintenance of stable 
cell lines). 
Puromycin 2 mg/ml solution in double-distilled water, 
sterilized by filtration (0.2 um pores) and 
stored at -20°C (stock solution). 2 µg/ml 
(working solution for stable cell line 
selection), and 1 µg/ml (working solution for 
maintenance of stable cell lines). 
 
Tetracycline 1 mg/ml solution in 70% Ethanol, sterilized 
by filtration (0.2 um pores) and stored at -
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20°C (stock solution). 5 µg/ml (working 
solution). 
 
3.2.5 SDS (Sodium Deodecyl Sulfate)-PAGE (Polyacrylamide Gel  Electrophoresis) 
solutions 
30% Acrylamide mix (1:29) Per 100 ml: 29 g acrylamide, 1 g bis-
acrylamide in double-distilled water, filtered, 
degassed, and stored at 4°C (stock solution).  
 
5X SDS gel-loading buffer 3.8 ml double-distilled water, 1 ml of 0.5 M 
Tris-HCl, 0.8 ml glycerol, 1.6 ml of 10% 
SDS, o.4 ml of  0.05% bromophenol-blue. 
Before use, β-mercaptoethanol was added to 
5% to reach 1% when mixed with samples. 
 
5X SDS-electrophoresis buffer Per liter: 15.1 g Tris base, 95 g Glycine, 5 g 
SDS. Diluted to 1 X for working solution. 
Stored up to 1 month at 4°C. 
 
10% Ammonium persulfate (APS)  0.1 g/ml solution in double distilled water 
(Prepared freshly). 
 
1.5 M Tris-HCl, pH 8.8 54.45 g Tris base (18.15 g/100 ml) ~150 ml 
distilled water Adjust to pH 8.8 with 1 N 
HCl. Completed to 300 ml with distilled 
water and stored at 4° C. 
 
1 M Tris-HCl, pH 6.8 12.14 g Tris base ~ 60 ml distilled water Adjust 
to pH 6.8 with 1 N HCl. Completed to 100 ml 
with distilled water and store at 4° C. 
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3.2.6 Immunoblotting solutions 
 
Semi-dry transfer buffer Per liter: 48 mM Tris-base, 39 mM glycine, 
0.037% SDS, 20% methanol. 
  
10X Tris-buffer saline (TBS) Per liter: 100 mM Tris-base, 1.5 M NaCl, pH 
7.6 in double distilled water.  
 
TBS-Tween (TBS-T) 0.1-0.5% Tween-20 solution in TBS. 
(Prepared freshly) 
 
Blocking solution 3-5% (w/v) non-fat milk, 0.1-0.5% Tween-20 
in TBS. (Prepared freshly). 
 
3.2.7 RNA Study Solutions 
 
DEPC-treated water 0.1% Diethylpyrocarbonate (DEPC) (v/v) in 
double-distilled water was stirred in loosely 
plugged bottle. Then autoclaved and stored at 
room temperature.    
 
5X Formaldehyde gel running buffer  Per liter: 20 ml of 2M Sodium Acetate, 20.6 
g MOPS, 780 ml of DEPC treated distilled 
water. pH was adjusted to 7.0 with 5M 
NaOH. Then 10 ml of 0.5 M EDTA pH 8.0 
and volume was completed to 1 liter with 
DEPC-treated water. Stored at room 
temperature. 
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RNA loading buffer  50% formamide, 20% formaldehyde, 15% 
5X running buffer, and 15% glycerol-dye. 
Stored at -20 °C.  
 
3.2.8    Immunofluorescence solutions 
 
H33258 fluorochrome dye 1 mg/ml solution in double-distilled water 
and stored at -20 °C. Working solution was 1 
µg/ml. 
 
DAPI (4', 6-diamidino-2-phenylindole)        0.1-1 µg/ml (working solution in PBS). 
 
4% paraformaldehyde 4 g paraformaldehyde, 5 mM NaOH in 100 
ml. PBS, pH 7.4. Stable at 4°C for a week. 
 
 PBS-TritonX-100 (PBS-T) 0.1 TritonX-100 in PBS. 
 
3.2.9 ELISA solutions 
10X Phosphate-buffered saline (PBS) Per liter: 80 g NaCl, 2 g KCl, 14.4 g 
Na2HPO4, 2.4 g KH2PO4, pH 7.4. 
 
Blocking solution 3-5% (w/v) non-fat milk, 0.1% Tween-20 in 
1X PBS. (Prepared freshly). 
 
AP reagent:      Sigma Fast p-Nitrophenyl Phosphate 
(Product No. N2770). Tablets were dissolved 
in 20 ml water. 150 µl is used per well. 
 
AP-Stop Solution:   3 N NaOH 
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3.3 METHODS 
 
3.3.1  General Methods 
 
3.3.1.1 Transformation of E .coli 
Transformation of plasmid DNA into E. coli was achieved by using calcium 
chloride method. Competent E. Coli was prepared by two different methods as described 
below. 
 
3.3.1.2 Preparation of competent cells 
3.3.1.2.1   Conventional “Calcium Chloride” method 
5 ml LB was inoculated with a single colony from a freshly grown plate of E. coli 
strain (DH5α)  and incubated for approximately 2.5 hours at 37oC, shaking at 200 rpm to 
an optical density 0.6 at 590 nm (OD 590). Then, 1.5 ml of growing cells was centrifuged 
at 13,000 rpm for 1 minute in a bench-top centrifuge. Excess LB was removed away. The 
cells were resuspended in 0.5 ml of 50 mM CaCl2 by gently vortexing, before being 
placed on ice for 30 minutes.  The cells were harvested by centrifugation for 1 minute at 
13,000 rpm and the supernatant was discarded. The pellet was resuspended in 0.1 ml of 
50 mM CaCl2 by gently vortexing. At this stage, bacterial cells were competent, and 
transformed as described in 3.3.1.3.1. 
 
3.3.1.2.2   Super competent E. Coli preparation 
 This method is based on a report by Inoue et al. 1990 (Inoue H. et al., 1990). 
DH5α cells were grown in SOB medium at 30oC to an A600 of 0.5-0.6 with 
vigorous shaking at 200 rpm and cooled down on ice for 10 minutes. Cells were 
transferred to 500 ml centrifuge bottles and centrifuged at 300 rpm (Beckman JA10 rotor, 
pre-cooled to 4oC). The pellet was resuspended in ice-cold transformation buffer (1/3 of 
initial culture volume) by gently swirling and kept on ice for 10 minutes. The suspension 
was then centrifuged at 3,000 rpm for 10 minutes. The pellet was gently resuspended in 
ice-cold transformation buffer (1/12.5 of initial culture volume), DMSO was added with 
gently swirling to a final concentration of 7 %, and incubated on ice for 10 minutes. 
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Tubes were immersed in liquid nitrogen to freeze rapidly and stored at –80oC. 
Supercompetent bacteria were transformed as described in 3.3.1.3.2. 
 
3.3.1.3.1   Conventional “Calcium Chloride” transformation  
This method was used for transformation of plasmids.20 ng plasmid was added to 
competent cells in 0.1 ml of 50 mM CaCl2 and incubated on ice for 30 minutes. Then, 
cells were incubated for 60-90 seconds at 42oC (heat-shock), and placed on ice for 2 
minutes. 800 µl of pre-warmed LB was added onto cells. Cells were cultured for 1hour at 
37oC with vigorous shaking (200 rpm).  After 1 hour incubation, samples were 
centrifuged at 13,000 rpm for 30 seconds, and excess LB was discarded but leaving 
approximately 100 µl of LB. The pellet was resuspended in the remaining LB. 
Resuspended bacteria cells were plated out on LB-agars with selection agents ampicillin, 
kanamycin or ampicillin/kanamycin) and incubated overnight at 37oC without shaking to 
allow the growth of the transformants. 
 
3.3.1.3.2   Super Competent E.coli Transformation  
This method was used for transformation of ligation products. Competent cells 
from –80oC stock were thawed on ice. 50-100 µl of cells was dispensed into plastic tubes. 
150 ng of ligation product was added onto supercompetent cells. Then cells were 
incubated on ice for 30 minutes. After heat-shock for 30 seconds at 42oC, the tubes were 
put on ice and 800 µl SOC was added. Following incubation for 1 hour at 37oC with 
vigorous shaking, cells were plated out on LB-agar with selective agent(s). 
 
3.3.1.3    Long term storage of bacterial strains  
To keep bacterial cells including plasmid in it or as empty for future experiments 
and to have a stock of strain in a laboratory is necessary. The most frequently used 
method is “Glycerol-Stock” method.  A single colony picked from either an agar plate or 
a loop-full of bacterial stock was inoculated into 5 ml LB (with a selective agent if 
necessary) in 15 ml screw capped tubes. Tubes were incubated overnight at 37oC and at 
200 rpm. For glycerol stock, 700 µl of saturated culture was added into 700 ml of 65% 
 60
glycerol v/v (32.5 ml glycerol, 5 ml MgSO4, 1.25 ml Tris-Cl pH 8.0 completed to 50 ml 
with sterile water).  This mix was frozen/stored at –70 or -80oC 
 
3.3.1.4   Purification of plasmids 
 
3.3.1.4.1   Small scale preparation of plasmids (miniprep) 
This method was preferred for isolation of plasmids to assess the existence of inserts in 
plasmids. This protocol is based on the alkaline lysis method of Birnboim and Doly 
(Birnboim HC. and Doly J., 1979) and modified in some parts. The transformed bacterial 
strain containing the plasmid of interest was grown in 5 ml LB+ selective agent overnight 
at 37oC with vigorous shaking at 200 rpm. 1.5 ml of the saturated bacterial culture was 
centrifuged for 1 minute at 13,000 rpm in a bench-top micro centrifuge.  After removal of 
supernatant, the pellet was resuspended in 100 µl ice-cold Solution I and stored at room 
temperature for 5 minutes. Freshly prepared 200 µl of Solution II was added and mixed 
by inverting the tube very gently and then tube was placed on ice for 5 minutes. Bacterial 
chromosomal DNA and proteins (cell debris) were precipitated by addition of 150 µl of 
ice-cold Solution III. This mixture was left on ice for 5 minutes, and then centrifuged for 
5 minutes at 13,000 rpm to pellet the host DNA and cell debris. The supernatant was 
mixed very well with an equal volume of phenol-chloroform (1:1) and centrifuged in a 
microcentrifuge for 3 minutes to separate the two phases. The top-phase was transferred 
to another 1.5 ml tube. The plasmid DNA was precipitated by adding 800 µl ice-cold 
absolute ethanol and mixture was incubated for 15 minutes to 1 hour at –20oC. The 
plasmid was pelleted by centrifugation at 13,000 rpm, room temperature for 15 minutes. 
The supernatant was discarded and the pellet was washed with 300 µl of 70% room 
temperature ethanol and centrifuged at 13,000 rpm for 15 minutes. The supernatant was 
discarded and the pellet was left at room temperature for 15-20 minutes to dry and then 
resuspended in 20 µl of sterile distilled H2O containing 20 µg/ml RNaseA and incubated 
for 30 minutes to 1 hour at 37oC. Samples were stored at 4oC for short term or at –20oC 
for long term. This procedure yields approximately 1-3 µg of DNA. The quality of mini-
prep was checked by loading 1-2 µl of 20 µl final yields on agarose gel and visualizing 
under U.V.  
 61
 
3.3.1.4.2   Purification of plasmid DNA using MN (Macherey-Nagel) miniprep kit 
This method was preferred for isolation of plasmids in order to use in sequencing 
or cloning procedures. 5 ml of saturated culture was used for isolation of plasmid DNA 
by using “MN miniprep plasmid DNA purification kit” (MN Macherey-Nagel, Duren, 
Germany) following manufacture’s instructions. 
 
3.3.1.4.3   Large-scale plasmid DNA purification 
This method was used for isolation of plasmids in order to use in sequencing or 
mammalian cell transfection procedures by using “Qiagen large-scale plasmid DNA 
purification kit” following manufacture’s instructions. 
 
3.3.1.5 Preparation of genomic DNA from cultured Cells for “TeloTAGGG Telomere 
Length Assay” 
 Cultured cells were grown in 15mm tissue culture dishes to 70-80% confluency, 
trypsinized, and washed with 1X PBS. Genomic DNA was isolated by using “MN 
Genomic DNA isolation kit” following manufacturer’s instructions. 
 
3.3.1.6 Quantification and qualification of nucleic acids 
Concentration and purity of the double stranded nucleic acids (plasmid and 
genomic DNAs), oligonucleotides and total RNAs were determined by using the 
Beckman Instruments Du Series 600 Spectrophotometer software programs (ds DNA, 
Oligo DNA Short and RNA methods) on the Beckman Spectrophotometer Du640 
(Beckman Instruments Inc. CA. USA). 
 
3.3.1.7 Restriction enzyme digestion of DNA 
 Restriction enzyme digestions were routinely performed in 20 µl reaction 
volumes and typically 0.5-5 µg DNA was used. Reactions were carried out with the 
appropriate reaction buffer and conditions according to the manufacturer’s 
recommendations. 
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 Digestion of DNA with two different restriction enzymes was performed in the 
same reaction buffer to provide the optimal condition for both restriction enzymes. If no 
single reaction buffer could be found to satisfy the buffer requirements of both enzymes, 
the reactions were carried out sequentially.  
 
3.3.1.8 Gel electrophoresis of nucleic acids 
 
3.3.1.8.1   Horizontal agarose gels of DNA samples 
DNA fragments were fractionated by horizontal electrophoresis by using standard 
buffers and solutions. DNA fragments less than 1 kb were generally separated on 1.0% or 
20 % agarose gel, those  greater than 1 kb (up to 11 kb) were separated on 0.8 % agarose 
gels. 
 Agarose gels were completely dissolved in 1x TAE electrophoresis buffer to 
required percentage in microwave and ethidium bromide was added to final concentration 
of 30 µg/ml. The DNA samples were mixed with one volume loading buffer and loaded 
onto gels. The gel was run in 1x TAE at different voltage and time depending on the size 
of the fragments at room temperature. 
 
3.3.1.8.2   Gel electrophoresis of total RNA 
 RNA was fractionated through 1% (w/v) agarose gels containing formaldehyde 
which disrupts hydrogen bonds. 0.5 g agarose was melted in 1X formaldehyde gel 
running buffer, allowed to cool, and 10 ml of 37% formaldehyde was added. The gel 
was immediately poured in a laminar hood. 5µl of RNA sample was mixed with 15 µl 
of RNA loading buffer and heated at 70 °C for 5 minutes. Samples were quenched on 
ice and loaded onto gel. Electrophoresis was performed at a constant voltage (85 V) 
for 4 hr at   4 °C in 1X formaldehyde gel running buffer. Following electrophoresis, 
gel was soaked for 5 min in 5 volumes water to remove formaldehyde. This step was 
repeated for 3 times. The gel was stained in 30ug/ml ethidium bromide solution for 5 
min, and destained overnight in double-distilled water.  
 
 63
 Nucleic acids were visualized under ultraviolet light (long wave, 340 nm) and 
GeneRuler (MBI Fermentas) DNA size markers was used to estimate the fragment 
sizes.1 kb DNA ladder for horizontal agarose gels and 100 bp ladder for vertical agarose 
gels. 
 
3.3.2 Computer analyses 
 Restriction endonuclease maps of the plasmid DNAs were analyzed by using the 
WebCutter program (Max Heiman, 1995, maxwell@minerva.cis.yale.edu) available for 
free and public use at http://rna.lundberg.gu.se/cutter2/. Primers were designed by using 
web software provided by Steve Rozen and Whitehead Institute for Biomedical Research 
at http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi. Alignments of nucleic acids 
or protein sequence were performed by using web page at 
http://www.ncbi.nlm.nih.gov/BLAST/. 
 
3.3.3 Production and characterization of anti-β-catenin monoclonal antibodies 
3.3.3.1 Immunization of mice with recombinant β-catenin protein  
  Production and isolation of 6x His-tagged recombinant 90-781 human β-
catenin were performed as described previously (Ozturk N., 2000). BALB/c mice 
were primed with complete Freund's adjuvant (CFA) plus 25 mg recombinant protein 
subcutaneously (s.c), and boosted with 25 mg recombinant protein plus incomplete 
Freund's adjuvant (IFA) s.c at days 14, 28, 42. 50 µl of blood was taken from the tail 
of immunized mouse 7 days after each boost. Serum obtained from tail blood was 
used to screen immunoreactivity by using ELISA. The spleen of immunized mouse 
was harvested at day 50, and used for fusion with SP-2 myeloma cell line. 
 
3.3.3.2 Fusion 
Harvested spleen was rinsed in the 100 mm petri dish containing 10 ml of 
serum-free high-glucose DMEM,  then placed in the second 100 mm petri dish 
containing 3 ml of serum-free high-glucose DMEM. With a medium-filled syringe (5 
ml) in each hand, the spleen was poked at 30-50 holes. Then, the spleen was minced 
with sterile small 26 gauge needles. Dissociated cells were centrifuged at 1000 rpm 
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for 5 minutes. When the spleen cells pellet is free of red blood cells, the cells were 
combined with SP-2 BALB/c myeloma cells by resuspending the cells in 15 ml of 
complete high-glucose medium at room temperature. Combined cells were 
centrifuged at 800 g for 5 minutes; supernatant was aspirated and washed for a second 
time. Then, supernatant was aspirated off all. Cell pellet was quickly resuspended in 1 
ml of 50% PEG-4000. Then, 10 ml of complete medium was added into tube in about 5 
minutes. Cells were carefully inverted to mix thus diluting the PEG. Cells were 
centrifuge at 400 g for 3 minutes and supernatant was aspirated off. 10 ml of HAT 
medium was added at a rate sufficient to dislodge the pellet without dispersing the cells. 
The fused cells were allowed to "rest" for 10 minutes then drew into a pipette and 
expelled with just enough force to disperse the cells. The cells were taken into a 75cm² 
tissue culture flask in a total of 150 ml of HAT medium, then plated evenly into eight 96-
well microtiter plates. The cultures were feed with one drop per well (approx. 60 µl) of 
fresh medium every 3-5 days. When cells were grown until their medium color got 
yellowish, supernatant samples were taken to test immunoreactivity with ELISA. 
Antibody producing hybridoma clones were selected for recloning. 
 
3.3.3.3 Recloning (Subcloning) 
96 well culture plates were coated with spleen cells from non-immunized mice. 
Next day, hybridoma clones were serially diluted into these wells.  Clones growing in the 
most diluted wells were taken and tested for immunoreactivity. Subclones were cultured 
in HAT medium for one month and then in HT medium for another month.  
 
3.3.3.4 Maintenance of hybridomas and collection of hybridoma supernatant 
Hybridoma cells were maintained in completed high-glucose medium and 
supernatant were collected when cells reach the confluency. Medium was centrifuged at 
800 g to rid off cell debris. Collected hybridoma supernatants were tested for 
immunoreactivity with ELISA, and stored at -20oC or 4oC. 
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3.3.3.5 Characterization of Ig subtypes of the anti-β-catenin antibodies 
Subtypes of anti-β-catenin antibodies were identified by using “ImmmunoPure 
Monoclonal Antibody Isotyping Kit II” (Pierce) following kit instructions. 
 
3.3.3.6 Production of anti-β-catenin ascites in BALB/c mice 
 The BALB/c mice was primed by injecting 200 µl incomplete Freund’s 
adjuvant into peritoneal cavity. 10x106 cells were washed twice in sterile PBS and 
centrifuged at 1500 rpm for 5 minutes. The cell pellet was resuspended in 500 µl PBS 
and injected to the intraperitoneal region of the mice after 7-14 days of priming. After 
7-14 days the ascitic fluid was aspirated from the animal by using an injector and was 
incubated at 37oC for 1 hour.  The ascitic fluid was then incubated at 4oC overnight 
and centrifuged at 800 g for 10 minutes. The oil layer was discarded and the 
supernatant was stored at –70oC or -20oC. 
 
3.3.4  Epitope mapping of home-made monoclonal anti β-catenin antibodies 
Epitopes of home-made monoclonal β-catenin antibodies were identified by using 
β-catenin fragments fused to GST protein. 
 
3.3.4.1 Bacterial expression constructs 
Short β-catenin fragment coding sequences were amplified from pCI-Neo-S33Y 
with Pfu Polymerase. Bam HI site and stop codon plus Sal I sites were added into 5’ of 
forward and reverse primers respectively. PCR products were cut with Bam HI and Sal I, 
and inserted into Bam HI and Sal I sites of pGEX4T1. Fidelity of constructs was verified 
by sequencing with pGEX4T1 sequencing primers. 
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Primer ID Sequence (5’ ? 3’) 
DTDL deletion (Reverse) AGGTCGACTTAAAACCAGGCCAGCTGATTG 
S Later deletion (Reverse) GCGTCGACTTAATCACCTGGGGGCAGCC 
BCAT-341-F (Forward) GGAGGATCCAGCAGAGTGCTGAAGGTGCT 
BCAT-535-F (Reverse) CAAGTCGACTTATCGTGGAATGGCACCCT 
BCAT-652 (Reverse) AGCGTCGACTTACGCCACACCTTCATTCCT 
BCAT-654-F  (Forward) TGGGATCCTACGCAGCTGCTGTCCTATT 
BCAT-644-F  (Forward) ACAGGATCCCTCCACTCCAGGAATGAAGG 
BCAT-725-F (Forward) TCTGGATCCTACGGCCAGGATGCCTT 
BCAT -739-R  (Reverse) ATGGTCGACTCACATCTCATGCTCCATCATAGG 
BCAT-749 (Reverse)  CAGGTCGACTTATGGATAGTCAGCACCAGG 
Table 3.1: The sequences of primers used for cloning and sequencing. Underlined sequences represent 
restriction enzymes sites, italic sequences represent stop codons. 
 
 
3.3.4.2 Induction and batch purification of GST fusion proteins. 
DH5α strain transformed with expression constructs were grown in LB until 
cultures reached 0.6 at OD600. Expression of recombinant proteins was induced by adding 
0.5 mM IPTG into cultures and incubating for 2 hours at 37oC. 10 ml of induced cultures 
were centrifuged for 10 minutes at 5500 rpm. The pellet was resuspended in 5 ml 1x ice-
cold PBS, and sonicated. 1 ml of Glutathione Sepharose 4B equilibrated with PBS was 
added onto the sonicated bacteria, and incubated with gentle agitation at room 
temperature for 30 minutes. The mixture were loaded into column, and washed with 20 
ml of 1x PBS at room temperature. Recombinant proteins were eluted with 2 ml of 50 
mM Tris-HCl, 10 mM reduced glutathione, and 50 µl aliquots were kept -20oC. 
 
3.3.5 Tissue culture techniques 
 
3.3.5.1 Cell Lines and stable clones 
 14 HCC derived cell lines (Huh7, FOCUS, Mahlavu, Hep40, Hep3B, HepG2, 
PLC/PRF/5, SK-Hep1, Snu182, Snu387, Snu398, Snu423, Snu449 and Snu475) were 
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used in this study, and cultured as described in previously (Cagatay T. and Ozturk M., 
2002). 
Breast cancer cell lines T-47D (ATCC) and BT-474 (ATCC) were cultivated in 
DMEM. hTERT-HME cells (Clontech) were cultivated in DMEM/Ham’s F-12 
(Biochrom) containing insulin (3.5 mg/ml), EGF (0.1 ng/ml), hydrocortisone (0.5 µg/ml), 
and 10% FBS (Biochrom). Huh7- and Hep3B-derived isogenic clones were obtained by 
either G-418 selection after transfection with neomycin- resistance pcDNA3.1 
(Invitrogen) or pEGFP-N2 (Clontech) plasmids, or by low-density cloning. Huh7-derived 
isogenic clones C1 and C3 were obtained with pCDNA3.1 and G12 with pEGFP-N2. 
Huh7-derived C11, and Hep3B-derived 3B-C6, 3B-C11 and 3B-C13 were obtained by 
low-density cloning. Cells transfected with calcium phosphate DNA-precipitation method 
were cultivated in the presence of geneticin G-418 sulfate (500 µg/ml; GIBCO), and 
isolated single cell-derived colonies were picked up by using cloning cylinders and 
expanded in the presence of  200 µg/ml geneticin G-418 sulfate. For low-density cloning, 
cells were plated at 30 cells per cm2 and single-cell derived colonies were expanded. 
Initial cell stocks were prepared when total number of cells became 1–3 x107, and the 
number of accumulated population doubling (PD) at this stage was estimated to be 24, 
assuming that the progeny of the initial colony-forming cells performed at least 24 
successive cell divisions until that step. Subsequent passages were performed every 4–7 
days, and the number of additional PD was determined by using a described protocol 
(Masutomi K. et al., 2003). Briefly, 5x104 cells were seeded in six-well plates in 
triplicates and cultured for 48 hr. Following trypsinization, cells were resuspended in 
culture medium and counted manually with a hemocytometer. PD were determined by 
the formula: PD = Log(Nf/Ni)/Log2, where Nf =the number of cells counted and Ni = the 
number of cells seeded. 
 
3.3.5.2 Thawing cell lines 
One vial of the frozen cell line from the liquid nitrogen tank was taken and 
immediately put into ice. The vial was left 1 minute on the bench to allow excess 
nitrogen to evaporate and then placed into 37oC water bath until the external part of 
the cell solution was thawed (takes approximately 1-2 minutes). The cells were 
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resuspended gently using a pipette and transferred immediately into a 15 ml. sterile 
tube containing 10 ml cold fresh medium. The cells were centrifuged at 1500 rpm at 
4oC for 5 minutes. Supernatant was discarded and the pellet was resuspended in 10 ml 
37oC culture medium to be plated into 100 mm dish. After overnight incubation in a 
humidified incubator at 37°supplied with 5% CO2, culture mediums were replenished. 
 
3.3.5.3 Growth conditions of cells 
 Dulbecco’s modified Eagle’s medium (DMEM) or RPMI 1640 supplemented 
with 10% FCS, 1 mM glutamine and penicillin and streptomycin (50 mg/ml), and 1% 
NEAA was used to culture the HCC cell lines. The cells were incubated in at 37°C in an 
incubator with an atmosphere of 5% CO2 in air. hTERT-HME cells (Clontech) were 
cultivated in DMEM/Ham’s F-12 (Biochrom) containing insulin (3.5 mg/ml), EGF (0.1 
ng/ml), hydrocortisone (0.5 µg/ml), and 10% FBS (Biochrom). Empty vector transfected 
stable clones were cultured in parental cell line’s culture medium + 200 µg/ml geneticin 
G-418 sulfate, or 1 µg/ml puromycin. Tetracycline inducible cells were cultured in 
parental cell line’s culture medium + 200 µg/ml geneticin G-418 sulfate + 5 µg/ml 
tetracycline.  
 The cells were passaged before reaching confluence. The growth medium was 
aspirated and the cells were washed once with calcium and phosphate-free PBS. Trypsin 
was added to the flask to remove the monolayer cells from the surface.  The fresh 
medium was added and the suspension was pipetted gently to disperse the cells. The cells 
were transferred to either fresh petri dishes or fresh flasks using different dilutions (from 
1:2 to 1:10) depending on requirements. 
 All media and solutions used for culture were kept at 4°C (except stock solutions) 
and warmed to 37°C before use. 
 
3.3.5.4 Cryopreservation of cell lines 
 Exponentially growing cells were harvested by trypsinization and neutralized with 
growth medium. The cells were counted and precipitated at 1500 rpm for 5 min. The 
pellet was suspended in a freezing solution (10% DMSO, 20% FCS and 70% DMEM for 
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adherent cells; 10% DMSO, 90% FCS for hybridoma cells) at a concentration of 
4x106cells/ml.  1 ml of this solution was placed into 1 ml screw capped-cryotubes.  The 
tubes were left at -70°C overnight. The next day, the tubes were transferred into the 
liquid nitrogen storage tank. 
  
3.3.5.5 Transient transfection of eukaryotic cells using BES method 
 Certain amount of cells was plated tissue culture dishes the day before the 
transfection to obtain 50-60% confluency on the day of transfection. 1 hour before 
transfection, growth medium was aspirated and replaced with 9 ml growth medium 
without antibiotics.  Appropriate amount of supercoiled eukaryotic expression/reporter 
were mixed with double-distilled water. Certain amount of 2.5 mM CaCl2 was added in 
dropwise manner while vortexing the DNA solution. After incubation at room 
temperature for 10 min, certain amount of 2X BBS was added to DNA-CaCl2 solution in 
dropwise fashion, and incubated at room temperature for 40 min until calcium phosphate-
DNA precipitates. Calcium phosphate-DNA solution was added dropwise to the plate of 
cells, and the mixture was stirred gently and incubated for 18 hr at 37°C in an incubator 
with an atmosphere of 5% CO2 in air. The medium was aspirated and rinsed twice with 
fresh growth medium, re-fed and placed back to the incubator for a further 24 hr. The 
appropriate amounts of DNA and reagents used for transfection in different culture plates 
were given in Table 3.2. 
 
Reagent 100 mm petri 
dishes 
6 well plates 24 well plates 
DNA Up to 24 µg Up to 4 µg Up to 0.8 µg 
2.5 mM 50 µl 15 µl 5 µl 
ddH2O 450 µl- DNA 
volume 
135 µl –DNA 
volume 
45  µl – DNA 
volume 
2xBBS 500 µl 150 µl 50 µl 
Culture medium 9 ml 2.7 ml 1 ml 
 
Table 3.2: The amounts of reagents and media used in BES- transfection method. 
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3.3.5.6 Transient transfection of eukaryotic cells using “Lipofectamine Reagent” 
Transfection was performed with Lipofectamin 2000 reagent (Invitrogen) 
following manufacturer’s instructions. 
 
3.3.6 Extraction of total RNA from tissue culture cells and tissue samples 
Total RNAs were isolated from cultured cells using the NucleoSpin RNA II Kit 
(MN Macherey-Nagel, Duren, Germany) according to the manufacturer’s protocol. 
 
3.3.7  First strand cDNA synthesis 
First strand cDNA synthesis from total RNA was performed using RevertAid First 
Strand cDNA synthesis kit (MBI Fermantas, Germany). The RevertAid kit relies on 
genetically engineered version of Moloney Murine Leukemia Virus reverse transcriptase 
(RevertAid M-MuLV RT) with low RNase H activity. This allows the synthesis of full-
length cDNA from long templates. The first strand reactions were primed with 
oligo(dT)18 primer to specifically amplified mRNA population with 3’-poly(A) tails. As 
the reaction conditions and components of this kit and those of conventional PCR are 
compatible, first strand synthesized with this system can be used as a template for PCR. 
 1 to 5 µg total RNA was used to synthesize the first stand cDNA following the 
manufacturer’s instruction.  After 1:1 dilution of total reaction products in DEPC-treated 
water, 2 µl of diluted first strand cDNA was used for PCR.  
 
3.3.8 Primer design for expression analysis by semi-quantitative PCR 
 The primer pairs that have been used in expression profile analyses were 
designed carefully. Forward and reverse primer were positioned on different exons of 
the gene of interest, so that the primer pair was either be able to produce a longer 
amplicon from genomic DNA or  not be able to amplify from the covered genomic 
DNA region in a given PCR condition (critical parameter was extension time). 
Therefore the amplicon, which was amplified from cDNA, was not be longer than 
1500 bp. Primers used for expression analysis have been designed strictly considering 
these criteria, and listed in Table 3.3. 
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3.3.9 Fidelity and DNA contamination control in first strand cDNAs 
The fidelity and genomic DNA contamination of first strand cDNAs were 
checked before performing expression analyses. 2µl of diluted first strand cDNA was 
used for cold-PCR amplification of the glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) transcript. GAPDH primer pair for this analysis was designed to produce a 
151 bp fragment from cDNA and 250 bp fragment from genomic DNA. 
 
3.3.10 Expression analysis of a gene by semi-quantitative PCR 
 Determination of optimal cycle of a gene for semi-quantitative PCR 
Using equal amount of templates for PCR amplifications of a gene of interest give 
comparable results at a certain number of PCR cycles. The number of optimal PCR cycle 
was determined by an initial study for each gene by performing 35-cycle PCR during 
which PCR amplicon samples were collected by 2-cycle intervals. Agarose gel analysis 
of samples from 20th, 23rd, 26th, 29th, 32nd, 35th, 36th 39th, 41st, 43rd, 45th cycles of PCR 
with an equal load defined the minimum number of cycle to visualize the product on 
agarose gel and the saturation cycle. Agarose gels were analyzed by Densitometric 
Fluorescence-Chemiluminescence image analyzer and The Molecular Analyst software 
(BioRad). The determined cycle number was used for amplification of the gene of 
interest.  
GAPDH normalization  
Equal volume (2µl) of all first strand cDNA samples was used for cold-PCR 
amplification of GAPDH transcript using the pre-determined optimal cycle number for 
GAPDH. Then an equal volume of each sample was loaded onto agarose gel and 
intensity of each band was analyzed by Densitometric Fluorescence-Chemiluminescence 
image analyzer and The Molecular Analyst software. After intensities were determined, 
intensity of sample with the highest densitometric reading  and 2 µl loading volume were 
used as reference points for normalization of input loading volume of other samples for 
expression analysis of both GAPDH and gene of interest by cold PCR amplification. 
Amplification products were analyzed in computer. 
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Target Oligos (5’? 3’) Tm=oC 
hTERT-F CGGAAGAGTGTCTGGAGCAA 
hTERT-R GGATGAAGCGGAGTCTGGA 58 
hSIP1-F GGAAGACAAGCTTCATATTGC   
hSIP1-R ATGGCTGTGTCACTGCGCTGA 60 
GAPDH-F GGCTGAGAACGGGAAGCTTGTCAT 
GAPDH-R CAGCCTTCTCCATGGTGGTGAAGA 62 
mSIP1-F GGCTTACCTGCAGAGCATC 
mSIP1-R CCTCTGAACTGTCGTCCATC 58 
Cyclin E-F TTGACCGGTATATGGCGACACAAG 
Cyclin E-R ATGATACAAGGCCGAAGCAGCAAG 62 
Mad1-F ACCAAATCGACCAGCTTCAG 
Mad1-R AGTTGTGGGCAGGTCCAATA 60 
Menin-F GACCTGTCCCTCTATCCTCG 
Menin-R TGACCTCAGCTGTCTGCTCC 55 
Rak-F CCGATGTATGGTCATTTGGA 
Rak-R CTGATTGTGCAGTTGGTTGA 58 
BRIT1-F CGAAGTGAGTGCCACTTGTC 
BRIT1-R ACGCCAGTTCCTTCTCTTCA 59 
Cyclin D1-F GAGAAGCTGTGCATCTACACCGAC 
Cyclin D1-R CACATCTGTGGCACAAGAGGCAAC 62 
p16INKa -F CGGAGAGGGGGAGAACAGAC 
p16INKa -R GGCAGTTGTGGCCCTGTAGG 60 
p14ARF -F TCACCTCTGGTGCCAAAGG 
p14ARF -R GGCAGTTGTGGCCCTGTAGG 60 
c-Myc-F GGAACTATGACCTCGACTACGACTC 
c-Myc-R GCGGCGGCCGAGAAGCCGCTCCACAT 62 
hSIR2-F GGTACCGAGATAACCTTCTGTTC 
hSIR2-R GGACCTATCCGTGGCCTT 58 
p21Cip1-F CAGGGGACAGCAGAGGAAGA 
p21Cip1-R TTAGGGCTTCCTCTTGGAGAA  
E-Cadherin-F TCCCATCAGCTGCCCAGAAA 
E-Cadherin-R TGACTCCTGTGTTCCTGTTA 60 
TGF-β1-F TGCGGCAGCTGTACATTGA 
TGF-β1-R TGGTTGTACAGGGCCAGGA 60 
Table 3.3: RT-PCR primer list. 
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3.3.11 Crude total protein extraction 
Adherent monolayer cells (both stable and parental cells) were grown to 70% 
confluency in growth medium lacking selective antibiotic. After removal of growth 
medium, cells were washed twice with ice-cold PBS to remove any serum residue. 400 µl 
of RIPA lysis-buffer (150 mM NaCl, 50 mM Tris-HCl pH 8.0, 0.5% sodium 
deoxycholate, 1 % NP-40, 0.1% SDS and 1X Complete Protein Inhibitor mix (Roche)) 
was added into 10 cm tissue culture petri dish, and cells were scraped with rubber 
scrapper. Complete lysis was achieved by pipetting of crude cell lysates several times and 
by incubating the lysates on ice for 30 min, and then centrifuged at 13.000 g for 30 
minutes. Total cell protein was collected as supernatant. 
 
 
3.3.12 Western blotting 
 The conventional Bradford protein assay was employed to quantity the protein in 
the lysates obtained from either Crude total. After protein quantification, protein lysates 
were aliquoted into fresh tubes and, stored at –70°C.  
 8%, 10%, 12%, or 15% resolving gel and 5% stacking gel was used in SDS-
PAGE analysis of protein lysates.  
EC-120 (E-C Apparatus Corp., Holbrook, NY, USA) and ProteanII-xi (BioRad) 
vertical gel system was set up according to manufacturer’s instructions. The standard 
SDS-electrophoresis buffer system was used.  
Equal amounts of cell lysates were solubilized in 1X SDS gel-loading buffer, 
denatured at 100°C for 7 min and incubated on ice for 2 min. After a quick spin, samples 
were loaded onto SDS-polyacrylamide gel. After electrophoresis at 80 V for 20 minutes 
followed by 120 V for 1-2 hours, proteins were transferred onto PVDF western blotting 
membrane (Roche) by using Transblot-Semi Dry (BioRad) elektroblotting apparatus 
according to the manufacturer’s instructions at 12V for 45 min for EC-120 gel. 
Membrane was immediately treated for an hour in blocking solution at room 
temperature and probed with primary antibody either for an hour at room temperature or 
overnight at 4°C. After washing 4 times for (5 min, 15 min, 5 min, 5 min) in TBS-T 
solution at room temperature, the membrane was incubated with appropriate HRP-
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conjugated secondary antibody for 1 hr. The membrane was washed 3 times for 5 min in 
TBS-T solution at room temperature. After final wash, the blot was exposed to ECL 
western blot detection kit (Amersham) according to manufacturer’s instructions. The 
chemiluminescence emitted was captured on X-ray film within 30 sec. to 5 min. exposure 
times.  
 
Antibody Working 
Dilution (WB) 
Source 
β-catenin (MAb) 1:5000 Transduction Labs. 
β-catenin (MAb) 1:5000 AbCam 
β-catenin (Rab. PAb) 1:2000 AbCam 
C/EBPα (Rabbit PAb) 1:500 Santa Cruz 
C/EBPα (Goat. GAb) 1:500 Santa Cruz 
p53 (MAb) 1:1 Clone 6B10; Yolcu E. et al., 2001 
Cyclin D1 1:500 Santa Cruz 
p16 1:500 Abcam 
Rb 1:1000 Santa Cruz 
Calnexin (Rabbit PAb) 1:10000 Sigma 
Cyclin E 1:500 Transduction 
Cyclin A 1:500 AbCam 
p21Cip1 1:500 Santa Cruz 
CDK4 1:500 Santa Cruz 
CDK2 1:500 Santa Cruz 
E-cadherin  1:2000 Santa Cruz 
 
Table 3.4: Antibodies used for immunoblot assays and their working dilutions. MAb: Mouse 
monoclonal antibody; Pab; PAb: Rabbit polyclonal antibody; Goat PAb: Goat Polyclonal antibody 
 
3.3.13 Immunofluorescence  
Autoclaved-sterilized coverslips were placed into the well of 6-multiwell plates. 
6x104 cells were seeded onto each coverslip and grown overnight in 1 ml growth 
medium. Cells were washed with PBS and fixed in 1 ml of 3% formaldehyde for 3 min. 
After fixation cells were permeabilized with 0.5% TritonX-100 in PBS for 3 min and 
blocked in 1 ml blocking solution (3% bovine serum albumin-Fraction V, 0.1% TritonX-
100 in 1X PBS) for 30 min at room temperature. Coverslips were probed with primary 
antibody in appropriate dilution for 1 hr at room temperature. After 3 times washing for 5 
min each with PBS-T, appropriate FITC-conjugated secondary antibody was applied for 
45 min at room temperature. Cells were washed 3 times for 5 min with PBS-T and DNA 
counter staining was performed by with Hoechst 33258 for 3 min. Hoechst 33258 was 
aspirated and destaining was done in double-distilled water for 15 min. Immediately after 
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coverslips were taken out from the well and excess water removed by tissue paper, 
coverslips were mounted onto slides containing 10 µl 80% glycerol. All steps after the 
addition of FITC-conjugated secondary antibody were performed in the dark.  
Stained cells were examined under fluorescence microscope (ZEISS) and pictures 
were captured in a digital Kodak Camera (DC290, Eastman Kodak Co., Rochester, NY), 
using Adobe Photo Deluxe (Adobe Systems Inc.) software. The pictures were edited 
using Adobe Photoshop 5.0 (Adobe Systems Inc.) software. Digital images were 
magnified when needed during picture editing. 
 
3.3.14 Immunoprecipitation and SAP treatment 
Huh7 cells were cultured to confluency in 100 mm petri dishes. Cells were lysed 
in NP40 buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1X protease inhibitor cocktail 
(Roche), 1.0% NP-40, 0.5% Sodium Deoxycholate, 1 mM Na3VO4, 1 mM NaF, and1 
mM PMSF). Lysate was pre cleared by centrifuging at 13,000 rpm, at 4°C for1 5 
minutes. Supernatant was transferred into a new tube, 4 µg of polyclonal anti-β-catenin 
antibody or E-cadherin antibody (for co-immunoprecipitation of E-cadherin associated β-
catenin pool) was added. However, for E-cadherin immunoprecipitation NP-40 lysis 
buffer included 1 mM EDTA, pH 8.0. The tubes were rotated overnight at 4oC to allow 
formation of immune complexes. 60 ml of 50% slurry Protein G equilibrated with NP-40 
buffer was added into the mixture, and rotated for 1 hour at 4oC. Immune complexes 
were washed three times with NP-40 lysis buffer. The bead-bound immune complexes 
were additionally washed with 50 mM Tris-HCl, pH 8.5 twice. Then immune complexes 
were resuspended and equal amounts were dispersed into two tubes. Mock or SAP treated 
tubes were incubated for 30 minutes at 37oC. The reaction was stopped by adding 1x 
SDS-loading dye. Samples were subjected to Immunoblotting with 4C9, 9E10 or 
commercial antibodies. 
For co-IP of β-catenin with C/EBPα, the same protocol was followed until 
washing step of immune complexes with NP-40 buffer. In this case, NP-40 lysis buffer 
did not include Na3VO4 and PMSF. Immune complexes were washed 5 times in this 
case, and then dissolved in 1x SDS-loading dye. 
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3.3.15 BrdU incorporation assay.  
Subconfluent cells were labeled with BrdU for 24 h in freshly added culture 
medium and tested as described (Erdal E. et al., 2005), using anti-BrdUrd antibody 
(Dako) followed by tetramethylrhodamine B isothiocyanate-labeled secondary antibody 
(Sigma). DAPI (Sigma) was used for counterstaining. 
 
3.3.16 Low-density clonogenic assay 
 Cells (30–50 per cm2) were plated in six-well plates and grown 1–3 weeks to 
obtain isolated colonies formed with 100–1,000 cells. The medium was changed every 4 
days, and colonies were subjected to SABG staining. 
 
3.3.17  In vivo studies 
 Cells were injected s.c. into CD-1 nude mice (Charles River Breeding 
Laboratory). Tumors and nontumorigenic cells at the injection sites were collected at day 
35 and analyzed directly or after in vitro culture by SABG assay. These experiments have 
been approved by the Bilkent University Animal Ethics Committee. 
 
3.3.18  SABG assay 
 SABG activity was detected by using a described protocol (Dimri GP. et al., 
1995). After DAPI or eosin counterstaining, SABG positive and negative cells were 
identified and counted. 
 
3.3.19 TRAP and telomere length assays 
Telomerase activity and telomere length assays were performed by using 
TeloTAGGG Telomerase PCR ELISAPLUS and TeloTAGGG Telomere Length Assay 
(Roche Diagnostics), following kit instructions. 
 
3.3.17  shRNA 
 SIP1-directed shRNA was designed according to a previously described effective 
siRNA sequence  using the pSUPER RNAi system instructions (Oligoengine) and cloned 
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into pSuper.retro.neo_GFP and pSUPER.puro (Oligoengine), respectively. SIP1 shRNA-
encoding sequence was inserted by using oligonucleotides described below. 
(sense, 5’ ? 3’) 
GATCCCCCTGCCATCTGATCCGCTCTTTCAAGAGAAGAGCGGATCAGATGCAGTTTTTA 
(antisense, 5’?3’)  
 AGCTTAAAAACTGCCATCTGATCCGCTCTTCTCTTGAAAGAGCGGATCAGATGGCAGGGG 
 The integrity of the inserted shRNA-coding sequence has been confirmed by nucleic acid 
sequencing of recombinant plasmids. Cells were transfected with calcium phosphate 
precipitation method, using either pSuper.retro.neo_GFP-based or pSUPER.puro-based 
SIP1 shRNA expression plasmid, and cells were maintained in the presence of 500 µg/ml 
geneticin G-418 sulfate and 2 µg/ml puromycin (Sigma), respectively. Empty vectors 
were used as control. Media changed every 3 days, and cells were tested at days 5 and 30. 
 
      3.3.21 ELISA (Enzyme-linked immunosorbant assay) 
        This method combines the specificity of antibodies with the sensitivity of simple 
spectrophotometric enzyme assay by using antibodies or antigens coupled to an easily 
assayed enzyme having also a high turnover number.  Indirect ELISA method may be 
used to measure the presence and/or levels of antibody in a liquid such as sera. The 
antiserum reacts with specific antigen attached to a solid phase. Specific antibody will 
bind to the antigen and all other material is washed away. A second antibody conjugated 
to an enzyme recognizes common parts of antibodies bound to the antigen. The complex 
is washed and substrate for enzyme is added. Color change rate will indicate the amount 
of specific antibody against the antigen. The color changes are read by a plate reader. 
 50-100 ng of antigen, which had been optimized by using increasing concentrations, 
was put in each well and incubated overnight at 4oC to coat the wells. Unbound regions 
were saturated with 5% nonfat dry milk in PBST. Wells were washed four times with 
PBST and incubated with primary antibody for 45 minutes at 37oC temperature. Again 
washed and incubated with secondary antibody coupled to AP for 1hour at room 
temperature. Following washing AP reagent (Sigma Fast) was added to wells and 
incubated for 1 hour. From 30th minute of the incubation, plates were read by a plate 
reader. 
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3.3.22 Luciferase assay 
The pGL3-OT and pGL3-OF reporter plasmids (gift from Bert Vogelstein) were 
used to test β-catenin-TCF/LEF-dependent transcriptional activity as described 
previously (Erdal E. et al., 2005) with minor modifications. Cells were transfected using 
Lipofectamin 2000 reagent (Invitrogen), following instructions provided by the supplier. 
Mutant β-catenin-induced TCF/LEF-dependent transcriptional activity was tested after 
co-transfection of cells with constructs and reporters as indicated in Chapter results. At 
total, 800 ng and 20 µg of DNA were transfected into 24 well-plates and into 100 mM 
plates, respectively. 200 ng of reporter vectors was used 200 ng/well for 24 well-plates. 
pEGFP-N2 construct was used at 1:16 ratio of total DNA for co-transfection experiments. 
At 48 hours following transfection, the luciferase assay was performed by using the 
Luciferase Reporter Gene Assay, constant light signal kit (Roche Diagnostics GmbH., 
Mannheim, Germany). Luciferase activity was read with The Reporter® Microplate 
Luminometer (Turner BioSystems Inc., Sunnyvale, CA) and data was normalized 
according to transfection efficiency as estimated by counting the GFP expressing cells 
obtained with each transfection. This method was used for experiments shown in 
“C/EBPα inhibits mutant β-catenin/TCF transcriptional activity in hepatocellular 
carcinoma cells” section (Results 4.2). The experiments shown in “Dual Role of 
canonical Wnt (Wnt/β-Catenin) signaling in hepatocellular carcinoma” section (Results 
4.1) were performed with Dual-luciferase assay kit (Promega) following instructions 
provided by the supplier. All experiments were performed in triplicate and TCF activity 
was reported as the ratio of normalized luciferase activities obtained with pGL-OT and 
pGL-OF plasmids, respectively. 
 
 79
CHAPTER 4. RESULTS 
 
 
4.1 Dual Role of canonical Wnt (Wnt/β-Catenin) signaling in hepatocellular 
carcinoma  
 
4.1.1 Differential activity of canonical Wnt signaling in well- and poorly- 
differentiated hepatocellular carcinoma cells 
According to most accepted hypothesis, HCC arises as a well differentiated tumor 
and progresses with a stepwise process of dedifferentiation (Kojiro M., 2005). HNF-4α 
and HNF-1α are necessary for hepatocyte-specific expression of genes encoding proteins 
involved in liver functions (Kaestner KH., 2000; Duncan SA., 2000). On the basis of 
HNF expression, our liver cancer cell lines formed two groups (Erdal E. unpublished 
data). The first group, well-differentiated (WD), included Huh7, Hep3B, Hep40, HepG2 
cell lines. The second group, poorly-differentiated (PD), formed by the remaining cell 
lines displayed an incomplete expression pattern. AFP and cytokeratin (CK19) are liver 
stem cell markers. α-foetoprotein (AFP), the earliest known marker for hepatic lineage 
competency, marks specifically hepatoblasts and “oval” cells, whereas CK19 is a marker 
for late hepatoblasts and “oval” cells, but also bile duct cells (Fausto N., 1994; Shafritz 
DA. and Dabeva MD., 2002). Well-differentiated cell lines, but not poorly differentiated 
cells also expressed albumin and AFP, as additional markers for hepatocyte-like 
differentiation (Erdal E. et al., unpublished data). These observations suggested that a 
subset of liver cancer cell lines (WD) have in common to specifically express the factors 
needed for hepatic lineage competency, as well as liver differentiation. The 
differentiation properties of the cell lines and the list of Wnt pathway mutations are given 
in Table 4.1. 
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Differentiation 
Markers 
Liver Stem Cell 
Markers 
Mutation in Wnt pathway 
components 
 Cell 
Line 
HNF4α HNF1α AFP CK19 CTNNB1 Axin-1 APC 
HepG2 + + + + ∆25-140/ 
WT 
WT WT 
Huh7 + + + + WT WT WT 
Hep3B + + + + WT WT WT W
el
l 
D
iff
er
en
tia
te
d 
 
Hep40 + + + + WT WT WT 
Snu398 - - - ND S33C/ 
WT 
WT WT 
Snu475 - very 
weak 
- - WT ∆exon 
1-2 
WT 
Snu449 weak very 
weak 
- - WT WT WT 
Snu387 - - - - WT WT WT 
Focus - - - - WT WT WT 
Mahlavu - - - - WT WT WT 
Po
or
ly
  
D
iff
er
en
tia
te
d 
Snu182 - weak - ND WT WT WT 
 
Table 4.1: The differentiation properties and the mutations of Wnt signaling components in HCC cell 
lines: Well-differentiated ones; HepG2, Huh7, Hep3B, Hep40. Poorly differentiated; Snu398, Snu475, 
Snu449, Snu387, Focus, Mahlavu, Snu182. AFP and CK19 expressions were determined with 
immunoblotting. HNF4α and HNF1α expression were determined with RT-PCR. WT: wild-type, ND: not 
determined. Modified from (Cagatay T. and Ozturk M., 2002; Erdal E. et al., unpublished data). 
 
4.1.2 Canonical Wnt signaling activity in hepatocellular carcinoma cells 
Canonical Wnt signaling activates TCF/LEF-dependent transcription, which can 
be monitored by reporters containing TCF-responsive elements (Morin PJ. et al., 1997). 
We surveyed canonical Wnt signaling activity in well-differentiated and poorly- 
differentiated cell line groups, using TCF/LEF reporter pGL3-OT and pGL3-OF 
plasmids, as described previously (Erdal E. et al., 2005; see also Material and Methods). 
First, we compared TCF/LEF activity in three cell lines with known mutations in 
canonical Wnt signaling pathway. The well-differentiated and hepatoblastoma-derived 
cell line HepG2 displays β-catenin mutation (∆25-140). Poorly differentiated Snu398 cell 
line displays β-catenin missense mutation (S37C), and Snu475 cell line harbor Axin1 
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mutation (Satoh S. et al., 2000; Cagatay T. and Ozturk M., 2002) (Table 4.1). Normalized 
TCF/LEF activity was the highest in HepG2 cells. Snu398 cells displayed 50% less 
activity compared to HepG2. More interestingly, despite a homozygous deletion leading 
to a loss of Axin1 expression (Satoh S. et al., 2000; Cagatay T. and Ozturk M., 2002), 
there was no detectable TCF/LEF activity (pGL3-OT/pGL3-OF ratio equals 1.07) in 
Snu475 cells (Figure 4.1). In contrast, another Axin-1-mutant, but well differentiated  
HCC cell line, namely PLC/PRF/5 (Alexander) (Satoh S. et al., 2000) displayed high 
TCF/LEF activity (Ozturk N. et al., unpublished data). Next, we compared TCF/LEF 
activity of eight other cell lines that display wild type β-catenin and Axin1 expression. 
Hep40 cells harbor a missense Axin1 polymorphism (R454H), but its functional 
significance is unknown (Erdal E. et al., 2005). In contrast to Cha et al. (Cha MY. et al., 
2004), we detected weak but significant TCF/LEF activity (more than 3 folds) in well 
differentiated Huh7 and Hep3B cell lines. On the other hand, all five poorly differentiated 
cell lines as well as the well-differentiated Hep40 cells displayed no detectable activity 
(Figure 4.1). Taken together, we collected TCF/LEF activity data from 12 hepatoma cell 
lines. Independent of β-catenin or Axin1 status, TCF/LEF activity was detected in four 
out of five (80%) well-differentiated cell lines, whereas only one out of seven (14%) 
poorly-differentiated cell lines had constitutive TCF/LEF activity. These findings clearly 
indicate that canonical Wnt signaling in HCC is closely dependent on the differentiation 
status. Well-differentiated HCC cells usually express constitutive canonical Wnt 
signaling, whereas poorly-differentiated HCC cells do not. Taken as a whole, this data 
suggested that canonical Wnt signaling is mostly active in well-differentiated cells, and 
inactive in poorly-differentiated cells. 
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Figure 4.1.1: TCF/LEF activity in WD and PD HCC cell lines. A) TCF activity in well-differentiated 
(WD) and poorly differentiated (PD) HCC cell lines without any mutations in CTNNB1 or Axin1. Huh7 and 
Hep3B cells had low but significant TCF/LEF activity. B) TCF/LEF activity was higher in WD cell line 
HepG2 than in PD cell line Snu398, both with CTNNB1 mutations. PD cell line Snu475 did not have any 
detectable activity. TCF activity denotes the ratio of signals detected with pGL3-OT (OT) and pGL3-OF 
(OF) plasmids, respectively. Assays in triplicate, error bars; SD. 
 
 
4.1.3 Canonical Wnt signaling is repressed in poorly-differentiated hepatocellular 
carcinoma cells 
The presence of canonical Wnt signaling in well-differentiated hepatoma cells 
was apparently due to β-catenin or Axin-1 mutation, as well as other unknown factors. On 
the other hand, lack of canonical Wnt activity in poorly-differentiated cells could be due 
to either a lack of significant signaling activity, or alternatively to an active repression. 
To test these possibilities, we compared TCF/LEF activity in Huh7, Snu449 and Snu182 
cell lines following transient expression of a mutant (S33Y)-β-catenin. Transfection with 
S33Y-β-catenin resulted in an increase in total β-catenin protein levels in all three cell 
lines. Changes in β-catenin levels in Huh7 and Snu449 cells were comparable, though 
Snu182 behaved slightly differently (Figure 4.1.2A) Well-differentiated Huh7 cells 
responded to S33Y-β-catenin expression by a strong activation of TCF/LEF reporter 
activity (pGL3-OT/pGL3-OF ratio >120). Under the same experimental conditions, the 
response of Snu449 cells was minimal (pGL3-OT/pGL3-OF ratio equals 5). More 
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importantly, Snu182 cells were totally unresponsive (pGL3-OT/pGL3-OF ratio <1) 
(Figure 4.1.2B). 
 
Figure 4.1.2: Ectopic expression of a mutant β-catenin (S33Y) results in high canonical Wnt activity 
in well-differentiated, but not in poorly-differentiated hepatocellular carcinoma cell lines. A) Well- 
differentiated Huh7, and poorly-differentiated Snu449 and Snu182 cell lines have been co-transfected with 
either pCI-neo-mutant –S33Y-β-catenin  plasmid (S33Y-β-catenin +) or empty pCI-neo plasmid (S33Y-β-
catenin -), and cellular β-catenin levels at post-transfection 48 h were tested by immunoblotting. Calnexin 
was used as a loading control. B) Cell lines were treated as described in (A), then pCI-neo-mutant-S33Y-β-
catenin (S33Y)-transfected cells were subjected to TCF reporter assay. TCF activity denotes the ratio of 
signals detected with pGL3-OT (OT) and pGL3-OF (OF) plasmids, respectively. Assays in triplicate, error 
bars; SD. Co-transfections included pGL3-OT or pGL3-OF, in addition to pCI-neo plasmids in both (A) 
and (B).  
 
These drastic differences between well-differentiated Huh7 and two different poorly- 
differentiated cell lines, Snu449 and Snu182, could not be explained by experimental 
differences, as the measured activities have been corrected for transfection efficiencies 
(see material and methods). Since β-catenin was already accumulated in these cell lines, 
we also transfected these cell lines with a truncated β-catenin encoding vector 
(pAUCT.∆N-β-catenin) to distinguish transfected β-catenin from endogenous one 
(Figure 4.1.3) 
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Figure 4.1.3: Ectopic expression of mutant β-catenin (∆N-β-catenin) results in high canonical Wnt 
activity in well-differentiated, but not in poorly-differentiated hepatocellular carcinoma cell lines. A) 
Well differentiated Huh7, and poorly differentiated Snu449 and Snu182 cell lines have been co-transfected 
with either pAUCT-∆N-β-catenin plasmid (+) or empty pAUCT plasmid  (-), and cellular β-catenin levels 
at post-transfection 48 h were tested by immunoblotting. B) Cell lines were treated as described in (A) plus 
reporter plasmids, and then cells were subjected to TCF reporter assay. TCF activity denotes the ratio of 
signals detected with pGL3-OT (OT) and pGL3-OF (OF) plasmids, respectively. Assays in triplicate, error 
bars; SD. Co-transfections included pGL3-OT or pGL3-OF, in addition to pAUCT plasmids in both (A) 
and (B).  
 
Since ∆N-β-catenin accumulation was lower in Snu449, we performed TCF reporter 
assay with Snu449.8 stable clones. This clone expressed ∆N-β-catenin in the absence of 
tetracycline. Snu449.8 cells were transfected with reporter assay, then cultured in the 
presence and absence of tetracycline. Even though, truncated β-catenin accumulated as 
much as endogenous β-catenin, TCF activity remained less than 4 folds (Figure 4.1.4). 
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Figure 4.1.4: Ectopic expression of mutant β-catenin (∆N-β-catenin) results in low canonical Wnt 
activity in PD Snu449 derived stable clone. A) Snu449.8 was cultured in the presence of tetracycline to 
repress the expression of the truncated β-catenin and in the absence of tetracycline to induce the expression 
of truncated β-catenin expression. B) Even though truncated β-catenin accumulated comparable to 
endogenous β-catenin, it produced only 4 fold TCF activity. TCF activity denotes the ratio of signals 
detected with pGL3-OT (OT) and pGL3-OF (OF) plasmids, respectively. Assays in triplicate, error bars; 
SD. 
 
In transient transfection experiments, truncated β-catenin protein accumulated more in 
Snu182 than in Huh7. However, TCF/LEF activity was not detected in Snu182 while 
TCF/LEF activity (>16 folds) was detected in Huh7 cells.  Therefore, our findings 
strongly support the hypothesis that canonical Wnt signaling is actively repressed in 
poorly-differentiated HCC cells. This repression appears to occur downstream to β-
catenin accumulation (at β-catenin localization or chemical modification), at least in 
Snu449 and Snu182 cells tested here. These unexpected findings led us to conclude that 
the regulation of canonical Wnt signaling in well-differentiated and poorly-differentiated 
hepatocellular carcinoma cell lines is complex. This complexity could arise from the 
cellular context, including epigenetic differences in the expression of multiple Wnt 
signaling components. Since, the expression of non-canonical Wnt5A and Wnt5B ligands 
is restricted to poorly-differentiated hepatocellular carcinoma cell lines, Wnt5A and 
Wnt5B may be responsible for the repression of canonical Wnt signaling in poorly- 
differentiated HCC cell lines (Benhaj K. et al., unpublished data). 
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4.2 C/EBPα inhibits mutant β-catenin/TCF transcriptional activity in 
hepatocellular carcinoma cells 
Oncogenic mutations of β-catenin are observed in hepatomas (de La Coste A. et 
al., 1998). The activation of canonical Wnt signaling by oncogenic form of β-catenin is 
not sufficient for tumorigenesis since transgenic mice expressing an oncogenic form of β-
catenin in their hepatocytes developed only hepatomegaly (Cadoret A. et al, 2001).  
C/EBPα functions as a potent inhibitor of cell division in hepatocytes (Iakova P. 
et al., 2003; Kurumiya Y. et al., 2000). The role of C/EBPα and β-catenin in liver 
prompted us to test if C/EBPα affects mutant β-catenin mediated TCF/LEF activity in 
hepatoma cells.  
 
4.2.1 C/EBPα inhibits transfected mutant β-catenin/TCF transcriptional activity 
in Huh7 cells 
Initially, we screened our HCC cell line collection for β-catenin/TCF activity by 
using luciferase reporters (Figure 4.1.1). We detected weak but significant TCF/LEF 
activity (more than 3 folds) in well differentiated Huh7 cell line, which may be due to the 
expression of a mutant p53 in this cell line causing β-catenin accumulation, as reported 
previously (Cagatay T. and Ozturk M., 2002). When a mutant β-catenin vector (S33Y) 
was overexpressed in Huh7, the protein accumulation was mild, since this oncoprotein is 
already accumulated in Huh7 (Figure 4.1.2A). However, this mild increase in β-catenin 
caused TCF fold activity (OT/OF) more than 120 times (Figure 4.1.2B). Transfection 
efficiency was normalized according to renilla luciferase signal.  
Next, we confirmed the overexpression of transfected p42 form of C/EBPα in 
transfected Huh7 by immunoblotting (Figure 4.2.1A). When C/EBPα was co-transfected 
in increased amounts (0, 200 and 400 ng) with 300 ng of S33Y, TCF activity was 
decreased to less than basal level (Figure 4.2.1B). Transfected vector amount were kept 
equal in each transfection by adding empty vector up to 700 ng of total amount. 
Transfection efficiencies were normalized according to GFP signal. 
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Figure 4.2.1: C/EBPα inhibits mutant S33Y-β-catenin driven TCF/LEF activity in Huh7 cell line. A) 
The overexpression of C/EBPα was confirmed with immunoblotting. B) Huh7 cells were co-transfected 
with pCDNA3-S33Y, pcDNA3 or pcDNA3-C/EBPα.  To keep the equal amount of plasmid , each well 
was transfected with 1) 200 ng of pCDNA3-S33Y, 400 ng pcDNA3; 2) 200 ng S33Y, 200 ng pcDNA3, 200 
ng C/EBPα; 3) 200 ng pCDNA3-S33Y, 400 ng pcDNA3.C/EBPα; and pGL3-OT or pGL3-OF. C/EBPα 
inhibited pcDNA3-S33Y driven TCF activity in Huh7 cells. Fold luciferase activity is the mean ±SD from 
3 independent experiments. 
 
4.2.2 C/EBPα inhibits endogenous mutant β-catenin/TCF transcriptional activity 
in HepG2 cells 
To demonstrate that C/EBPα inhibits endogenous β-catenin/TCF activity, we 
selected HepG2 cell line for transfection. This hepatoblastoma cell line harbors a wild-
type and a truncated β-catenin. Truncated β-catenin (∆25-140) are resistant to 
proteasome-mediated degradation and accumulates compared to wild-type form. C/EBPα 
was transfected in increasing amounts (0, 200 and 400 ng) by adding empty vector in 
each transfection in order to keep equal amount of vector transfected. Transfection 
efficiencies were normalized according to GFP signal. 200 ng and 400 ng of C/EBPα 
decreased TCF/LEF activity from 55 times to ~8 and ~3 times respectively (Figure 
4.2.2). The differences at inhibition between Huh7 and HepG2 systems may come from 
the following reason. In HepG2, overexpressed C/EBPα protein is not enough to repress 
reporter expression in 48 hours since there is already active endogenous β-catenin.  
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Figure 4.2.2: C/EBPα inhibits endogenous mutant β-catenin driven TCF/LEG activity in HepG2 
cells. A) HepG2 has a ∆25-140 deleted β-catenin allele. This mutation renders β-catenin resistant to 
ubiqitin degradation, and truncated form of β-catenin accumulates. B) This cell line were transfected with 
1) 600 ng pCDNA3; 2) 300 ng pCDNA3, 300 ng C/EBPα; 3) 600 ng C/EBPα and pGL3-OT or pGL3-OF. 
C/EBPα inhibited endogenous mutant β-catenin driven TCF/LEF activity in HepG2 cells. Fold luciferase 
activity is the mean ±SD from 3 independent experiments. 
 
 
4.2.3 C/EBPα inhibits an inducible truncated β-catenin driven TCF/LEF activity 
To show that the inhibition in Huh7 system is not an experimental artifact, we 
used an inducible system. Snu499 hepatoma cell line does not have any detectable 
TCF/LEF activity. We prepared an inducible Snu449 stable cell line expressing a 
truncated β-catenin (a.a. 98-781) in the absence of tetracycline (Snu449.8). The 
expression of truncated β-catenin was confirmed by immunoblotting (Figure 4.2.3A). 
This cell line was transfected with empty vector or pcDNA3.C/EBPα in the presence of 
tetracycline. After 12 hours of incubation, media was replaced with tetracycline plus or 
minus media. Transfection efficiencies were normalized according to GFP signal. 
C/EBPα inhibited β-catenin driven TCF/LEF activity when cells were incubated in 
tetracycline-free medium for 36 hours following medium replacement (Figure 4.2.3B). 
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Figure 4.2.3: C/EBPα inhibits truncated β-catenin driven TCF/LEF activity in tetracycline regulated 
Snu449.8 stable clone. A) This stable cell line expresses N-terminal-deleted (∆1-97) β-catenin form when 
cultured in the absence of tetracycline. The expression of mutant β-catenin was confirmed by 
immunoblotting. B) Snu449.8 cell does not have any detectable TCF/LEF activity in the presence of 
tetracycline.  It has low but significant TCF/LEF activity in the absence of tetracycline, and this activity is 
inhibited when transfected with C/EBPα. Fold luciferase activity is the mean ±SD from 3 independent 
experiments. 
 
4.2.4 Overexpressed C/EBPα and mutant β-catenin proteins interact in Huh7 cells 
To get a clue about the mechanism of this inhibition, we tested if C/EBPα and 
mutant β-catenin physically interact. Since C/EBPα protein level was low, and β-catenin 
was wild type in Huh7 cells, we co-transfected p42 form of C/EBPα and mutant S33Y- 
β-catenin vectors. Then, C/EBPα and interacting proteins were immunoprecipitated with 
a goat polyclonal anti-C/EBPα antibody. Immune-complexes were subjected to 
immunoblotting with anti β-catenin antibody. C/EBPα immunoblotting was performed to 
check the equal loading of immune complexes. Additionally, we also checked the 
specifity of this interaction by immunoprecipitating with unrelated goat polyclonal 
antibody (anti-connexin32 antibody) and showing the absence of β-catenin in these 
complexes (Figure 4.2.4). 
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Figure 4.2.4: The overexpressed C/EBPα and β-catenin interacts in Huh7 cells: Huh7 cells were 
transfected with mutant S33Y-β-catenin and C/EBPα. Proteins were immunoprecipitated with anti 
connexin 32, and anti C/EBPα. Immune-complexes were subjected to immunoblotting with anti β-catenin 
and anti C/EBPα antibodies.  β-catenin was detected in complexes which interacted with p42 of C/EBPα. 
 
To study the long term effect of C/EBPα expression on β-catenin, we obtained 
tetracycline inducible Huh7-pAUCT-C/EBPα stable clones.  We selected 6 Huh7 clones 
expressing C/EBPα for future experiments (Figure 4.2.5). 
 
 
Figure 4.2.5: Screening of Huh7-pAUCT-C/EBPα clones for inducible C/EBPα expression. Clones 1, 
6, 7, 9, 10, and 18 expressed C/EBPα in the absence of tetracycline. For clones, + indicates that cells were 
grown in tetracycline including medium. Control: Transient pcDNA3 (-) or pcDNA3-C/EBPα (+) 
transfected Huh7 cells were used as controls. Clones 11 and 12 did not overexpressed C/EBPα at all. 
  
In this study, we showed that C/EBPα inhibits β-catenin driven TCF/LEF reporter 
activity in hepatoma cells. Since C/EBPα physically interacted with β-catenin, it is 
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possible that C/EBPα inhibits β-catenin driven TCF/LEF transcriptional activity by 
binding to β-catenin and altering its function.  
 
4.3 Monoclonal anti-β-catenin antibodies as a novel tool to distinguish cellular 
pools of β-catenin 
 
4.3.1 Production of home-made anti-β-catenin antibodies 
β-catenin is found in different pools in cells. It is reasonable to believe that E-
cadherin unbound β-catenin is more available for target gene activation. Therefore, it was 
important to obtain molecular tools distinguishing these cellular pools. For this purpose, 
we produced our monoclonal antibodies. N-terminal (∆1-89) deleted form of human β-
catenin protein fused to 6xHis tag at its N-terminus was produced in M15, and purified 
with affinity chromatography (Ozturk N., 2000). BALB/c mouse was immunized with 
the recombinant protein. Spleen was fused with SP2 cell line to obtain hybridomas. 
Immunoreactive clones were selected by using ELISA assay. 53 hybridoma clones were 
tested with immunofluorescence assay. From these clones, 12 hybridomas were selected 
for further study since they reacted with wild-type and/or truncated β-catenin proteins in 
HepG2 cell lysates (Figure 4.3.1). 
 
 
Figure 4.3.1: Home-made monoclonal anti-β-catenin antibodies recognize wild-type and mutant β-
catenin forms differentially. HepG2 cell line harbors one wild-type and a deleted (∆25-140) β-catenin. In 
this cell line, truncated β-catenin is accumulated compared to wild-type protein. However, our antibodies 
have different affinities for two forms. Commercial: Anti-β-catenin antibody purchased from Transductions 
Labs. 
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Since the antigen used for immunization has a 6 tag, some antibodies might cross-reacted 
with tag. For this reason, we produced human β-catenin fragment (∆1-89) fused to GST 
protein. By using GST fused β-catenin as antigen, we selected two monoclonal antibodies 
for further study (9E10, and 4C9).  
 
4.3.2 Epitope mapping and immunoglobulin subtyping for monoclonal antibodies 
9E10 and 4C9  
We produced human β-catenin fragment fused to GST protein for epitope 
mapping. First, we restricted binding sites of 9E10, and 4C9 to C-terminus of β-catenin 
(Figure 4.3.2).  Both antibodies were IgG1 with kappa light chain. 
 
 
Figure 4.3.2: Restriction of 9E10 and 4C9 binding sites.  Mouse β-catenin fragments fused to GST 
protein were blotted with hybridoma supernatants. 9E10 and 4C9 binds to epitopes between 728-781. 
 
 
Since β-catenin C-terminus has a DTDL motif and possible phosphorylation of serine 
residue at codon 771, we decided to delete these sites to see if our antibodies require two 
sites for immunoreactivity. 9E10 and 4C9 immunoreactivity were lost when codons 771-
781, and 778-781 were deleted, respectively (Figure 4.2.3). 
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Figure 4.3.3: Epitopes of 4C9 and 9E10. DTDL and 771-781 a.a (which include a S residue) were deleted 
from GST-β-catenin fragment fusion proteins. 4C9 epitope was restricted to 778-781(DTDL), and 9E10 
epitope was restricted to 771-777(SNQLAWF). 
 
4.3.3 9E10 and 4C9 recognize different pools of β-catenin 
We performed immunoperoxidase staining by using different cell lines. 
Characteristically, 9E10 recognize both membrane-associated and cytoplasmic/nuclear 
forms. However, 4C9 could not recognize membrane-associated β-catenin in HCC cells 
with immunoperoxidase assay (Figure 4.3.4). 
 
Figure 4.3.4: 4C9 and 9E10 can differentiate β-catenin forms in HCC cells. Huh7 cell line was stained 
with 4C9 and 9E10 hybridoma supernatants by using immunoperoxidase assay. 4C9 could not recognize 
membrane-associated β-catenin, while 9E10 can recognize. 
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Since 4C9 can not recognize membrane-associated β-catenin, we suspected that a 
chemical modification at this motif in membrane-associated β-catenin prevents 
immunoreactivity. T residue in DTDL motif was a good candidate for phosphorylation. 
We assumed that this residue is phosphorylated in membrane-associated but not in 
cytoplasmic or nuclear β-catenin. We immunoprecipitated β-catenin from confluent 
Huh7 cells by using a polyclonal antibody raised against the full length human β-catenin. 
Precipitated immune complexes were divided into two equal aliquots. The aliquots were 
SAP- or mock-treated at 37οC for 30 minutes. When equal amount of these aliquots were 
immunoblotted, 9E10 immunoreactivity slightly increased in SAP treated samples but 
4C9 immunoreactivity did not change on contrary to our expectation. Additionally, we 
failed to detect 4C9 immunoreactivity difference in E-cadherin co-immunoprecipitated 
and SAP treated β-catenin (Figure 4.3.5). However, we did not check if we properly 
removed phosphate groups from the precipitated β-catenin in our system. 
 
Figure 4.3.5: 4C9 immunoreactivity did not change when β-catenin is treated with SAP to remove 
phosphorylation. A) Huh7 cell line was grown to confluency to increase E-cadherin bound β-catenin pool. 
β-catenin was immunoprecipitated with a rabbit polyclonal antibody. When immunoprecipitated samples 
unphosphorylated with SAP treatment, 9E10 immunoreactivity was slightly increased. Membranes were 
striped and blotted with polyclonal anti-β-catenin antibody to check equal loading. B) Huh7 cells were 
grown to confluency, and membrane-associated β-catenin was co-immunoprecipitated with E-cadherin. 
Then, aliquots were mock- or SAP-treated. 4C9 immunoreactivity did not change.  
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4.4 Reprogramming of replicative senescence in hepatocellular carcinoma 
derived cells. 
 
4.4.1 Senescent phenotype in cancer cell lines 
While analyzing mock- transfected clones from established cancer cell lines 
related to our Wnt/β-catenin study, we observed that some clones change morphology 
and cease proliferation at late passages with features reminiscent of cellular senescence 
(Figure 4.4.1). 
 
 
Figure 4.4.1: Huh7 derived clone C3 displays senescent phenotype when cultured extensively. MRC5 
is a normal fibroblast, which enter senescent at passage 40. MRC5 was used as a positive control for SABG 
assay. C3 is a single cell derived clone of Huh7 cell line. When this clone and MRC5 were tested with 
SABG assay at late passages, both cease proliferation and display flattened morphology and SABG positive 
staining (blue color).  SABG assay: Senescence associated β-galactosidase assay. 
 
We reasoned that this could be an indication for generation of progeny 
programmed for replicative senescence. We surveyed a panel of HCC and breast 
carcinoma cell lines, and hTERT-immortalized human mammary epithelial cells 
(hTERT-HME). Plated at low clonogenic density, cells were maintained in culture until 
they performed 6-10 population doublings (PD), and tested for senescence-associated β-
galactosidase (SABG) activity as described previously (Dimri GP. et al., 1995). Different 
cancer cell lines generated progeny with greatly contrasting SABG staining patterns. The 
first group, represented here by HCC-derived Huh7 and breast cancer-derived T-47D and 
BT-474 cell lines, generated heterogeneously staining colonies. Cells of some colonies 
were mostly positive for SABG, but others displayed significantly diminished or 
complete lack of staining (Figure 4.4.2A). The second group, represented by HCC-
derived Hep3B and Mahlavu, and hTERT-HME generated only SABG-negative colonies 
(Figure 4.4.2B). Manual counting of randomly selected colonies demonstrated that mean 
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SABG-labelling indexes for Huh7, T-47D and BT-474 progenies were 45±23%, 40±29% 
and 33 ±7%, respectively (Figure 4.4.2C, lanes 1-3). In contrast, Hep3B, Mahlavu and 
hTERT-HME progenies displayed less than 3±3 % mean SABG-labelling indexes 
(Figure 4.4.2C, lanes 4-6). Clones from representative cell lines were expanded and 
subjected to the same analysis. SABG-staining patterns of all clones tested were closely 
similar to the patterns of their respective parental cell lines. For example, mean SABG 
staining indexes of Huh7-derived clones were 14±15%, 47±27% and 17±11% (Figure 
4.4.2C, lanes 7-9), whereas Hep3B-derived clones generated less than 2±3% SABG-
positive progenies (Figure 4.4.2C, lanes 10-12). We speculated that the first group of cell 
lines comprised progenies in different stages of replicative senescence process at the time 
of analysis, whereas second group of cell lines were composed mostly of immortal cells. 
The results obtained with the first group were unexpected. These cell lines have been 
established more than 20 years ago (Lasfargues ET. et al., 1978; Keydar I. et al., 1979; 
Nakabayashi H. et al., 1982) and expanded in culture over many years, with PD well 
beyond the known senescence barriers for normal human cells (Shay JW. and Wright 
WE., 2005), but they were still capable of generating presumably senescent progeny. 
 
Tumor Origin 
of Cell Lines 
Senescence-reversible 
Phenotype* 
Immortal 
Phenotype 
Senescence- 
reversible/ 
Total (%) 
Hepatocellular 
Carcinoma 1 13 1/14 (7.1%) 
Breast Cancer 2 4 2/6 (33.3%) 
Colorectal Cancer 0 13 0/ 13 (0.0%) 
Total 3 30 3/33 (10.0%) 
Table 4.2: Spontaneous senescence in epithelial cancer cell lines: *At least 50 % of colonies showing 
SA-βGal positive cells, as compared to HME1-hTERT cells. 
 
We expanded our study to other epithelial cancer cell lines in our laboratory for their 
senescence phenotype (Table 4.2). 
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Figure 4.4.2: Established human cancer cell lines generate senescence-associated β-galactosidase 
(SABG)-expressing progeny. A) Representative pictures of HCC (Huh7) and breast cancer (T-47D and 
BT-474) cell lines that generates both SABG-positive (top) and SABG-negative (bottom) colonies. B) 
Representative pictures of HCC (Hep3B and Mahlavu) and telomerase-immortalized mammary epithelial 
(hTERT-HME) cell lines that generate only SABG-negative colonies. Cells were plated at clonogenic 
density to generate colonies with 6-10 population doublings, and stained for SABG activity (blue), 
followed by eosin counter-staining (red).  C) Quantification of SABG-positive cells in colonies.  Randomly 
selected colonies (n≥10) obtained from parental (lanes 1-6) cell lines and expanded clones (lanes 7-12) 
were counted to calculate the average % SABG positive cells per colony (% SABG index). Lanes 1-6 
designate Huh7, T-47D, BT-474, Hep3B, Mahlavu, and hTERT-HME, respectively. Lanes 7-9 are Huh7-
derived C1, C3 and C11 clones, and lanes 10-12 are Hep3B-derived 3B-C6, 3B-C11 and 3B-C13 clones. 
Error bars; S.D.  
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4.4.2 A model for cancer cell derived replicative senescent progeny: C3 clone 
The study of a potentially active replicative senescence program in the progeny of 
immortal cancer cell lines requires the long-term follow up of single cell-derived clones.  
To this end, we chose to focus our investigations on Huh7 cell line. We expanded 
different Huh7-derived clones in long-term culture and examined their potential to 
undergo replicative senescence. Some clones performed more than 100 PD in culture 
with stable proliferation rates and heterogeneous SABG staining, while others sustained a 
limited number of PD, then entered a growth arrest phase with full SABG staining 
patterns. For example, Huh7 derived C3 clone performed only 80 PD, whereas Huh7 
derived C1 clone replicated over 150 PD. Permanently arrested C3 cells (PD 80) 
displayed enlarged size, flattened shape, and fully positive SABG staining, whereas early 
passage C3 (PD 57) and C1 (PD 179) cells displayed normal morphology with 
heterogeneous SABG staining (Figure 4.4.4A-top). Normal human cells at replicative 
senescence (M1) are refractory to mitotic stimulation and display <5% BrdU index (Wei 
W. and Sedivy JM., 1999). Growth-arrested C3 cells displayed very low BrdU staining 
(2±2%), in contrast to early passage C3 and late passage C1 cells which exhibited 
89±6%, and 96±3% BrdU indexes, respectively (Figure 4.4.4A-bottom). Senescent C3 
cells remained growth-arrested, but alive when maintained in culture for at least 3 
months, with no emergence of immortal clones. The cell proliferation rate were decreased 
in C3 clonal cells as telomeres lengths were decreased (Figure 4.4.3). 
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Figure 4.4.3: Proliferation rates of C1 and C3 clonal cells at different passages. C1 cells grow 
exponentially when supplied with mitosis stimuli. However, C3 cells cease proliferation at late passages. 
Initial PD (40) was calculated by considering the time passed from isolation of C3 clonal cell until the 
initial PD assay. Black circles, C1; white circles, C3.  
 
Biological mechanisms of replicative senescence observed here are of particular 
interest, since senescence-regulatory p53 is inactivated (Bressac B. et al., 1990; 
Volkmann M. et al., 1994; Kubica S. et al., 1997) and p16INK4a promoter is 
hypermethylated (Roncalli M. et al., 2002) in Huh7 cells. Accordingly, there was no 
change in p53 levels, whereas low level p16INK4a expression further decreased in 
senescent C3 (PD 80) cells, when compared to presenescent C3 (PD 57) or immortal C1 
(PD 179) cells. Retinoblastoma protein (pRb) displayed partial hypophosphorylation in 
senescent C3 cells, apparently in a p53- and p16INK4a–independent manner (Figure 
4.4.4B). Cyclin E and cyclin A levels were also decreased, but p21cip1 levels were 
elevated in both presenescent and senescent C3 cells Cyclin D1, CDK4 and CDK2 
protein levels (Figure 4.4.5A), and p14ARF transcript levels (Figure 4.4.5B) did not 
change. 
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Figure 4.4.4: p53-and p16INK4a-deficient Huh7 cells generate progeny that undergo in vitro and in vivo 
replicative senescence resulting in loss of tumorigenicity. A) Huh7-derived clones C3 and C1 were 
tested for replicative senescence arrest by SABG and BrdU staining at different passages. Presenescent C3 
and immortal C1 cells display low SABG staining (top) and high BrdU incorporation (bottom), whereas 
senescent C3 cells are fully positive for SABG (top) and fail to incorporate BrdU into DNA following 
mitogenic stimuli (bottom). B) p53 and p16INK4a protein levels show no increase in senescent C3 cells, 
compared to presenescent C3 and immortal C1 cells, but senescent C3 cells display partial 
hypophosphorylation of pRb. Calnexin was used as a loading control. Proteins were tested by 
immunoblotting. PS; presenescent (PD 57), S; senescent (PD 80), I; immortal (PD 179). C and D) C1 cells 
form tumors, but C3 cells undergo senescence in nude mice. C) C1 cells (black line) were fully 
tumorigenic, but C3 cells (red line) were not.  D) C1 tumors displayed low SABG staining (top-right), 
whereas implanted C3 cells remaining at the injection site are fully positive for SABG in situ (top-left), as 
well as after short-term in vitro selection (bottom). Animals were injected with presenescent C3 (PD 59) 
and immortal C1 (PD 119) cells, tumors and non-tumorigenic cell samples were collected at day 35, and 
analyzed. 
 
Cancer cell senescence that we characterized here shared many features with normal cell 
replicative senescence (Shay JW. and Wright WE., 2005), except that it was not 
accompanied with wild-type p53 or p16INK4a induction. However, in vivo relevance of the 
replicative senescence observed in cell culture is debated (Ben-Porath I. and Weinberg 
RA., 2004). Therefore, we compared in vivo replicative potentials of C3 (PD 59) and C1 
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(PD 119) cells in CD-1 nude mice. C3 cells did not form visible tumors, whereas C1 cells 
were fully tumorigenic in the same set of animals (Figure 4.4.4C), like parental Huh7 
cells (data not shown; Kaneko S. et al., 1995). C1 tumors collected at day 35 displayed 
scattered but low-rate SABG-positive staining, but remnant C3 cell masses collected 
from their injection sites were fully SABG-positive (Figure 4.4.4D-top). For 
confirmation, these remnants were removed from two different animals, passaged twice 
in cell culture for selection, and examined. Nearly all cells displayed senescence features 
including enlarged size, flattened shape and highly positive SABG staining (Figure 
4.4.4D-bottom). We concluded that loss of C3 tumorigenicity was due to replicative 
senescence in vivo.  
 
Figure 4.4.5: Complementary information on presenescent and senescent C3 cells, as compared to 
immortal C1 cells. A) Immunoblot data shows decreased levels of cyclin E and cyclin A, but not cyclin 
D1, CDK4 or CDK2. p21Cip1 levels were slightly augmented in presenescent and senescent C3 cells (see 
Discussion for an explanation). B) RT-PCR data shows that p14ARF expression is similar between C1 and 
C3 clones. GAPDH was used as a control. PS; presenescent (PD 57), S: senescent (PD 80), I; immortal (PD 
179). 
 
Replicative senescence, also called telomere-dependent senescence is associated with 
progressive telomere shortening due to inefficient telomerase activity (Shay JW. and 
Wright WE., 2005). When compared to parental Huh7 cells, presenescent C3 cells at PD 
57 had telomeres which have already been shortened to ~7 kbp from ~12 kbp. These cells 
eroded their telomeres to less than 5 kbp at the onset of senescence. In contrast, immortal 
C1 clone (PD 179) telomeres did not shorten (Figure 4.4.6A). These observations showed 
a perfect correlation with telomerase activity and hTERT expression.  Immortal C1 cells 
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displayed robust telomerase activity, whereas both presenescent and senescent C3 cells 
had no detectable telomerase activity (Figure 4.5.6B). Accordingly, the expression of 
hTERT gene was high in C1, but barely detectable in Huh-C3 cells (Figure 4.4.6C). 
Thus, senescence observed with C3 cells was characterized with the loss of hTERT 
expression and telomerase activity, associated with telomere shortening.  
 
Figure 4.4.6: C3 clonal cells undergo telomere-dependent replicative senescence associated with SIP1 
expression and hTERT repression. SIP1 expression is lost, while hTERT is repressed in primary 
HCC tumors. A) Genomic DNAs from parental Huh7 and immortal C1 cells display long telomeres, 
whereas C3 telomeres are progressively shortened in presenescent and senescent stages, respectively. Equal 
amounts of genomic DNAs were blotted with a telomere repeat probe. C. Low; short telomere control 
DNA.  B) Presenescent and senescent C3 cells have lost telomerase activity, as measured by TRAP assay. 
Telomerase activity was shown as % value of test samples (±SD) compared to “high positive” control 
sample. C) hTERT expression as tested by RT-PCR was high in immortal C1, but decreased to weakly 
detectable levels in C3 cells. Inversely, SIP1 expression tested by RT-PCR was undetectable in C1 cells, 
but showed a progressive increase in presenescent and senescent C3 cells. D) Inverse relationship between 
SIP1 and hTERT expression was confirmed with another senescence-programmed Huh7 clone named G12 
(see Figure S3 for SABG and BrdU assays).  hTERT expression in G12 showed a slight decrease in 
presenescent stage, followed by a loss at the onset of senescence. Inversely, the expression of SIP1 gene 
was weakly positive in presenescent G12, but highly positive in senescent G12 cells. C1 was used as 
control. PS; presenescent, S; senescent, I; immortal. E) Negative correlation between hTERT and SIP1 
expression in primary tumors (T) and non-tumor liver tissues (NT).   
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Mechanisms of hTERT expression are presently unclear, but several genes including 
SIP1, hSIR2, c-myc, Mad1, Menin, Rak and Brit1 have been implicated (Wang J. et al., 
1998; Lin SY. and Elledge SJ., 2003). We analyzed their expression in C1 and C3 clones. 
All tested genes, except SIP1, were expressed at similar levels in both C1 and C3 clones, 
independent of hTERT expression (Figure 4.4.7). 
 
Figure 4.4.7: Complementary information on the expression of hTERT regulatory genes. RT-PCR 
data shows that the expression of hTERT regulators hSIR2, c-myc, Mad1, Menin, Rak and BRIT1 is 
similar in C1 and C3 clonal cells.     
 SIP1 transcripts were undetectable in C1 cells, but elevated in C3 cells, moderately in 
presenescent, but strongly in senescent stages (Figure 4.4.7). We verified these findings 
with another Huh7-derived clone (G12) that displayed replicative senescence resulting in 
permanent cell proliferation arrest. Like C3, presenescent G12 cells that displayed low 
SABG staining with high BrdU index (98±1%), and became fully positive for SABG, and 
nearly negative for BrdU (3±2%) at the onset of senescence (Figure 4.4.8). Presenescent 
G12 cells displayed only a weak hTERT repression associated with a slight increase in 
SIP1 expression, whereas SIP1 was strongly elevated in hTERT-negative senescent cells 
(Figure 4.4.6D). Thus, there was a close correlation between SIP1 expression and hTERT 
repression in all Huh7 clones tested. The analysis of SIP1 and hTERT expression in 
primary HCCs and their corresponding non-tumor liver tissues confirmed this 
relationship.  SIP1 transcript levels were high, but hTERT expression was low in non-
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tumor liver tissues, whereas respective HCC tumors displayed diminished SIP1 
expression associated with upregulated hTERT expression (Figure 4.4.6E).  
 
Figure 4.4.8: Data showing replicative senescence in Huh7-derived G12 clone. Presenescent G12 cells 
display low SABG staining (top) and high BrdU incorporation (bottom), whereas senescent G12 cells are 
fully positive for SABG (top) and fail to incorporate BrdU into DNA following mitotic stimulus (bottom). 
PS; presenescent, S; senescent. 
 
The SIP1 gene (Zinc finger homeobox 1B; ZFHX1B) encodes a transcriptional repressor 
protein that interacts with SMAD proteins of the TGF-β signalling pathway and CtBP co-
repressor (Verschueren K. et al., 1999; Postigo A. et al., 2003). This gene has recently 
been implicated in TGF-β-dependent regulation of hTERT expression in breast cancer 
cells (Lin SY. and Elledge SJ., 2003). Our observations implicated SIP1 gene as a 
candidate regulator of replicative senescence in HCC cells. To investigate whether SIP1 
expression constitutes a protective barrier against hTERT expression and senescence 
bypass, we constructed SIP1 shRNA-expressing plasmids, based on a previously reported 
effective SIP1 siRNA sequence (Lin SY. and Elledge SJ., 2003). SIP1 shRNA suppressed 
the accumulation in SIP1 in presenescent C3 (PD 75) cells, when expressed transiently 
(Figure 4.4.9A-day 5). This resulted in a weak increase in hTERT expression. 
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Transfected cells were maintained in culture and observed for 30 days. At this period, C3 
cells transfected with a control plasmid reached senescence-arrested stage with further 
upregulation of SIP1 expression (Figure 4.4.9A-day 30) and resistance to BrdU 
incorporation after mitogenic stimuli (BrdU index=3±1%; Fig 4B-top-left). In sharp 
contrast, SIP1 shRNA-transfected cells lost SIP1 expression and upregulated hTERT 
transcripts (Figure 4.4.9A-day 30). Furthermore, SIP1-inactivated cells escaped 
senescence, as evidenced with 70±9% BrdU index (Figure 4.4.9B-top-right). 
Morphologically, SIP1 shRNA-transfected cells formed proliferating clusters, whereas 
cells transfected with control plasmid displayed hallmarks of senescence such as 
scattering, enlargement and multiple nuclei (Figure 4.4.9B-bottom). Twelve independent 
clones were selected from SIP1 shRNA-transfected C3 cells. All but one of these clones 
have performed so far more than 12 PD beyond the expected senescence barrier (data not 
shown). As an additional confirmatory assay, C3 cells were transfected with a 
puromycin-selectable SIP1 shRNA vector and subjected to puromycin selection. SIP1 
shRNA-transfected cells survived and formed a large number of colonies after 30 days of 
puromycin selection. In contrast, no surviving colony was obtained from cells transfected 
with the control plasmid, as expected (Figure 4.4.9C).   
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Figure 4.4.9:  ShRNA-mediated downregulation of endogenous SIP1 transcripts releases hTERT 
repression and rescues C3 cells from senescence arrest. A) At day 5 following transfection, SIP1 
shRNA-transfected cells (Sh-SIP1) show decreased expression of SIP1 and weak upregulation of hTERT 
expression. At day 30, the expression of SIP1 is lost completely, and hTERT expression is stronger. B) 
Cells transfected with empty vector (Control) are senescence-arrested as evidenced by resistance to BrdU 
incorporation (top-left) and morphological changes (bottom-left), but cells transfected with SIP1 shRNA 
vector (Sh-SIP1) escaped senescence arrest as indicated by high BrdU index (top-right) and proliferating 
cell clusters (bottom-right).C) Colony forming assay shows that C3 cells formed large number of colonies 
following puromycin selection after transfection with a puromycin-resistant SIP1-shRNA-expressing 
plasmid (right), whereas cells transfected with empty vector did not survive (left). Presenescent C3 cells at 
PD 75 were transfected with either SIP1 shRNA-expressing or empty plasmid vectors and tested at days 5 
(A) and 30 (A, B and C).      
 
4.4.3 Senescence in human tissues  
We have analyzed human liver tissues and breast tissues for their senescence 
phenotype by using SABG staining (Figures 4.4.10, Figure 4.4.11, and Figure 4.4.12; 
Table 4.3). We have found that colorectal cancer, stomach cancer, and breast cancer 
samples had SABG positive cells. This indicated that tumors are composed of both 
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mortal and immortal cells. Additionally, we detected SABG positive cells in cirrhotic 
samples which was expected since telomere shortening and senescence are general 
markers of liver cirrhosis. In parallel to this view, we could not find SABG positive cells 
in liver samples with hepatitis. 
 
 
 
 
Figure 4.4.10: SABG staining in pathological liver tissues: Only cirrhotic liver had SABG positive areas. 
Arrows indicates SABG positive cells. 
 
 
 
 
Figure 4.4.11: SABG staining in primary liver tissues. A primary liver tissue was SBAG- stained. 
Tumor tissue had some SABG positive cells. Picture was taken at 10X magnification (left) and 40 X 
magnification (right). Arrows indicates SABG positive cells. 
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Figure 4.4.12: SABG staining in human breast tissues. Human breast cancer samples had some SABG 
positive areas. Non tumor breast tissue did not have any SABG positive areas. On the right, SABG positive 
area of tumor tissue (insert) was shown at higher magnification. MFN58, non tumor breast tissue; MFT58, 
adjacent breast tumor. 
 
 
 
 
 
Tissues Tested Positive % Positive 
Chronic Hepatitis 7 0 0 
Liver Cirrhosis 2 2 100 
Hepatocellular Carcinoma 6 3 50 
Breast Cancer 20 2 10 
Colorectal Cancer 5 1 20 
Stomach Cancer 11 1 9 
Total Tumor 42 7 17 
 
Table 4.3: Senescence in primary tumors and pathologic liver tissues. We tested pathological liver 
tissues and some primary cancer tissues. Interestingly, colorectal cancer samples had SABG staining, even 
though our colorectal cancer cell lines did not produce spontaneous senescent cells. 
 
 
4.4.4 Analysis of HCC cells for SIP1, TGF-β1, hTERT and E-cadherin expressions 
We have analyzed hTERT, SIP1, E-cadherin, TGF-β1 expression in HCC cell 
lines. TGF-β1 was expressed in all HCC at variable levels, hTERT was expressed in all 
HCC cells independent of SIP1 expression. Since SIP1 is suggested as a negative 
regulator of E-cadherin in HCC cells, we included expression analysis of E-cadherin in 
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our HCC cells. SIP1 and E-cadherin displayed inverted correlation. However, we could 
not see this inverted correlation in C3 and C1 clonal cells, this indicated that there are 
others factors regulating E-cadherin expression in these cells (Figure 4.4.7). 
 
 
Figure 4.4.13: Sip1 and E-cadherin expression is conversely correlated. TGF-β1 is expressed in our 
HCC collection at variable degrees. Our HCC cell lines expressed hTERT. GAPDH was used for equal 
loading. 
 
 
4.4.5 Overexpression of SIP1 in Hep3B cells 
To confirm our findings that SIP1 knock-down release hTERT repression in our 
clones independent of p53 status, we decided to overexpress SIP1 in p53-null Hep3B 
cells. Stable transfectants were established following transfection of Hep3B cells with 
mouse SIP1-expressing or empty plasmids. Three SIP1-expressing (3B-S1, 3B-S3, 3B-
S4) clones and one negative control (3B-C1) clone were selected for further study. Since 
parental Hep3B cells are deficient in p53 and pRb expression, Hep3B clones did not 
express p53 and pRb proteins as expected (Figure 4.4.14A). The expression of SIP1 in 
these clones resulted in partial repression of hTERT expression (Figure 4.4.14B). Hep3B 
clones were then subjected to SABG staining. Morphologically senescent cells were 
frequently identified in SIP1-expressing clones, but not in 3B-C1 clone (Figure 4.4.14C-
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left). Next, the ability to generate senescent progeny was tested by plating cells at 
clonogenic density and maintaining in culture for 6-10 PD. Colonies derived from the 
3B-C1 clone were usually SABG-negative, similar to parental Hep3B cells, whereas 
SIP1-expressing clones were able to generate colonies with highly SABG-positive 
progeny (Figure 4.4.14C -right). To test the significance of these findings, we calculated 
SABG-labelling indexes of randomly selected colonies (n=30) from each clone. The 
average SABG-labelling index was 2±2% for 3B-C1 cells. A statistically significant 
increase (P<0.0001) in the ability to generate SABG-positive progeny was observed with 
3B-S1, -S2, and -S3 clones which respectively displayed 6±4%, 9±7%, and 10±6% 
SABG-labelling indexes (Figure 4.4.14D). We also performed SABG/BrdU double 
staining and calculated BrdU index for SABG-positive and SABG-negative cells. SABG-
negative cells from all four isogenic clones displayed high labelling indexes (84±4% to 
89±2%), as expected. SABG-positive cells of the 3B-C1 clone displayed a high BrdU 
index (61±6%), suggesting that they are not truly senescent. In contrast, BrdU-labelling 
indexes for SABG-positive 3B-S1, 3B-S3 and 3B-S4 cells were 16±3%, 14±7%, and 
21±4%, respectively 1 (Figure 4.4.14E). Thus, ~80% of SABG-positive progeny in SIP1-
expressing clones displayed permanent proliferation arrest, suggesting that they entered a 
senescent state. These observations provide plausible evidence that SIP1 expression in 
p53- and pRb-negative HCC cells can generate progeny with a fate change from 
immortality to replicative senescence.     
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Figure 4.4.14:  Ectopic expression of SIP1 in p53- and pRb-negative Hep3B hepatocellular carcinoma 
cells results in the repression of hTERT expression, and confers the ability to generate senescent 
progeny. A) Immunoblot analysis of proteins from Hep3B-derived clones demonstrate lack of pRb and p53 
expression. Control: Huh7.  B) RT-PCR analyses indicate that hTERT transcript levels are decreased in 
clones stably expressing mouse SIP1 (3B-S1, 3B-S3, 3B-S4), but not in control clone (3B-C1) transfected 
with empty vector.  C) When tested at high cell density (HD), SIP1 expressing clones, but not control clone 
displayed frequently SABG-positive (blue) cells. SABG-staining of colonies generated after low density 
(LD) plating show that SIP1-expressing 3B-S1, 3B-S3 and 3B-S4, but not control (3B-C1) clones are able 
to generate senescent progeny. D) Ratios of senescence marker-positive progeny in randomly selected 
colonies (n=30) from control and SIP1-expressing clones were shown. * denotes that the increases 
observed SIP1-expressing clones were statistically significant (P <0.0001). E) BrdU incorporation index of 
SABG-positive and SABG-negative cells (assays in triplicate) are shown. SABG-negative cells from all 
four clones displayed high (>80%) index. SABG-positive cells from 3B-C1 clones displayed relatively high 
BrDU incorporation index (>60%), whereas SIP1-expressing clones had consistently low index (<20%). 
Studies were performed with the following passage numbers: 3B-C1, passages 13-17; 3B-S1 and 3B-S3, 
passage 9; 3B-S4, passage 6.    
 
 
When compared to parental mock transfected Hep3B clone, SIP1-expressing clones (3B-
S1, 3B-S3 and 3B-S4) had telomeres which have already been shortened (Figure 4.4.15). 
 
 112
 
 
Figure 4.4.15:  Ectopic expression of SIP1 in p53- and pRb-negative Hep3B hepatocellular carcinoma 
cells results in telomere shortening. Studies were performed with the following passage numbers: 3B-C1, 
passages 13-17; 3B-S1 and 3B-S3, passage 9; 3B-S4, passage 6.  Equal amounts of genomic DNAs were 
blotted with a telomere repeat probe. C. Low; short telomere control DNA. H. Low; short telomere control 
DNA. 
 
 
We cultured Hep3B stables long-term, and noticed that senescence markers were lost in 
late passages. Telomere lengths were longer in late passages than in early passages 
(Figure 4.4.16). Late passage clones reconstituted telomerase activity comparable to 
control clone (Figure 4.4.17). This phenomenon contrasted with our expectations. Then 
we analyzed the expression levels of mouse SIP1 and the functionality of it by analyzing 
E-cadherin expression. Mouse SIP1 expression was repressed in late passages by an 
unknown mechanism (Figure 4.4.18A). This resulted in the release of E-cadherin 
repression (Figure 4.4.18B). This data indicated that cells escaped SIP1 induced 
replicative senescence by repressing exogenous SIP1 expression. 
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Figure 4.4.16:  Telomere lengths in Hep3B clones at early and late passages. When SIP1 
overexpressing Hep3B clones were cultured long term, the length of telomeres was restored since SIP1 
expression was repressed in late passages.  Equal amounts of genomic DNAs were blotted with a telomere 
repeat probe. C. Low; short telomere control DNA. H. Low; short telomere control DNA. . Early passages: 
3B-S4, p3; 3B-S3, p2; 3B-S1, p5; 3B-C1, p3. Late passages: 3B-S4, p16; 3B-S3, p17; 3B-S1, p17; 3B-C1. 
 
 
 
Figure 4.4.17: Telomerase activity in Hep3B clones at early and late passages. Hep3B-SIP1 clones 
have partially lost telomerase activity at early passages; however they reconstituted telomerase activity at 
late passages. Early passages: 3B-S4, p3; 3B-S3, p2; 3B-S1, p5; 3B-C1, p3. Late passages: 3B-S4, p16; 3B-
S3, p17; 3B-S1, p17; 3B-C1. For early passages, telomerase activity was shown as % value of test samples 
(±SD) compared to “low positive” control sample. * donates that telomerase activity of duplicate assays 
and the average values were shown as % value of test samples compared to “low positive” control sample. 
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Figure 4.4.18: Exogenous SIP1 expression and repression of E-cadherin in early and late passages. A) 
SIP1 expression was repressed in late passages by an unknown mechanism. B) E-cadherin repression was 
released as a result of SIP1 repression in late passages. Early passages: 3B-S4, p3; 3B-S3, p2; 3B-S1, p5; 
3B-C1, p3. Late passages: 3B-S4, p16; 3B-S3, p17; 3B-S1, p17; 3B-C1, p20. mSIP1: mouse SIP1. In this 
study, E-cadherin and calnexin immunoblottings for early and late passages were not performed using the 
same membrane. Therefore, the signal ratio of E-cadherin to calnexin has been considered to interpret the 
results.  
 
Overall, our data indicated cells mouse SIP1 expression induced senescence program in 
Hep3B cells. However, mouse SIP1 induced senescence was escaped in these clones by 
repression of mouse SIP1 with an unknown mechanism. 
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CHAPTER 5.  DISCUSSION 
 
5.1 Canonical Wnt signaling in well- and poorly-differentiated HCC cell lines 
 
5.1.1  Canonical Wnt signaling is active in well-differentiated and inactive in 
poorly-differentiated HCC cell lines 
Our results provide evidence for the dual involvement of canonical Wnt signaling 
in HCC cells.  We detected constitutive canonical Wnt signaling in 80% of well 
differentiated HCC cell lines, including two cell lines (Huh7 and Hep3B) with wild-type 
β-catenin and Axin-1 genes (Figure 4.1.1) This strongly supports the hypothesis that 
canonical Wnt signaling is active in most well-differentiated HCC cells. This can occur 
by an autocrine mechanism, as shown recently in breast and ovarian cancer cell lines 
(Bafico A. et al., 2005). Additionally, the activity of canonical Wnt signaling in Huh7 can 
be explained by the existence of mutant p53 as suggested by Cagatay T. and Ozturk M. 
(Cagatay T. and Ozturk M., 2002). New components and the cross-talk of canonical Wnt 
signaling with other signaling pathways are being discovered continuously. Therefore, 
there is possibility that somatic alterations cause the constitutive canonical Wnt signaling 
in Huh7 and Hep3B cells.   Constitutive canonical Wnt signaling has been linked to both 
stem cell and cancer cell self-renewal in certain cancer types. It was proposed that some 
adult cancers derive from stem/progenitor cells and canonical Wnt signaling in stem and 
progenitor cells can be subverted in cancer cells to allow malignant proliferation (Reya T. 
and Clevers H., 2005). Thus, our observations raise the interesting possibility that well 
differentiated HCCs represent a group of liver tumors originating from liver stem cells. In 
accordance with this hypothesis, our group showed that well-differentiated cell lines 
studied here display liver stem cell-like features, such as generation of differentiated 
progeny (Erdal E. et al., unpublished data). Additionally, we obtained two subpopulations 
from Huh7 cells, one with immortal and the other with mortal phenotype (see 
“Reprogramming of replicative senescence in hepatocellular carcinoma derived cells” 
section). Moreover, we have recently noticed that the overexpression of a mutant β-
catenin in Huh7 cells altered the expression of liver differentiation markers (Ozturk N. et 
al., unpublished data). Overall, these findings support the hypothesis that well-
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differentiated HCC cells display liver stem cell-like features, and canonical Wnt signaling 
is involved in this process.  
 
5.1.2 Canonical Wnt signaling is easily activated in well-differentiated HCC cells 
and repressed in poorly-differentiated HCC cell lines 
In sharp contrast with well differentiated HCC cell lines, most poorly 
differentiated HCC cell lines display no detectable canonical Wnt activity (Figure 4.1.1). 
More interestingly, we failed to detect TCF/LEF reporter activity in Snu475 cells with 
homozygous Axin-1 deletion (Figure 4.1.2B). On the other hand, well-differentiated 
PLC/PRF/5 with Axin-1 (∆ Exon 4, 13 bp) mutation had significant TCF/LEF reporter 
activity (Ozturk N. et al., unpublished data). This data indicated that canonical Wnt 
signaling is not only inactive in poorly-differentiated cells but also repressed. 
Additionally, well-differentiated HepG2 cells (β-catenin; WT/∆N25-140) had more 
TCF/LEF reporter activity than poorly-differentiated Snu398 cells (β-catenin; WT/S37C) 
(Figure 4.1.1B). However, one can suggest the possibility that difference at mutation type 
and at the origins of these cell lines (HepG2, Hepatoblastoma; Snu398, HCC) might 
affect the level TCF/LEF reporter activity in these cells. Therefore, we transfected Huh7 
(WD), Snu499 (PD), and Snu182 (PD) cell lines with full length mutant β-catenin 
(S33Y) encoding vector. S33Y resulted in strong TCF/LEF reporter activity in Huh7 cell 
lines, while it resulted in weak and no TCF/LEF reporter activity in Snu449 (PD), and 
Snu182 (PD) respectively. Even though, the accumulation of β-catenin was highest in 
Snu182 cell line (Figure 4.1.2). This data supported the hypothesis that canonical Wnt 
signaling is repressed in poorly-differentiated HCC cell lines. All these cell lines already 
had accumulated β-catenin; therefore it was hard to differentiate the overexpressed β-
catenin from endogenous one. For this reason, we repeated this experiment with an N- 
terminally truncated β-catenin, and obtained similar results (Figure 4.1.3). Finally, we 
obtained an inducible Snu449 clone (Snu449.8) overexpressing truncated β-catenin in the 
absence of tetracycline. The truncated β-catenin accumulated as much as the endogenous 
β-catenin in this clone, but resulted in a weak TCF/LEF reporter activity (less than 4 
fold), which confirmed the results obtained with transient transfection (Figure 4.1.4).  
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The high accumulation of β-catenin in poorly-differentiated Snu182, and Snu449 derived 
Snu449.8 cells, and the absence of significant TCF/LEF activity provide evidence for that 
the signal generated by mutant protein is blocked at β-catenin level or downstream. As all 
poorly differentiated cell lines express both TCF1 and TCF4, a deficit at TCF/LEF family 
of transcription factors is unlikely (Benhaj K. et al., unpublished data). However, we did 
not explored if dominant negative TCF4 forms exist in poorly-differentiated cells. 
Moreover, we did not check the levels of negative regulators of canonical Wnt signaling 
in HCC cell lines. Therefore, the possibility that canonical Wnt signaling is repressed by 
Groucho, ICAT, CtBP, or Chibby remains unexplored.  Moreover, in some contexts 
Wnt5A and Wnt5B inhibit the canonical pathway, at the level of β-catenin function 
(Topol L. et al., 2003; Ishitani T. et al., 2003; Kanazawa A. et al., 2005). Interestingly, 
both Wnt5A and Wnt5B are expressed in all poorly differentiated HCC cell lines, but not 
in well differentiated cell lines with the exception of Hep40 which also lacks canonical 
Wnt activity (Benhaj K. et. al., unpublished data). Although, it is not known at this time 
how the canonical Wnt signaling is repressed in poorly differentiated HCC cell lines, it is 
clear that this type of HCC cells do not need canonical Wnt signaling for survival and 
self-renewal. Pathological analyzes, and “nodule-in-nodule” HCC lesions strongly 
support the hypothesis that the progression of HCC is a stepwise process of 
dedifferentiation (Kojiro M., 2005). However, primary tumor data showing a gradual 
decrease in β-catenin mutation and nuclear accumulation frequencies in less 
differentiated HCCs (Hsu HC. et al., 2001; Wong CM. et al., 2001; Mao J. et al., 2001; 
Inagawa S. et al., 2002; Fujito T. et al., 2004) is in apparent contradiction with this 
prediction. 
Our results provide evidence that canonical Wnt signaling is not active in most 
poorly differentiated cells. Taken together, these observations raise the possibility that 
poorly differentiated HCCs form a distinct type of tumor not directly related to well- 
differentiated HCCs with β-catenin mutation and constitutively active canonical Wnt 
signaling. It has been recently shown that activated β-catenin is localized in the 
perivenular area and the negative regulator APC is localized in periportal hepatocytes 
(Benhamouche S. et al., 2006). This may raise the possibility that well-differentiated 
HCC cells originated from perivenular area while poorly-differentiated HCC cells 
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originated from periportal hepatocytes. Another possibility is that well differentiated 
HCCs with activated canonical Wnt signaling rarely progress by a dedifferentiation 
process. Otherwise, the hypothesized dedifferentiation process would have to take into 
account a mechanism for selective elimination of mutant β-catenin, or active repression 
of the canonical Wnt signaling in the progeny of well differentiated HCC cells during 
tumor progression. Repression of canonical Wnt signaling, as shown here experimentally 
with Snu449 and Snu182 cell lines seems possible in less-differentiated HCC.. 
Alternatively, elimination of mutant β-catenin gene, although highly unlikely, is possible 
theoretically, since β-catenin mutations in HCC are heterozygous, leaving one allele in 
the wild-type form (de La Coste A. et al., 1998). To our knowledge, mutant β-catenin can 
not activate TCF/LEF reporter in certain cell lines (personal communications). Therefore, 
it seems possible that cell lines can be classified as “open” and “closed” cell lines 
according to the activation status of canonical Wnt signaling by mutant β-catenin. It 
would be interesting to confirm our results by activating endogenous β-catenin and 
comparing TCF/LEF reporter activity in well- and poorly-differentiated cells. This can be 
achieved by measuring TCF/LEF activity after cells are treated with lithium (which 
activates canonical Wnt signaling by inhibiting GSK3β) or Wnt-conditioned medium. 
 
5.2 C/EBPα inhibits mutant β-catenin/TCF transcriptional activity in 
hepatocellular carcinoma cells 
C/EBPα functions as a potent inhibitor of cell proliferation in hepatocytes 
(Kurumiya Y. et al., 2000; Iakova P. et al., 2003). Additionally, the somatic alterations of 
CEBPΑ gene  were observed in HCC cell lines and samples; however their biological 
functions are not known yet (Yuva Y. et al., unpublished data).  Even though, β-catenin 
mutations have been found in 22% of HCC cases in average, the activation of canonical 
Wnt signaling by oncogenic form of β-catenin is not sufficient for tumorigenesis since 
transgenic mice expressing an oncogenic form of β-catenin in their hepatocytes develop 
only hepatomegaly. Moreover, it has been recently shown that C/EBPα knock-in mouse 
are more resistant to diethylnitrosamine-induced liver tumorigenesis (Tan EH. et al., 
2005). Additionally, it has been shown that overexpressed β-catenin and C/EBPα co-
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immunoprecipitated from Hek293 cells (Kennell JA. et al., 2003). These observations 
prompted us to investigate the effect of C/EBPα on mutant β-catenin-TCF transcriptional 
activity in HCC cells. We have shown that the overexpression of C/EBPα inhibited both 
endogenous and transfected mutant β-catenin driven TCF/LEF reporter activity in HCC 
cell lines (Figures 4.2.1, 4.2.2., 4.2.3 and 4.2.4). Moreover, we have shown that β-catenin 
co-immunoprecipitated with the overexpressed C/EBPα from Huh7 cells (Figure 4.2.5). 
This data propose that C/EBPα regulate β-catenin in HCC. Therefore, the regulation of 
C/EBPα and β-catenin should be investigated from this point during liver regeneration 
following partial hepatectomy. Additionally, our preliminary studies indicated that β-
catenin alter C/EBPα reporter activity (Tasdemir N. et al., unpublished data). Therefore, 
the interactions between C/EBPα and canonical Wnt signaling remain as an unexplored 
area. 
  
5.3 Monoclonal anti-β-catenin antibodies as novel tools to differentiate cellular 
pools of β-catenin 
β-catenin is tightly regulated at protein and localization levels, and the β-catenin 
pool out of adherens junctions is likely to be more important for tumor development. We 
decided to use monoclonal antibodies (MAb) in order to distinguish the cellular β-catenin 
pools.  For this aim, we produced monoclonal antibodies against a truncated human β-
catenin protein. We selected two MAbs (9E10 and 4C9) for further study since they 
differentially reacted with β-catenin pools in HCC cells. Their epitopes (located at the 
last 11 aa of C-terminus of β-catenin) were adjacent, however 4C9 did not recognized the 
membrane-associated β-catenin pool (Figure 4.3.4). Therefore, 4C9 is a good candidate 
to screen tumor samples in order to investigate aberrantly accumulated β-catenin. 
Although the carboxyl domain possesses important functions for Wnt signaling, details of 
the underlying molecular mechanisms are obscure. Using C-terminal residues in a 
sequence-specific manner (Hung AY. and Sheng M., 2002) several PDZ domain-
containing proteins localize to sites of cell-cell contacts. β-catenin is one of the targets of 
at least two PDZ proteins, LIN-7 and MAGI-1 (Dobrosotskaya IY. et al., 2000). The β-
catenin carboxyl terminal sequence (DTDL) 777-781, which is necessary for 4C9 
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immunoreactivity, is matching to a consensus PDZ-binding sequence, S/T-X-L/V (X: any 
amino acid). These PDZ proteins may recognize covalently modified forms of β-catenin 
by discriminating other forms of the molecule and translocates it to the cell-cell contracts. 
Since 4C9 (of which epitope includes DTDL motif) do not recognize β-catenin at the cell 
membrane, it is plausible that this motif can be covalently modified at adherens junctions. 
When β-catenin was immunoprecipitated or co-immunoprecipitated with E-cadherin and 
treated with SAP enzyme to remove any possible phosphorylation at this motif, we could 
not detect any difference in the immunoreactivity of 4C9 (Figure 4.3.6). However, in our 
experimental system, we could/did not confirm if we properly removed putative 
phosphorylation(s) at 4C9 epitope. It is also possible that this motif is hindered by a PDZ 
motif binding protein, which prevented 4C9 immunoreactivity in our staining assays. In 
summary, we could not conclude about the differential staining patterns of our MAbs. 
 
5.4 Reprogramming of replicative senescence in hepatocellular carcinoma 
derived cells. 
While analyzing clones from established cancer cell lines, we observed that some 
clones change morphology and cease proliferation at late passages with features 
reminiscent of cellular senescence (Figure 4.4.1). We reasoned that this could be an 
indication for generation of progeny programmed for replicative senescence. Our 
observations provide experimental evidence for generation of senescence-arrested clones 
from immortal HCC and breast cancer cell lines (Figure 4.4.2). Detailed analysis of 
clones from Huh7 cell line further indicated that what we observed is a replicative 
senescence, but not a stress-induced premature senescence-like arrest. Clonal C3 cells 
displayed telomerase repression (Figures 4.4.6B, 4.4.6C), progressive telomere 
shortening (Figure 4.4.6A), and permanent growth arrest after ~80 PD with senescence-
associated morphological changes and SABG-positive staining (Figures 4.4.4A, 4.4.4D). 
Similar changes have also been observed with another independently derived clone, 
namely G12 (Figure 4.4.6D, Figure 4.4.8). Thus, we demonstrated that immortal cancer 
cells have the intrinsic ability to reprogram the replicative senescence. As expected, this 
shift in cell fate resulted in a complete loss of tumorigenicity (Figure 4.4.4C). It is of 
great interest that senescence-programmed Huh7 cells express a mutant p53 protein 
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(Bressac B. et al., 1990; Volkmann M. et al., 1994; Kubica S. et al., 1997) and they are 
deficient in p16INK4a expression (Roncalli M. et al., 2002). More importantly, the 
replicative senescence arrest that we identified with clonal C3 cells was not accompanied 
with the induction of p53, p16INK4a, p14ARF or p21Cip1 gene (Figure 4.4.4B, Figure 4.4.5). 
Although, the levels of p21Cip1 protein displayed a slight increase in C3 cells, this was not 
related to senescence arrest, as early passage proliferating C3 cells also displayed this 
slight increase (Figure 4.4.5A). The early loss of hTERT expression in this clone could 
contribute to early p21Cip1 up-regulation, since hTERT is known to down regulate p21Cip1 
promoter activity (Young JI. et al., 2003). p53, p16INK4a, p14ARF and p21Cip1 form a group 
of replicative senescence-related cell cycle checkpoint genes. The lack of induction of 
these genes in senescence-arrested C3 cells clearly indicated that, there were additional 
genes involved in senescence arrest in these tumor-derived cells.    
The loss of hTERT expression in senescence programmed clones prompted us to 
analyze the expression of genes that have been implicated in hTERT regulation. Among 
seven candidate genes studied, only one, the SIP1 gene displayed a differential 
expression between immortal and senescence-programmed clones. This gene has been 
identified by Lin and Elledge (Lin SY. and Elledge SJ., 2003) as a mediator of TGF-β- 
regulated repression of hTERT expression in a breast cancer cell line, although it was not 
effective in an osteosarcoma cell line. In our studies, SIP1 was not expressed in immortal 
hTERT-expressing C1 clone, but expressed in senescence-programmed hTERT-repressed 
C3 and G12 clones (Figures 4.4.6C, 4.4.6D). Experimental depletion of SIP1 transcripts 
in senescence-programmed C3 cells resulted in hTERT upregulation (Figure 4.4.9A). 
Thus, SIP1 gene acts as an hTERT repressor in HCC cells. More importantly, we also 
showed the bypass of senescence arrest, following functional inactivation of SIP 
expression by shRNA in senescence-programmed C3 clonal cells. In contrast to C3 cells 
transfected with a control plasmid, SIP1 shRNA-treated cells displayed continued 
proliferation beyond PD ~80 as evidenced by 70% BrdU incorporation index (Figure 
4.4.9B), and formation of a large number of colonies (Figure 4.4.9C). Selected shRNA-
transfected clones from these experiments have already performed more than 15 PD 
beyond the senescence barrier. Thus, our findings indicate, for the first time that the 
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functional inactivation of SIP1 in senescence-programmed cancer cells is sufficient to 
bypass senescent arrest.  
When we overexpressed mouse SIP1 in Hep3B cell line (with p53 gene deleted), 
telomerase activity was partially repressed, and telomere lengths was shortened as a 
result of hTERT expression down-regulation (Figures 4.14, 4.15, 4.16) However, when 
these Hep3B clones were passaged extensively, they started to repress the expression of 
mouse SIP1, which is accompanied by restoration of both telomerase activity and 
telomere lengths (Figures 4.4.16, 4.4.17 and 4.4.18A). We checked the expression of E-
cadherin in Hep3B cells as SIP1 reporter as suggested by others (Comijn J. et al., 2001). 
And found that repression of E-cadherin was released at late passages (Figure 4.18B). 
This data indicated that Hep3B cells escaped mouse SIP1 induced senescence program by 
repressing exogenous SIP1 expression. 
SIP1 is a zinc finger and homeodomain containing transcription factor that exerts 
a repressive activity by binding to CACCT sequences in regulatory elements of target 
genes (Remacle JE. et al., 1999; Verschueren K. et al., 1999). The SIP1 gene is expressed 
at high levels in almost all human somatic tissues tested, including liver (Cacheux V. et 
al., 2001). Therefore, we also performed comparative analysis of hTERT and SIP1 
expression in non tumor liver and primary HCC tissues. SIP1 was strongly positive in 
non-tumor liver samples, but its expression was significantly decreased in corresponding 
HCC samples. Inversely, hTERT expression was negative or low in non tumor liver 
samples, but highly positive in HCC tumors (Figure 4.4.6E). We also detected complete 
loss of SIP1 expression in 5/14 (36%) of HCC cell lines (Figure 4.4.13). Although there 
was no mutation in SIP1 gene, it is highly likely that SIP1 expression is altered in these 
cell lines by alternative mechanisms such as promoter methylation (Acun T., Yakicier C, 
and Ozturk M., unpublished data). Taken together with in vitro studies, these 
observations strongly suggest that SIP1 acts as a tumor suppressor gene in HCC. 
Although the SIP1, as a repressor of E-cadherin promoter, has been suggested to be a 
promoter of invasion in malignant epithelial tumors (Comijn J. et al., 2001), a tumor 
suppressive activity by the repression of hTERT and inhibition of senescence arrest can 
not be precluded.  
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Telomere shortening and senescence play a major role in liver cirrhosis which 
eventually gives rise to HCC associated with high rate of telomerase reactivation 
(Satyanarayana A. et al., 2004). Furthermore, p53 and p16INK4a are the most frequently 
inactivated genes in HCC, one of the most common cancers worldwide, with limited 
therapeutic options (Thorgeirsson SS. and Grisham JW., 2002; Bruix J. et al., 2004). This 
enhances the importance of our findings for potential therapeutic applications of 
replicative senescence programming in HCC. Additionally, isolation of  two sub-
populations from well-differentiated Huh7 cells, and the constitutive activity of canonical 
Wnt signaling in well-differentiated cells indicates that well-differentiated HCC cells 
may have a stem-like cell properties, as suggested by Erdal E. et al. (Erdal E. et al. 
unpublished data; see sections 5.1.1 and 4.1). 
Overall, our study showed that heterogeneity exists even in established HCC cell 
lines. 
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CHAPTER 6. FUTURE PERSPECTIVES 
 
Our work has opened new avenues to explain the heterogeneity of HCC. The 
follow-up experimental strategy will be explained for each item separately. 
 
1) Dual role of canonical Wnt signaling in HCC: Mutant β-catenin has significant 
activity in well-differentiated HCC cells while does not have or have little activity in 
poorly-differentiated HCC cells. Since the accumulation of mutant β-catenin was higher 
in poorly-differentiated cells compared to well-differentiated ones, the difference at the 
activity should be explained at β-catenin itself or the down-stream of β-catenin. It is 
possible that mutant β-catenin is subjected to different chemical modification in poorly-
differentiated cells, rendering overexpressed β-catenin transcriptionally inactive. APC is 
a nuclear–cytoplasmic shuttling protein that can export nuclear β-catenin to the 
cytoplasm for degradation. It has been shown that Pin1 regulates β-catenin turnover and 
subcellular localization by interfering with its interaction with APC (Ryo A. et al., 2001). 
This indicates that Pin1 should be considered to see if they contribute to differentiation-
dependent canonical Wnt activity in HCC cells. 
Even though, β-catenin can translocates into nucleus, it may still be 
transcriptionally inactive since inhibitory factors such as Groucho, ICAT, Chibby, CtBP, 
might be overexpressed in poorly-differentiated HCC cells. Expression analysis of these 
negative regulators in HCC cell should be performed. We could not explain the 
differential TCF/LEF reporter activity with TCF/LEF family of transcription factors since 
they were expressed in all HCC cells (Benhaj K. et al., unpublished data). However, this 
analysis did not include the dominant negative TCF forms. Since dominant negative TCF 
forms prevent β-catenin-TCF transcriptional activity, these forms should be analyzed in 
further studies. As we have shown that C/EBPα inhibits β-catenin-TCF reporter activity 
in HCC cells, the basal C/EBPα activity should be measured in HCC cells in order to see 
if C/EBPα functions as a negative regulator of canonical Wnt signaling in poorly-
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differentiated HCC cells. On the other hand, Wnt5a and Wnt5b (functioning in non-
canonical Wnt signaling) are overexpressed in poorly-differentiated HCC cells, and 
noncanonical Wnt signaling can inhibit canonical Wnt signaling. Therefore, Wnt5a and 
Wnt5b are good candidates to explain this phenomenon. Knock-down of these ligands in 
poorly-differentiated cells by siRNA technology, or treatments of well-differentiated cells 
with Wnt5a- or Wnt5b-conditioned medium are alternative strategies to follow. There is 
still possibility that all partners of β-catenin in nucleus do not affect the activity but an 
unidentified molecular alteration of  β-catenin may render it inactive. Co-
immunoprecipitation of tagged β-catenin with TCF from poorly-differentiated HCC cells 
may reveal if they are making complexes. Additionally, β-catenin can convert Pitx2 from 
a transcriptional repressor into an activator (Kioussi C. et al., 2002), similar to its 
interaction with LEF1/TCF. Therefore, Pitx2 should be considered for further study. 
 
2) Monoclonal anti-β-catenin antibody study: We have characterized the epitopes of 
our two monoclonal antibodies (9E10 and 4C9), and have shown that 4C9 do not react 
with membrane-associated β-catenin. These antibodies should be tested with confocal 
microscopy to confirm our preliminary results. Any chemical modification at 
corresponding epitopes may change immunoreactivity. Therefore, all possible chemical 
modifications should be addressed. Tissue samples should be screened to find out if these 
antibodies differentiate aberrantly accumulated β-catenin pools.  
 
3) Inhibition of mutant β-catenin-TCF transcriptional activity by C/EBPα: Since 
C/EBPα is a potent inhibitor of cell proliferation, it is necessary to work with inducible 
stable cell lines over expressing C/EBPα.  The use of inducible of C/EBPα in a mutant β-
catenin expression cell lines, such as HepG2, and analysis of canonical Wnt signaling 
target genes are necessary for confirmation of our findings in vivo. Immunohistochemical 
analysis for β-catenin localization or immunoblot analysis for β-catenin protein levels in 
C/EBPα expressing cells would be the first step to explain the mechanism of C/EBPα 
mediated canonical Wnt signaling inhibition in HCC cells. Additionally, our inducible 
C/EBPα overexpressing Huh7 (CEBPA gene is WT in this cell line) cells could be used 
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to study the target genes of C/EBPα by microarray technology. This inducible system 
should be analyzed for C/EBPα effects on HCC cell phenotype for properties such as cell 
proliferation rate, soft-agar growth assay, and tumorigenicity in nude mice.  
 
4) Replicative senescence in HCC-derived cell lines: Microarray analysis for 
differentially expressed genes in our immortal, early and late senescent clones is 
immediate work to be done. Differentially expressed genes between immortal and early 
mortal clones can be used to extract the regulatory networks involved in the reversal of 
immortality and the initiation of replicative senescence program. On the other hand, 
differentially expressed genes between early and late mortal clones may be used to 
extract the regulatory networks functioning in the execution of senescence program. In 
order to identify the genes responsible for tissue-specific senescence, our gene list should 
be compared to the one involved in replicative senescence of fibroblasts. Since telomere 
shortening and senescence are proposed as general markers of human liver cirrhosis, 
microarray data should be explored in order to find candidate genes involved in liver 
cirrhosis program. Further genetic and functional analysis of selected genes may identify 
the regulatory networks and genes involved in replicative senescence and human liver 
cirrhosis. 
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Tumor cells have the capacity to proliferate indefinitely that is
qualified as replicative immortality. This ability contrasts with the
intrinsic control of the number of cell divisions in human somatic
tissues by a mechanism called replicative senescence. Replicative
immortality is acquired by inactivation of p53 and p16INK4a genes
and reactivation of hTERT gene expression. It is unknown whether
the cancer cell replicative immortality is reversible. Here, we show
the spontaneous induction of replicative senescence in p53-and
p16INK4a-deficient hepatocellular carcinoma cells. This phenome-
non is characterized with hTERT repression, telomere shortening,
senescence arrest, and tumor suppression. SIP1 gene (ZFHX1B) is
partly responsible for replicative senescence, because short hairpin
RNA-mediated SIP1 inactivation released hTERT repression and
rescued clonal hepatocellular carcinoma cells from senescence
arrest.
immortality  liver cancer  SIP1  telomerase  p53
Tumor cells are clonal (1), and tumorigenesis usually requiresthree to six independent mutations in the progeny of pre-
cancerous cells (2). For this to occur, preneoplastic somatic cells
would need to breach the replicative senescence barriers. Rep-
licative senescence is a telomere-dependent process that sets a
limit to the successive rounds of cell division in human somatic
cells (3). Progressive telomere shortening is observed in almost
all dividing normal cells. This phenomenon is linked to the lack
of efficient hTERT expression that is observed in most human
somatic cells (3). Replicative senescence (permanent growth
arrest also called M1 stage) is believed to be initiated by a DNA
damage-type signal generated by critically shortened telomeres,
or by the loss of telomere integrity, leading to the activation of
cell cycle checkpoint pathways involving p53, p16INK4a, andor
retinoblastoma (pRb) proteins (4, 5). In the absence of func-
tional p53 and p16INK4apRb pathway responses, telomeres
continue to shorten resulting in crisis (also called M2 stage).
Cells that bypass the M2 stage by reactivating hTERT expression
gain the ability for indefinite cell proliferation, also called
immortality (3, 4, 6). There is accumulating evidence that cancer
cells undergo a similar process during carcinogenesis to acquire
immortality. Telomerase activity associated with hTERT reex-
pression is observed in 80% of human tumors (7), and senes-
cence controlling p53 and p16INK4A genes are commonly inacti-
vated in the majority of human cancers (8). Moreover,
experimental transformation of normal human cells to tumor
cells requires hTERT-mediated immortalization, as well as
inactivation of p53 and pRb genes (9).
Aberrant expression of hTERT, together with the loss of p53
and p16INK4apRb control mechanisms, suggests that the repli-
cative immortality is a permanent and irreversible characteristic
of cancer cells. Although some cancer cells may react to extrinsic
factors by a senescence-like stress response, this response is
immediate, telomere-independent, and cannot be qualified as
replicative senescence (10). Experimental inactivation of telom-
erase activity in cancer cells mostly results in cell death (11),
whereas ectopic expression of p53, p16INK4a, or pRb provokes an
immediate senescence-like growth arrest or cell death (10).
Thus, to date there is no experimental evidence for spontaneous
reprogramming of replicative senescence in immortalized cancer
cells. Using hepatocellular carcinoma (HCC)-derived Huh7 cells
as a model system, here we show that cancer cells with replicative
immortality are able to spontaneously generate progeny with
replicative senescence. Thus, we provide preliminary evidence
for the reversibility of cancer cell immortality. The replicative
senescence of cancer cells shares many features with normal cell
replicative senescence such as repression of hTERT expression,
telomere shortening, and permanent growth arrest with mor-
phological hallmarks of senescence. However, the p53 gene is
mutated, whereas p16INK4a promoter is hypermethylated in these
cells. Thus, we show that fully malignant and tumorigenic HCC
cells that display aberrant hTERT expression and lack functional
p53 and p16INK4a genes are able to revert from replicative
immortality to replicative senescence by an intrinsic mechanism.
Furthermore, we demonstrate that the SIP1 gene, encoding a
zinc-finger homeodomain transcription factor protein involved
in TGF- signaling (12, 13) and hTERT regulation (14), serves
as a molecular switch between replicative immortality and
replicative senescence fates in HCC cells.
Results
When analyzing clones from established cancer cell lines, we
observed that some clones change morphology and cease pro-
liferation at late passages with features reminiscent of cellular
senescence (data not shown). We reasoned that this could be an
indication for generation of progeny programmed for replicative
senescence. We surveyed a panel of HCC and breast carcinoma
cell lines and hTERT-immortalized human mammary epithelial
cells (hTERT-HME). Plated at low clonogenic density, cells
were maintained in culture until they performed 6–10 popula-
tion doublings (PD), and tested for senescence-associated -
galactosidase (SABG) activity (15). Different cancer cell lines
generated progeny with greatly contrasting SABG staining
patterns. The first group, represented here by HCC-derived
Huh7 and breast cancer-derived T-47D and BT-474 cell lines,
generated heterogeneously staining colonies. Cells of some
colonies were mostly positive for SABG, but others displayed
significantly diminished or complete lack of staining (Fig. 1A).
The second group, represented by HCC-derived Hep3B and
Mahlavu, and hTERT-HME generated only SABG-negative
colonies (Fig. 1B). Manual counting of randomly selected col-
onies demonstrated that mean SABG-labeling indexes for Huh7,
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T-47D and BT-474 progenies were 45  23%, 40  29%, and
33  7%, respectively (Fig. 1C, lanes 1–3). In contrast, Hep3B,
Mahlavu, and hTERT-HME progenies displayed 3  3%
mean SABG-labeling indexes (Fig. 1C, lanes 4–6). Clones from
representative cell lines were expanded and subjected to the
same analysis. SABG-staining patterns of all clones tested were
closely similar to the patterns of their respective parental cell
lines. For example, mean SABG staining indexes of Huh7-
derived clones were 14  15%, 47  27%, and 17  11% (Fig.
1C, lanes 7–9), whereas Hep3B-derived clones generated 2 
3% SABG-positive progenies (Fig. 1C, lanes 10–12). We spec-
ulated that the first group of cell lines comprised progenies in
different stages of replicative senescence process at the time of
analysis, whereas the second group of cell lines were composed
mostly of immortal cells. The results obtained with the first
group were unexpected. These cell lines have been established
20 years ago (16–18) and expanded in culture over many years,
with PD well beyond the known senescence barriers for normal
human cells (3), but they were still capable of generating
presumably senescent progeny.
The study of a potentially active replicative senescence pro-
gram in the progeny of immortal cancer cell lines requires the
long-term follow up of single cell-derived clones. To this end, we
chose to focus our investigations on Huh7 cell line. We expanded
different Huh7-derived clones in long-term culture and exam-
ined their potential to undergo replicative senescence. Some
clones performed 100 PD in culture with stable proliferation
rates and heterogeneous SABG staining, whereas others sus-
tained a limited number of PD, then entered a growth arrest
phase with full SABG staining patterns. For example, C3 clone
performed only 80 PD, whereas C1 clone replicated 150 PD.
Permanently arrested C3 cells (PD 80) displayed enlarged size,
f lattened shape, and fully positive SABG staining, whereas early
passage C3 (PD 57) and C1 (PD 179) cells displayed normal
morphology with heterogeneous SABG staining (Fig. 2AUpper).
Normal human cells at replicative senescence (M1) are refrac-
tory to mitotic stimulation and display 5% BrdUrd index (19).
Growth-arrested C3 cells displayed very low BrdUrd staining
(2  2%), in contrast to early passage C3 and late passage C1
cells, which exhibited 89  6%, and 96  3% BrdUrd indexes,
respectively (Fig. 2A Lower). Senescent C3 cells remained
growth arrested, but alive when maintained in culture for at least
3 months, with no emergence of immortal clones (data not
shown).
Biological mechanisms of replicative senescence observed
here are of particular interest, because senescence-regulatory
p53 is inactivated (20–22) and p16INK4a promoter is hypermethy-
lated (23) in Huh7 cells. Accordingly, there was no change in p53
levels, whereas the low level p16INK4a expression did not in-
crease, but decreased in senescent C3 (PD 80) cells, when
compared to presenescent C3 (PD 57) or immortal C1 (PD 179)
cells. Retinoblastoma protein (pRb) displayed partial hypophos-
Fig. 1. Established human cancer cell lines generate senescence-associated
-galactosidase (SABG)-expressing progeny. (A) Representative pictures of
HCC (Huh7) and breast cancer (T-47D and BT-474) cell lines that generate both
SABG-positive (Upper) and SABG-negative (Lower) colonies. (B) Representa-
tive pictures of HCC (Hep3B and Mahlavu) and telomerase-immortalized
mammary epithelial (hTERT-HME) cell lines that generate only SABG-negative
colonies. Cells were plated at clonogenic density to generate colonies with
6–10 population doublings, and stained for SABG activity (blue), followed by
eosin counterstaining (red). (C) Quantification of SABG-positive cells in colo-
nies. Randomly selected colonies (n 10) obtained from parental (lanes 1–6)
cell lines and expanded clones (lanes 7–12) were counted to calculate the
average % SABG positive cells per colony (% SABG index). Lanes 1–6 designate
Huh7, T-47D, BT-474, Hep3B, Mahlavu, and hTERT-HME, respectively. Lanes
7–9 are Huh7-derived C1, C3, and C11 clones, and lanes 10–12 are Hep3B-
derived 3B-C6, 3B-C11, and 3B-C13 clones. Error bars indicate SD.
Fig. 2. p53-and p16INK4a-deficient Huh7 cells generate progeny that un-
dergo in vitro and in vivo replicative senescence resulting in loss of tumori-
genicity. (A) Huh7-derived clones C3 and C1 were tested for replicative senes-
cence arrest by SABG and BrdUrd staining at different passages. Presenescent
C3 and immortal C1 cells display low SABG staining (Upper) and high BrdUrd
incorporation (Lower), whereas senescent C3 cells are fully positive for SABG
(Upper) and fail to incorporate BrdUrd into DNA after mitogenic stimuli
(Lower). (B) p53 and p16INK4a protein levels show no increase in senescent C3
cells, compared to presenescent C3 and immortal C1 cells, but senescent C3
cells display partial hypophosphorylation of pRb. Calnexin was used as a
loading control. Proteins were tested by Western blotting. PS, presenescent
(PD 57); S, senescent (PD 80); I, immortal (PD 179). (C) C1 cells (black line) were
fully tumorigenic, but C3 cells (red line) were not in nude mice. (D) C1 tumors
displayed low SABG staining (Upper Right), whereas implanted C3 cells re-
maining at the injection site are fully positive for SABG in situ (Upper Left), as
well as after short-term in vitro selection (Lower). Animals were injected with
presenescent C3 (PD 59) and immortal C1 (PD 119) cells, and tumors and
nontumorigenic cell samples were collected at day 35 and analyzed.
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phorylation in senescent C3 cells, apparently in a p53- and
p16INK4a-independent manner (Fig. 2B). Cyclin E and A levels
were also decreased, but p21cip1 levels were elevated in both
presenescent and senescent C3 cells (Fig. 5A, which is published
as supporting information on the PNAS web site). Cyclin D1,
CDK4, and CDK2 protein levels (Fig. 5A) and p14ARF transcript
levels (Fig. 5B) did not change.
Cancer cell senescence that we characterized here shared
many features with normal cell replicative senescence (3), except
that it was not accompanied with wild-type p53 or p16INK4a
induction. However, in vivo relevance of the replicative senes-
cence observed in cell culture is debated (6). Therefore, we
compared in vivo replicative potentials of C3 (PD 59) and C1
(PD 119) cells in CD-1 nude mice. C3 cells did not form visible
tumors, whereas C1 cells were fully tumorigenic in the same set
of animals (Fig. 2C), like parental Huh7 cells (data not shown;
ref. 24). C1 tumors collected at day 35 displayed scattered but
low-rate SABG-positive staining, but remnant C3 cell masses
collected from their injection sites were fully SABG-positive
(Fig. 2D Upper). For confirmation, these remnants were re-
moved from two different animals, passaged twice in cell culture
for selection, and examined. Nearly all cells displayed senescence
features including enlarged size, f lattened shape, and highly
positive SABG staining (Fig. 2D Lower). We concluded that loss
of C3 tumorigenicity was due to replicative senescence in vivo.
Replicative senescence, also called telomere-dependent se-
nescence is associated with progressive telomere shortening due
to inefficient telomerase activity (3). When compared to paren-
tal Huh7 cells, presenescent C3 cells at PD 57 had telomeres that
have already been shortened to 7 kbp from 12 kbp. These
cells eroded their telomeres to5 kbp at the onset of senescence.
In contrast, immortal C1 clone (PD 179) telomeres did not
shorten (Fig. 3A). These observations showed a perfect corre-
lation with telomerase activity and hTERT expression. Immortal
C1 cells displayed robust telomerase activity, whereas both
presenescent and senescent C3 cells had no detectable telom-
erase activity (Fig. 3B). Accordingly, the expression of hTERT
gene was high in C1, but barely detectable in C3 cells (Fig. 3C).
Thus, senescence observed with C3 cells was characterized with
the loss of hTERT expression and telomerase activity, associated
with telomere shortening.
Mechanisms of hTERT expression are presently unclear, but
several genes including SIP1, hSIR2, c-myc, Mad1, Menin, Rak,
and Brit1 have been implicated (14, 25). Therefore, we analyzed
their expression in C1 and C3 clones. All tested genes, except
SIP1, were expressed at similar levels in both C1 and C3 clones,
independent of hTERT expression (Fig. 6, which is published as
supporting information on the PNAS web site). SIP1 transcripts
were undetectable in C1 cells, but elevated in C3 cells, moder-
ately in presenescent, but strongly in senescent stages (Fig. 3C).
We verified these findings with another Huh7-derived clone
(G12) that displayed replicative senescence resulting in perma-
nent cell proliferation arrest. Like C3, presenescent G12 cells
that displayed low SABG staining with high BrdUrd index (98
1%), became fully positive for SABG, and nearly negative for
BrdUrd (3  2%) at the onset of senescence (Fig. 7, which is
published as supporting information on the PNAS web site).
Presenescent G12 cells displayed only a weak hTERT repression
associated with a slight increase in SIP1 expression, whereas
SIP1 was strongly elevated in hTERT-negative senescent cells
(Fig. 3D). Thus, there was a close correlation between SIP1
expression and hTERT repression in all Huh7 clones tested. The
analysis of SIP1 and hTERT expression in primary HCCs and
their corresponding nontumor liver tissues confirmed this rela-
tionship. SIP1 transcript levels were high, but hTERT expression
was low in nontumor liver tissues, whereas respective HCC
tumors displayed diminished SIP1 expression associated with
up-regulated hTERT expression (Fig. 3E).
The SIP1 gene (Zinc finger homeobox 1B; ZFHX1B) en-
codes a transcriptional repressor protein that interacts with
SMAD proteins of the TGF- signaling pathway and CtBP
corepressor (12, 13). This gene has recently been implicated in
TGF--dependent regulation of hTERT expression in breast
cancer cells (14). Our observations implicated SIP1 gene as a
candidate regulator of replicative senescence in HCC cells. To
investigate whether SIP1 expression constitutes a protective
barrier against hTERT expression and senescence bypass, we
constructed SIP1 short hairpin RNA (shRNA)-expressing
plasmids, based on a reported effective SIP1 siRNA sequence
(14). SIP1 shRNA was expressed by using either G-418-
resistance plasmid pSuper.retro.neoGFP or puromycin-
resistance plasmid pSUPER.puro (see shRNA in Methods).
Presenescent C3 cells at PD 75 were used for transfections, 3–4
weeks before expected senescence arrest stage.
pSuper.retro.neoGFP-based SIP1 shRNA suppressed the
accumulation in SIP1 when expressed transiently (Fig. 4A, day
5). This resulted in a weak increase in hTERT expression.
Transfected cells were maintained in culture in the presence of
500 gml G-418 and observed for 30 days. At this period, C3
cells transfected with a control plasmid reached senescence-
arrested stage with further up-regulation of SIP1 expression
(Fig. 4A, day 30) and resistance to BrdUrd incorporation after
mitogenic stimuli (BrdUrd index  3  1%; Fig. 4B Upper
Left). In sharp contrast, SIP1 shRNA-transfected cells lost
Fig. 3. C3 clonal cells undergo telomere-dependent replicative senescence
associated with SIP1 expression and hTERT repression. SIP1 expression is lost,
whereas hTERT is induced in primary HCC tumors. (A) Genomic DNAs from
parental Huh7 and immortal C1 cells display long telomeres, whereas C3
telomeres are progressively shortened in presenescent and senescent stages,
respectively. Equal amounts of genomic DNAs were blotted with a telomere
repeat probe. C. Low, short telomere control DNA. (B) Presenescent and
senescent C3 cells have lost telomerase activity, as measured by TRAP assay.
Telomerase activity was shown as % value of test samples ( SD) compared to
‘‘high positive’’ control sample. (C) hTERT expression as tested by RT-PCR was
high in immortal C1, but decreased to weakly detectable levels in C3 cells.
Inversely, SIP1 expression tested by RT-PCR was undetectable in C1 cells, but
showed a progressive increase in presenescent and senescent C3 cells. (D)
Inverse relationship between SIP1 and hTERT expression was confirmed with
another senescence-programmed Huh7 clone named G12 (for SABG and
BrdUrd assays, see Fig. 7). hTERT expression in G12 showed a slight decrease in
presenescent stage, followed by a loss at the onset of senescence. Inversely,
the expression of SIP1 gene was weakly positive in presenescent G12, but
highly positive in senescent G12 cells. C1 was used as control. PS, presenescent;
S, senescent; I, immortal. (E) Negative correlation between hTERT and SIP1
expression in primary tumors (T) and nontumor liver tissues (NT).
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SIP1 expression and up-regulated hTERT transcripts (Fig. 4A,
day 30). Furthermore, SIP1-inactivated cells escaped senes-
cence, as evidenced with 70 9% BrdUrd index (Fig. 4B Upper
Right). Morphologically, SIP1 shRNA-transfected cells formed
proliferating clusters, whereas cells transfected with control
plasmid displayed hallmarks of senescence such as scattering,
enlargement, and multiple nuclei (Fig. 4B Lower). Twelve
independent clones were selected from SIP1 shRNA-
transfected C3 cells. All but one of these clones have per-
formed so far 15 PD beyond the expected senescence barrier
(data not shown). As an additional confirmatory assay, C3 cells
were transfected with the puromycin-selectable pSUPER.puro-
based SIP1 shRNA vector and subjected to puromycin selec-
tion. SIP1 shRNA-transfected cells survived and formed large
number of colonies after 30 days of puromycin selection. In
contrast, no surviving colony was obtained from cells trans-
fected with the control plasmid, as expected (Fig. 4C).
Discussion
Our observations provide experimental evidence for the gen-
eration of senescence-arrested clones from immortal HCC and
breast cancer cell lines. Detailed analysis of clones from
HCC-derived Huh7 cell line further indicates that what we
observe is a replicative senescence, but not a stress-induced
premature senescence-like arrest. Clonal C3 cells displayed
telomerase repression, progressive telomere shortening, and
permanent growth arrest after 80 PD with senescence-
associated morphological changes and positive SABG stain-
ing. Similar changes have also been observed with G12,
another independently derived clone. Thus, we demonstrate
that immortal cancer cells have the intrinsic ability to repro-
gram the replicative senescence. As expected, this shift in cell
fate results in a complete loss of tumorigenicity. The replica-
tive senescence arrest that we identified with clonal C3 cells
was not accompanied with the induction of the p53, p16INK4a,
p14ARF, or p21Cip1 gene. The nonparticipation of p53 and
p16INK4a to the senescence arrest described here was expected,
in the light of published observations showing that Huh7 cells
express a mutant p53 protein (20–22) and they are deficient in
p16INK4a expression (23). Although the levels of p21Cip1 protein
displayed a slight increase in C3 cells, this was not related to
senescence arrest, as early passage proliferating C3 cells also
displayed this slight increase (Fig. 5). The early loss of hTERT
expression in this clone could contribute to early p21Cip1
up-regulation, because hTERT is known to down-regulate
p21Cip1 promoter activity (26). p53, p16INK4a, p14ARF, and
p21Cip1 form a group of replicative senescence-related cell
cycle checkpoint genes. The lack of induction of these genes in
senescence-arrested C3 cells clearly indicates that there are
additional genes involved in senescence arrest in these tumor-
derived cells.
The loss of hTERT expression in senescence programmed
clones prompted us to analyze the expression of genes that have
been implicated in hTERT regulation. Among seven candidate
genes studied, only one, the SIP1 gene, displayed a differential
expression between immortal and senescence-programmed
clones. This gene has been identified as a mediator of TGF--
regulated repression of hTERT expression in a breast cancer cell
line, although it was not effective in an osteosarcoma cell line
(14). In our studies, SIP1 was not expressed in immortal hTERT-
expressing C1 clone, but expressed in senescence-programmed
hTERT-repressed C3 and G12 clones (Fig. 3 B and C). Further-
more, experimental depletion of SIP1 transcripts resulted in
hTERT up-regulation in C3 clonal cells (Fig. 4A). This effect has
been confirmed by using SKHep1, another HCC cell line (data
not shown). Thus, we demonstrate that the SIP1 gene acts as an
hTERT repressor in HCC cells. More importantly, we also
showed the bypass of senescence arrest after functional inacti-
vation of SIP expression by shRNA in senescence-programmed
C3 clonal cells. In contrast to C3 cells transfected with a control
plasmid, SIP1 shRNA-treated cells displayed continued prolif-
eration beyond PD 80 as evidenced by 70% BrdUrd incorpo-
ration index, and formation of large number of colonies. Se-
lected shRNA-transfected clones from these experiments have
already performed15 PD beyond the senescence barrier. Thus,
our findings indicate that the functional inactivation of SIP1 in
senescence-programmed cancer cells is sufficient to bypass
senescent arrest.
SIP1 is a zinc finger and homeodomain containing tran-
scription factor that exerts a repressive activity by binding to
CACCT sequences in regulatory elements of target genes (12,
27). The SIP1 gene is expressed at high levels in almost all
human somatic tissues tested, including liver (28). Therefore,
we also performed comparative analysis of hTERT and SIP1
expression in nontumor liver and primary HCC tissues. SIP1
Fig. 4. ShRNA-mediated down-regulation of endogeneous SIP1 transcripts
releases hTERT repression and rescues C3 cells from senescence arrest. (A) At
day 5 after transfection, SIP1 shRNA-transfected cells (Sh-SIP1) show decreased
expression of SIP1 and weak up-regulation of hTERT expression. At day 30, the
expression of SIP1 is lost completely, and hTERT expression is stronger. (B) Cells
transfected with empty vector (Control) are senescence-arrested as evidenced
by resistance to BrdUrd incorporation (Upper Left) and morphological
changes (Lower Left), but cells transfected with SIP1 shRNA vector (Sh-SIP1)
escaped senescence arrest as indicated by high BrdUrd index (Upper Right)
and proliferating cell clusters (Lower Right). (C) Colony-forming assay shows
that C3 cells formed large number of colonies following puromycin selection
after transfection with a puromycin-resistant SIP1-shRNA-expressing plasmid
(Right), whereas cells transfected with empty vector did not survive (Left).
SIP1 shRNA was expressed by using either G-418-resistance plasmid
pSuper.retro.neoGFP (A and B) or puromycin-resistance plasmid pSUPER.
puro (C). Presenescent C3 cells at PD 75 were transfected with either SIP1
shRNA-expressing or empty plasmid vectors, maintained in culture in the
presence of appropriate selection media and tested at days 5 (A) and 30 (A–C).
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was strongly positive in nontumor liver samples, but its ex-
pression was significantly decreased in corresponding HCC
samples. Inversely, hTERT expression was negative or low in
nontumor liver samples, but highly positive in HCC tumors
(Fig. 3E). We also detected complete loss of SIP1 expression
in 5 of 14 (36%) of HCC cell lines (data not shown). Taken
together with in vitro studies, these observations strongly
suggest that SIP1 acts as a tumor suppressor gene in HCC.
Although SIP1, as a repressor of E-cadherin promoter, has
been suggested to be a promoter of invasion in malignant
epithelial tumors (29), a tumor suppressive activity by the
repression of hTERT and inhibition of senescence arrest is not
precluded.
Hepatocellular carcinoma is one of the most common
cancers worldwide. Liver cirrhosis is the major etiology of this
tumor with limited therapeutic options (30, 31). Telomere
shortening and senescence play a major role in liver cirrhosis,
from which the neoplastic HCC cells emerge with high rates of
telomerase reactivation (32). Furthermore, p53 and p16INK4a
are the most frequently inactivated genes in these tumors. This
fact enhances the importance of our findings for potential
therapeutic applications of replicative senescence program-
ming in HCC.
Methods
Tissues, Cells, and Clones. Snap-frozen HCC and nontumor liver
tissues were used. HCC and breast cancer cell lines T-47D
(ATCC) and BT-474 (ATCC) were cultivated as described (33).
hTERT-HME cells (Clontech) were cultivated in DMEM
Ham’s F-12 (Biochrom) containing insulin (3.5 gml), EGF
(0.1 ngml), hydrocortison (0.5 gml), and 10% FBS (Bio-
chrom). Huh7- and Hep3B-derived isogenic clones were ob-
tained by either G-418 selection after transfection with neomy-
cin-resistance pcDNA3.1 (Invitrogen) or pEGFP-N2 (Clontech)
plasmids, or by low-density cloning. Huh7-derived isogenic
clones C1 and C3 were obtained with pCDNA3.1, and G12 with
pEGFP-N2. Huh7-derived C11, and Hep3B-derived 3B-C6,
3B-C11 and 3B-C13 were obtained by low-density cloning. Cells
transfected with calcium phosphateDNA-precipitation method
were cultivated in the presence of geneticin G-418 sulfate (500
gml; GIBCO), and isolated single cell-derived colonies were
picked up by using cloning cylinders and expanded in the
presence of 200 gml geneticin G-418 sulfate. For low-density
cloning, cells were plated at 30 cells per cm2 and single-cell
derived colonies were expanded. Initial cell stocks were pre-
pared when total number of cells became 1–3  107, and the
number of accumulated population doubling (PD) at this stage
was estimated to be 24, assuming that the progeny of the initial
colony-forming cells performed at least 24 successive cell divi-
sions until that step. Subsequent passages were performed every
4–7 days, and the number of additional PD was determined by
using a described protocol (34).
Low-Density Clonogenic Assay. Cells (30–50 per cm2) were plated
in six-well plates and grown 1–3 weeks to obtain isolated colonies
formed with 100–1,000 cells. The medium was changed every 4
days, and colonies were subjected to SABG staining (see below).
In Vivo Studies. Cells were injected s.c. into CD-1 nude mice
(Charles River Breeding Laboratory). Tumors and nontumori-
genic cells at the injection sites were collected at day 35 and
analyzed directly or after in vitro culture by SABG assay (see
below). These experiments have been approved by the Bilkent
University Animal Ethics Committee.
SABG Assay. SABG activity was detected by using a described
protocol (15). After DAPI or eosin counterstaining, SABG-
positive and negative cells were identified and counted.
BrdUrd Incorporation Assay. Subconfluent cells were labeled with
BrdUrd for 24 h in freshly added culture medium and tested as
described (33), using anti-BrdUrd antibody (Dako) followed by
tetramethylrhodamine B isothiocyanate-labeled secondary an-
tibody (Sigma). DAPI (Sigma) was used for counterstaining.
Immunoblotting. Antibodies against cyclin D1, CDK4, CDK2,
p21Cip1, pRb (all from Santa Cruz Biotechnology), cyclin E
(Transduction), cyclin A (Abcam), p16INK4a (Abcam), p53 (clone
6B10; ref. 35), and calnexin (Sigma) were used for immunoblot-
ting as described (33).
RT-PCR.RT-PCR expression analysis was performed as described
(33), using primers listed in Table 1, which is published as
supporting information on the PNAS web site.
TRAP and Telomere Length Assays. Telomerase activity and telo-
mere length assays were performed by using TeloTAGGG
Telomerase PCR ELISAPLUS and TeloTAGGG Telomere
Length Assay (Roche Diagnostics), following kit instructions.
shRNA. SIP1-directed shRNA was designed according to a pre-
viously described effective siRNA sequence (14) using the
pSUPER RNAi system instructions (Oligoengine) and cloned
into pSuper.retro.neoGFP and pSUPER.puro (Oligoengine),
respectively. SIP1 shRNA-encoding sequence was inserted
by using 5-GATCCCCCTGCCATCTGATCCGCTCTT-
TCAAGAGAAGAGCGGATCAGATGGCAGTTTTTA-3
(sense) and 5-AGCTTAAAAACTGCCATCTGATCCGC-
TCTTCTCTTGAAAG AGCGGATCAG ATGGCAGGGG-3
(antisense) oligonucleotides.
The integrity of the inserted shRNA-coding sequence has been
confirmed by nucleic acid sequencing of recombinant plasmids.
Clone C3 cells were transfected with calcium phosphate precipita-
tion method, using either pSuper.retro.neoGFP-based or pSU-
PER.puro-based SIP1 shRNA expression plasmid, and cells were
maintained in the presence of 500 gml geneticin G-418 sulfate
and 2 gml puromycin (Sigma), respectively. Empty vectors were
used as control. Media changed every 3 days, and cells were tested
at days 5 and 30.
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